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ABSTRACT 
 Elevations in GC concentrations are well-known to cause a variety of negative systemic side 
effects, and subtle alterations in GC secretion and tissue-specific actions are a possible link between 
insulin resistance, the metabolic syndrome and T2DM development. These pathological conditions impair 
insulin-stimulated skeletal muscle blood flow and glucose uptake, in addition to causing profound 
myopathy, all of which could be significant contributors to the metabolic complications associated with 
insulin resistance. The focus of this dissertation was to understand how elevations in GC concentrations 
can be associated with skeletal muscle insulin resistance and diabetes development and whether 
augmentation to the muscle microvasculature is beneficial or even possible during conditions that 
generate significant exposure to elevations in GCs. To examine these situations, two rodent models of 
diabetes were used; exogenous elevations in GCs either combined with a HFD or provided a standard 
chow diet, to reproduce T2DM, and STZ-treated rats to induce β-cell destruction, simulating T1DM. As 
both regular exercise and circulating insulin levels have been well documented in the regulation of 
microvascular augmentation, we assessed the therapeutic potential of voluntary exercise and 
pharmacologically enhancing hyperemia in both GC-induced skeletal muscle insulin resistance and STZ-
induced diabetes.  
 We revealed that the skeletal muscle is severely altered (decreased glycolytic muscle insulin-
stimulated glucose transport and considerable glycolytic fibre atrophy) in the presence of 
hypercortisolemia coupled with HFD, but these alterations could be attenuated with the administration of 
voluntary aerobic exercise. The hypercortisolemia also resulted in alterations to the microvasculature 
(capillary rarefaction), which, when attenuated through α1-antagonism, produced a correlative 
enhancement in insulin sensitivity. Finally, the combination of voluntary exercise and α1-antagonism, in a 
model of chemically-induced (STZ) diabetes, demonstrated synergistic qualities through the increase in 
capillary growth within both glycolytic and oxidative skeletal muscle and enhanced glycemic control. 
This thesis provides considerable evidence proving that manipulation of the skeletal muscle 
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microvasculature, either through voluntary exercise or pharmacologically enhanced hyperemia, can 
attenuate the hypercortisolemia-induced skeletal muscle capillary rarefaction and improve glucose 
metabolism through enhanced glucose uptake and insulin sensitivity. 
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Chapter 1. 
Literature Review and Introduction 
Animal models of diabetes 
1.1 Outline and introduction to diabetes.  
 Diabetes mellitus is a disease characterized by a relative or absolute lack of insulin, 
ultimately causing hyperglycemia. There are several types of diabetes, however the two main 
types are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Both T1DM 
and T2DM are multifaceted diseases in which a very complex genetic background interacts with 
environmental factors contributing to disease development (Ikegami, 2004). T1DM (commonly 
known as juvenile-onset diabetes) typically represents ~10% of all diabetes cases (Atkinson 
2014; Cefalu, 2006) and is a chronic, autoimmune disease, targeting the insulin-producing 
pancreatic β-cells by effector lymphocytes (Mylona-Karayannia 2006). T2DM represents ~90% 
of all diabetes cases, and is a complex and diverse disease which occurs as the result of insulin 
resistance coupled with a failure of β-cell compensation (Jackerott 2006).  
 T1DM is characterized by a selective and specific involvement of the β-cells, without 
major immune filtration of other pancreatic cells, such as α-cells, which secrete glucagon, or δ-
cells, which secrete somatostatin (Willcox 2009). In predisposed individuals, the initial 
'activating' event is still unclear, however, it is suggested that early-life environmental triggers, 
such as infection, nutrition or chemical exposure, could initiate self-targeting immune cascades 
(Zaccardi 2016). In the initial stages of T1DM development, the progressive destruction of β-
cells and serological positivity (presence of detectable autoantibodies) (Toivonen 2001) are not 
directly associated with alterations to blood glucose, as it seems the available β-cells are capable 
of maintaining euglycemia. Upon disease progression, there is further β-cell destruction followed 
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by insulin deficiency and hyperglycemia, with subsequent overt diabetes development. Tight 
glycaemic control after diagnosis is extremely important as it has been shown to reduce the risk 
of diabetic complications (Nathan 2005) in addition to the preservation of remaining β-cell 
mass/function (Picardi 2006).  
 T2DM, on the other hand, is more like a group of progressive diseases with different 
genetics and pathophysiologies but similar symptoms and outcomes; ultimately diminished 
pancreatic function over time creating chronic hyperglycemia. This progression to overt diabetes 
does not happen overnight, and typically is preceded by a deterioration of the insulin secretory 
capacity of the β-cells (Buchanan, 2003; Weyer 1999), which begins years prior to the clinical 
diagnosis of diabetes, characterized by the presence of insulin resistance (Kahn, 2000). The 
pancreatic dysfunction fails to compensate for the insulin resistance and leads to a state of 
relative insulin deficiency, progressing eventually to hyperglycemia. It is at this stage that 
impaired glucose tolerance and elevated fasting glucose (i.e. blood glucose ≥ 7.0 mmol/L) may 
be present. With worsening islet dysfunction and the inability for adequate compensation in 
relation to the degree of insulin resistance, clinically overt T2DM develops, defined by the 
Canadian Diabetes Association Clinical Practise Guidelines as a fasting blood glucose ≥ 7.0 
mmol/L or a 2hr post oral glucose challenge of ≥ 11.1 mmol/L (Goldenberg 2013).  Once 
hyperglycemia has manifest, multiple abnormalities are present, such as obesity, hyperlipidemia, 
hypercortisolemia, and increased levels of inflammatory cytokines (Defronzo, 2004). Ultimately, 
high levels of plasma glucose, free fatty acids (FFA), glucocorticoids (GCs) and cytokine 
concentrations can all worsen insulin resistance, making it quite difficult to identify the 
individual contributions of each of these metabolic defects in the pathogenesis of the disease. 
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 Utilizing animal models that mimic diabetes pathophysiology provides a unique 
opportunity to study the onset, development and course of the disease in addition to the 
molecular mechanisms that lead to diabetes development. This thesis contains animal models of 
both T1DM and T2DM, as well as references to other animal models of diabetes. 
1.2 Animal models of type 1 diabetes  
 As described above, T1DM is characterized by an autoimmune destruction of the β-cells, 
leading to impaired insulin production. Animal models of T1DM are insulin deficient through a 
number of different mechanisms ranging from chemical destruction of the β-cells to spontaneous 
development of autoimmune diabetes (Table 1). 
1.2.1. Chemically-induced type 1 diabetes 
 The chemical induction of diabetes characteristically causes targeted necrosis to the 
pancreatic beta cells (Jorns, 1997; Peschke 2000), resulting in limited endogenous insulin 
production, hyperglycemia and weight loss (King, 2012). Diabetes is usually induced prior to the 
start of any experimental observation period to ensure stable hyperglycemia. Chemically-induced 
diabetes is not used for studies of the autoimmune processes in T1DM development, but may be 
used to examine the effects of insulin deficiency or hypoglycemia on various physiological 
processes. The two predominant compounds used to chemically-induce diabetes are 
streptozotocin (STZ) or alloxan, and while they induce cytotoxicity through distinct pathways, 
their β-cell selectivity is the same (Lenzen, 2008). 
1.2.1.a. Streptozotocin-induced diabetes  
 STZ is a nitrosourea analogue, and its toxic action requires transport into the cell through 
the plasma membrane. STZ has also been used as a chemotherapeutic alkylating agent (Drímal 
2006) and can be administered as a single large dose or as multiple smaller doses, with the 
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general goal of the induction of insulinopenic diabetes. Typically, multiple low doses of STZ 
(ranging from 20-40 mg/kg-1/day, species dependant) have been used to study the immunological 
pathways causing insulitis and beta cell death (Mensah-Brown 2002; Yang 2003), while a single 
high dose can induce overt insulin-dependent diabetes in rodents. Once administered either 
subcutaneously or intraperitoneally, STZ, which is similar in structure to glucose, is selectively 
accumulated in pancreatic beta cells through the low-affinity GLUT2 glucose transporter situated 
in the plasma membrane (Karunanayake 1976). The toxicity of STZ is the result of its DNA 
alkylating action, which ultimately depletes cellular energy stores causing β-cell necrosis and 
insulin deficiency (Elsner 2000). It should be noted that STZ does not result in compete 
insulinopenia but does result in severe hyperglycemia.   
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Table 1.1. Rodent models of type 1 diabetes mellitus 
Induction mechanism Model Main features 
 
Elevated GCS 
 
 
Chemical induction 
 
High dose STZ 
Alloxan 
Multiple low dose STZ 
 
Simple model of 
hyperglycemia 
Model of induced insulitis 
 
 
(Selyatitskaya 2008) 
(Zhang 2009a) 
Spontaneous autoimmune 
 
NOD mice 
BB rats 
β-cell destruction due to an 
autoimmune process 
(Fitzpatrick 1992) 
 (Smith, 1991) 
 
Genetically-induced 
 
 
Akita mice 
 
 
β-cell destruction due to ER 
stress 
 
Not yet characterized 
Virally-induced 
 
Coxsackie B virus 
Encephalomyocarditis virus 
Kilham rat virus 
 
β-cell destruction induced by 
viral infection of β-
cells 
 
Not yet characterized 
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1.2.1.b. Alloxan-induced diabetes  
 Alloxan is a pyrimidine derivative and toxic glucose analogue which selectively inhibits 
glucose-induced insulin secretion by inhibition of glucokinase (Lenzen, 2008). This agent also 
causes the selective destruction of β-cells by preferential accretion (GLUT2) within the β-cell 
and subsequent reactive oxygen species (ROS) generation (Lenzen, 2008). Due to its relative 
instability, alloxan has a narrow diabetogenic dose, as even nominal overdosing can cause 
general toxicity within the kidney (Szkudelski, 2001). The toxicity of alloxan occurs through a 
redox cycle that is initiated by its reduction to dialuric acid, and subsequent re-oxidation back to 
alloxan. This redox cycling generates the formation of superoxide radicals that undergo 
dismutation creating hydrogen peroxide and later reactive hydroxyl radicals that cause beta cell 
DNA fragmentation (Oberley, 1988; Szkudelski, 2001).  
1.2.2. Spontaneous autoimmune models of type 1 diabetes 
 Autoimmunity is a multifaceted process with pathogenic mechanisms resulting from 
genetic predisposition and environmental modulation (Filippi 2005). As previously mentioned 
T1DM is a result of the destruction of the insulin-producing beta cells and is associated with 
infiltration of these cells by macrophages, dendritic cells and T and B cells (Giarratana, 2007). 
The spontaneously diabetic nonobese diabetic (NOD) mouse strain is the model of choice when 
studying the relationship between autoimmunity and T1DM, as its diabetes shares some of these 
characteristic autoimmune responses with human T1DM. The Biobreeding (BB) diabetic prone 
(BBDP) rat is the other commonly used autoimmune model of T1DM, which spontaneously 
develops hyperglycemia and ketoacidocis, characteristic of clinical T1DM (Mordes, 2004).   
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1.2.2.a. Nonobese diabetic mouse model 
 The NOD mouse was first developed in Osaka, Japan (Hanafusa 1994). Typically, these 
mice develop  insulinitis and an associated infiltration of CD4+ and CD8+ lymphocytes, with the 
presence of B cells and natural killer (NK) cells, into the pancreatic β-cells around 3-6 weeks of 
age (Kim 2010). This insulitis is what causes β-cell destruction and severely limited insulin 
production around 10-14 weeks of age, resulting in weight loss and insulin therapy. Overt 
diabetes can develop up to 30 weeks of age and is more prevalent in females than males 
(Hanafusa, 1994; Pozzilli 1993). These mice also require fastidious housing to maintain the 
diabetic phenotype and must be kept in a specific pathogen-free (SPF) environment (King, 
2012). While there are similarities to human T1DM, one factor that is inconsistent is the time 
point of intervention. A number of drugs that have been found to be effective in ameliorating 
hyperglycemia in the NOD mouse are ineffective when translated to humans (Von Herrath 
2009), suggesting the autoimmune process in human disease is more complex than in this rodent 
model.   
1.2.2.b. Biobreeding rat model 
 The BB rat was derived accidentally from outbred Wistar rats, and spontaneous diabetes 
was first identified in a Canadian colony. This lead to the creation of two founding colonies, 
from which all substrains are derived, one inbred (BBDP/Wor) and one outbred (BBDP) 
(Mordes, 2004). The development of diabetes occurs later in these animals, after puberty from 8-
16 weeks of age, and is also the result of insulitis with infiltration of macrophages, T, B and NK 
cells. The animals are also lymphopenic with significant reduction in CD4+ cells and an absence 
of CD8+ cells, which is not characteristic of human T1DM (Mordes, 2004). Nonetheless, these 
animals have been deemed helpful in clarifying the genetics of the disease (Wallis 2009), and 
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have been used for numerous intervention studies (Hartoft-Nielsen 2009) and the study of 
diabetic complications such as neuropathy (Zhang 2007). 
1.2.3. Other models of type 1 diabetes 
 One of the most basic ways of studying the effects of hyperglycemia in animals is to 
partially or completely remove the pancreas, termed a pancreatectomy. This surgery can be 
performed on both mice and rats, in addition to other animals such as pigs (Mellert 1998; Morel 
1991), dogs (Fisher 2001) and primates (He 2011). While the reliability of hyperglycemia 
induction is quite high, it is a very invasive method which can increase the possibility of 
hypoglycemia and pancreatic exocrine insufficiency (He, 2011). Finally, viruses have been 
implicated in the pathogenesis of T1DM (Van Der Werf 2007) which has led to the utilization of 
viruses to induce β-cell destruction. Beta-cell death can be induced through direct infection or 
initiation of an autoimmune response against the β-cell (Jun 2003). The viruses used to induce 
diabetes in animal models are the coxsacki B virus (Jaidane 2009), Kilham rat virus (Ellerman 
1996) and encephalomyocarditis virus (Shimada 2004). Using a virus model is complicated by 
the fact that the induction of diabetes is dependent on the replication of the virus in addition to 
the timing of the infection, and while a limited number of human T1DM cases have been linked 
to a single virus (Richardson 2009; Van Der Werf, 2007), the degree of the involvement of 
viruses in the pathogenesis of T1DM remains uncertain. 
1.3 Animal models of type 2 diabetes  
 T2DM is typically characterized by peripheral insulin resistance, hyperinsulinemia and 
subsequent β-cell dysfunction (with or without a decrease in β-cell mass) and as such, insulin 
levels and glycemic control can be quite varied, ultimately depending on the phase of the disease 
and the compensation of hyperinsulinemia to improve high glucose levels. Another added 
 9 
variable is that a large number of T2DM patients are not obese and can experience a reduced 
insulin secretion and less insulin resistance than the obese phenotype (Chatizigeorgiou 2009). 
Despite genetic predisposition, the risk of developing T2DM in humans increases with age, 
obesity, cardiovascular disease and a lack of physical activity (Cheng 2013; Meigs 2003). T2DM 
can manifest as multiple clinical and pathophysiological conditions, as there are a number of 
environmental factors and various genetic effects linked to its development (Chatizigeorgiou, 
2009). To account for the individual differences in T2DM expression, animal models of T2DM 
must be capable of generating different degrees of both β-cell failure and insulin resistance, in 
addition to varying environmental and genetic triggers (Table 2). 
 
 
 
 10 
Table 1.2. Rodent models of type 2 diabetes mellitus 
Induction mechanism Model Main features 
 
Elevated GCS 
 
 
Obese models 
 
Lepob/ob mouse 
Leptdb/db mouse 
ZDF rat 
KK mice 
NZO mice 
OLETF rat 
 
 
 
Obesity-induced 
hyperglycemia 
 
 
 
 
(Alberts 2005) 
Not yet characterized 
 (Noguchi 2007) 
Non-obese models 
Cohen diabetic rat 
GK rat 
 
Hyperglycemia induced 
by insufficient β-
cell 
function/mass 
Not yet characterized 
Not yet characterized 
Induced obesity 
Israeli Sand rat 
Spiny mouse 
C57/BL 6J mouse 
Rapid onset diabetes (ROD) 
model 
 
Obesity-induced 
hyperglycemia 
(Amirat 1980) 
(Lamers W.H., 
1986) 
(Alberts, 2005) 
(Shpilberg 2012) 
 
Genetically-induced models of β-cell dysfunction 
 
 
Akita mice 
 
 
Β-cell destruction due to 
ER stress 
 
Not yet characterized 
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1.3.1. Rodent models of type 2 diabetes 
 T2DM is likely a polygenic disease (Mccarthy, 2001) and the use of rodent models 
allows for a versatile approach in understanding the disease, through naturally occurring 
mutations, inbred and genetically engineered rodent models and more specifically in mice, global 
and tissue specific knockouts and transgenics. Like in humans, the phenotype of the rodent 
model also depends on the genetic background, sex and age of the rodent (Neubauer, 2006). 
While the affected genes in the rodent model might not perfectly match human disease, the 
increased propensity to develop diabetes based on a specific background is likely similar.  
1.3.1.a. Obese rodent models of spontaneous type 2 diabetes 
 T2DM is well-known to be tightly connected to obesity, and there are a number of obese 
rodent models commonly used to further understand this association. Among the most widely 
studied models for T2DM are the ob/ob (obese) and db/db (diabetic) mice and the Zucker (fa/fa) 
rat. These models have mutations in leptin signaling (gene: ob/ob, and receptor: db/db, fa/fa), 
which is a hormone that induces satiety, and without functional signaling, these rodents develop 
hyperphagia and severe obesity (Chua 1996). With both mouse models, the expression of obesity 
predisposes these mice to diabetes, evidence which is important when studying the influence of 
obesity on the development of the disease. The db/db mouse typically becomes hyperinsulinemic 
early in life (within 2 weeks of age) followed by obesity by 3-4 weeks of age and hyperglycemia 
at 4-8 weeks of age succeeding  β-cell failure, a similar progression as that seen in human T2DM 
(Bates 2005). The ob/ob mouse becomes hyperinsulinemic around 3-4 weeks of age, although 
the associated hyperglycemia is more mild than the db/db model, and is coupled with 
hyperphagia and insulin resistance (Folli 1993; Saad 1992). The Zucker fatty rat is similar in 
pathophysiology to the db/db mouse model, and is used to replicate human obesity coupled with 
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hyperlipidemia and hypertension (Ramarao, 2007). A mutation in this strain lead to the 
development of the inbred Zucker diabetic fatty (ZDF) rat, of which only the males develop 
severe diabetes around 8 weeks of age as the result of β-cell apoptosis. The reason for diabetes 
protection in the females is unclear.. Combined with the peripheral insulin resistance, the ZDF 
rat becomes hypoinsulinemic and hyperglycemic around 14 weeks of age (Pick 1998).  
 Genetic background, gender and age all play important roles on influencing the 
phenotype of both human and animal diseases, and selected inbreeding, which takes some of 
these variables into consideration, has yielded additional mouse models that correspond with the 
human condition. The KK mouse is moderately obese and hyperleptinaemic, and develops severe 
hyperinsulinemia and insulin resistance in both skeletal muscle and adipose tissue (Clee 2007; 
Reddi 1988). These animals also show signs of diabetic nephropathy (Ikeda, 1994). Additionally, 
there is a derivative of this strain, the KK-Aγ mouse, which was generated by the introduction of 
the yellow obese Aγ gene into the KK strain (Chakraborty 2009). These mice develop obesity 
later in life along with more severe hyperinsulinaemia. The New Zealand Obese (NZO) mouse is 
another polygenic model of obesity, also created through selected breeding. These animals are 
hyperphagic and obese as well as hyperleptinaemic by 9-12 weeks of age (Leiter 2004), as they 
have a defect in leptin transport across the blood-brain barrier (Halaas 1997). Generally, NZO 
mice develop hepatic insulin resistance from an early age which induces impairments in glucose 
tolerance, hyperglycemia and subsequent hyperinsulinemia, all of which progressively worsen 
with age (Haskell 2002).   
 In contrast with both the KK and NZO mice, the Otsuka Long Evans Tokushima Fatty 
(OLETF) rat, while also a model of obesity-induced T2DM, develops a more mild obese 
phenotype and late onset hyperglycemia (~18 weeks of age) (Ramarao, 2007). Diabetes develops 
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in males only, likely via a genetic link, with the general progression of diabetes development 
occurring with beta cell failure over three distinct stages. Cellular infiltration and degeneration of 
the β-cell occurs between 6-20 weeks of age, followed by hyperplasia between 20-40 weeks with 
the final stage causing the islets to become fibrotic and eventually replaced by connective tissue 
(Kawano 1994).  
1.3.1.b. Nonobese rodent models of type 2 diabetes 
 As previously mentioned, not all humans with T2DM are obese, and it is very important 
to also have lean rodent models of the disease. These models usually center on β-cell failure, 
which is the primary impairment responsible for the subsequent development of overt diabetes in 
humans (Weir 2009). The Goto-Kakizaki (GK) rat is generated through the repetitive breeding of 
Wistar rats with the worst glucose tolerance, creating the development of a lean model of T2DM, 
characterized by glucose intolerance and impaired glucose-stimulated insulin secretion (Ohneda 
1993). Interestingly, islet morphology and metabolism can be different between colonies, 
suggesting the hyperglycemia ensues from insulin secretory deficits that are genetically 
determined (Zong-Chao 1998). GK rats are used to study β-cell dysfunction in T2DM (Movassat 
2007; Portha 2009) in addition to multiple diabetic complications associated with T2DM 
(Liepinsh 2009). The nonobese mutant (Akita) mouse is a genetically induced model of β-cell 
dysfunction. These mice contain a spontaneous mutation in the INS2 gene, which is the mouse 
homologue of human preproinsulin (Yoshioka 1997). Insulin dependent diabetes development is 
complemented by hyperglycemia, polydipsia and polyuria, which is usually more severe in males 
than females. The Akita mouse does not develop obesity or insulitis, and has been used mainly 
for β-cell transplantation studies and the study of diabetic retinopathy (Mathews 2002).  
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1.3.1.c. Other models of type 2 diabetes 
 T2DM is not only represented through spontaneous models but also through inducible 
paradigms of the disease, such as diet-induced diabetic models, chemically or surgically induced 
models or transgenic models that are associated with disease development (i.e. hyperglycemia 
and, in some cases, hyperinsulinemia).  
 Human studies have shown that increased fat intake is associated with body weight gain 
which can lead to obesity and other related diseases. High-fat feeding induced diabetes, which 
was established in 1988 (Surwit 1988) using C57BL/6J mice, has become a very popular and 
easily inducible model of T2DM, as rodents readily gain weight when fed high-fat diets (HFD). 
High-fat feeding results in obesity, hyperinsulinemia and impaired glucose homeostasis as the 
consequence of inadequate β-cell compensation (Winzell 2004). The standard rodent diet, on a 
caloric basis, is ~26% protein, 63% carbohydrate and 11% fat and general high-fat diets contain 
~60% of energy derived from fat. Typically, rodents are fed the high-fat diet for several weeks to 
induce a more pronounced weight gain, which is associated with insulin resistance, impaired β-
cell compensation and eventually glucose intolerance. Interestingly, not all rat models develop 
hyperglycemia on a HFD, likely because of insufficient β-cell compensation for the whole body 
insulin resistance (liver, muscle, adipose tissue). The Israeli sand rat is an established diet-
induced diabetic animal model, which becomes obese and diabetic when given a standard 
laboratory chow diet, which is much higher in energy density than its natural diet (Ziv 1999). 
These rats develop hyperphagia, obesity, hyperinsulinemia, increased hepatic glucose 
production, glucose intolerance and peripheral insulin resistance (Cefalu, 2006; Kaiser 2005), in 
addition to a progressive loss of β-cell mass due to increased apoptotic mechanisms (Masiello, 
2006). The sand rat is generally used to study the interaction between obesity and diabetes, the 
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effects of diet and exercise and also for pharmacological research (Kaiser, 2005). The C57BL/6J 
mouse and the spiny mouse are other diet-inducible rodent models (King, 2012), as background 
and strain ultimately work together to determine the susceptibility to diet-induced metabolic 
changes. Inbred C57BL/6J mice demonstrate a heterogeneic response to high-fat feeding, 
suggesting that the different outcomes are not solely genetic (Burcelin 2002). High fat feeding 
can also be used in transgenic or knock-out animals to generate the diabetic phenotype by adding 
further stress to the β-cells. 
 While both alloxan and STZ are potent diabetogenic agents, well known to induce 
T1DM, they have also been used in T2DM development. Alloxan or STZ injection, neonatally or 
immediately after birth in rats, generates adult onset T2DM (Portha 1974; Weir 1981). Of course 
each agent requires a specific dose and time of administration. As these chemicals are toxic to 
the β-cells, diabetes development is accompanied by decreased β-cell mass and subsequent 
impairments to insulin secretion. However, when combined with a genetically insulin resistant 
rodent strain or a high-fat diet, overt hyperglycemia and normal plasma insulin are produced, 
which is much more appropriate for the study of T2DM (Reaven 1991). There are also a number 
of therapeutic agents that can predispose to or precipitate diabetes development, especially in 
combination with pre-existing risk factors. These agents can be weakly diabetogenic, such as 
antihypertensive agents and statins, or more strongly diabetogenic, like steroids, antipsychotics 
and multiple immunosuppressive compounds. 
The rapid onset diabetes (ROD) rodent model was very recently established in the 
Riddell laboratory (Shpilberg, 2012) to examine the collective effect of elevations in stress 
hormones, specifically cortisol, which is a potent diabetogenic stimulus, and high-fat feeding. 
With two weeks of exogenous corticosterone treatment (4x100mg pellets) plus a high fat diet, 
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male Sprague-Dawley rats become severely hyperglycemic, hyperinsulinemic, and insulin 
resistant (Shpilberg, 2012), through the development of hepatic steatosis (D'souza, 2011), 
impaired β-cell function (Beaudry 2013) and increased lipid deposition in both the liver and 
skeletal muscle. The ROD model mimics many of the symptoms observed in patients with 
T2DM, and provides evidence that elevations in GCs induce diabetes development, especially if 
susceptible individuals do not consume a balanced diet. The model is limited; however, in its 
translational application to humans undergoing exogenous GC therapy since the GC levels are 
supraphysiologic/pharmacologic in this model (Shpilberg, 2012). 
 As seen with T1DM animal models, partial removal of the pancreas is another possible 
mechanism for the induction of T2DM, however this method can cause the development of 
moderate hyperglycemia without overt changes in body weight or circulating insulin levels 
(Risbud 2002). In order to induce a more T2DM phenotype, partial pancreatectomies are 
typically combined with the administration of a diabetogenic agent, such as STZ, which is 
sometimes used for the study of transplantation or regeneration factors in T2DM (Risbud, 2002). 
 Finally, many transgenic models have been developed to study the complex and 
polygenic mechanisms involved in the pathogenesis of T2DM. As insulin and insulin growth 
factor-1 (IGF-1) both belong to the growth factor family and play important roles in metabolism 
and growth of almost every mammalian tissue, numerous mouse models of diabetes have 
focused on targeting proteins in the skeletal muscle insulin/IGF-1 signaling pathways. The role 
of genes implicated in muscle insulin resistance (IRS-1, IRS-2, GLUT-4) (Kido 2000; Stenbit 
1997), lipid and glucose metabolism (Evans 2004b) and pancreatic insulin secretion (GLUT-2, 
glucokinase) (Cani 2007) are likely better understood through transgenic or knockout methods. 
However, global knockout models can be limited in their scope, as some genes can vary 
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considerably between tissues, necessitating a tissue-specific approach for some studies. 
Additionally, the organism has the capacity to compensate for the affected gene(s), possibly 
obscuring the precise phenotype, results that have been observed in both IRS-1 and GLUT-4 null 
mice  (Stenbit 1996). 
1.3.2. Nonrodent models of type 2 diabetes 
 Larger animals have also been used to understand the development of T2DM. In fact, the 
development of T2DM in the domestic cat is actually quite similar to the human condition 
(Henson 2006). Typically, diabetes onset occurs later in life and is influenced by similar 
environmental risk factors, such as inactivity and obesity (O'brien, 2002; Panciera 1990) and can 
be associated with diseases, pharmacological agents and hormones that impair peripheral tissue 
insulin sensitivity, such as treatment with corticosteroids or progestins (Rand 2004). 
Interestingly, humans and pigs seem to have comparable gastrointestinal structure and function, 
pancreas morphology and overall metabolic status (Larsen 2004), and several strains of pigs have 
a phenotype that resembles human T2DM (Bellinger 2006). obviously, primates are the most 
analogous animal model for humans, and T2DM in primates is common with obesity and with 
advanced age (Wagner 2001; Wagner 2006).  
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Effects of diabetes on skeletal muscle  
This thesis focuses primarily on the effects of diabetes on skeletal muscle and as such an 
overview of the effects of the disease on this tissue is warranted here. 
2.1. Overview of peripheral effects of diabetes 
 The ability to maintain normal blood glucose levels involves complex interaction 
between insulin secretion by pancreatic β-cells and insulin metabolic responsiveness in skeletal 
muscle, liver, adipose and other tissues. Insulin facilitates the uptake of glucose into the cell in 
addition to promoting storage through the stimulation of glycogen synthase (muscle and liver) 
and triglyceride production and suppression of lipolysis and proteolysis. Without insulin, the 
metabolic process is disturbed and a catabolic state is created. Skeletal muscle is particularly 
important in the maintenance of glucose homeostasis as it comprises ~40-50% of body mass and 
mediates over 75% of all insulin-mediated glucose disposal under normal physiologic conditions 
(Stump 2006).  
2.2. Skeletal muscle insulin resistance  
 Insulin resistance, which is an impaired response of insulin-sensitive tissues to insulin, is 
a characteristic feature of T2DM and plays a key role in the pathogenesis of the disease 
(Defronzo, 2004; Defronzo 2009). While β-cell failure is the final outcome in the development of 
overt diabetes, skeletal muscle insulin resistance is typically observed prior to hyperglycemia 
and β-cell exhaustion, and is considered the primary defect in T2DM development (Lillioja 
1988; Warram 1990). Systemic insulin sensitivity, under postprandial conditions, is mostly 
driven by skeletal muscle insulin sensitivity (Kelley 2001). As observed during physiological 
hyperinsulinemia (80-100uU/ml), there is an increase in leg muscle glucose uptake, which 
increases in a linear fashion, ultimately reaching a plateau after ~60 minutes (Defronzo 1981). 
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When examined in lean T2DM patients, the ability of insulin to maximally stimulate glucose 
uptake is attenuated (~50%) as the onset of insulin action is delayed. It has also been established 
that physiologic elevations in insulin concentrations over a period of 72 hours, in healthy 
subjects, can induce reductions to insulin-stimulated muscle glycogen synthase activity, total 
body glucose uptake and nonoxidative glucose disposal (which primarily reflects muscle 
glycogen synthesis) (Defronzo, 2009). Moreover, chronic hyperinsulinemia in conscious rats for 
7 days decreases insulin-stimulated total body glucose uptake, glucose storage and glycolysis 
and fails to promote the normal suppression of hepatic glucose production (Koopmans 1999; 
Koopmans 1997). These findings suggest that, since the majority of glucose disposal occurs in 
skeletal muscle, even physiologic elevations in insulin concentrations can aggravate any 
underlying muscle insulin resistance. Or in other words, hyperinsulinemia may actually promote 
a further worsening of insulin sensitivity in diabetes, thereby promoting a vicious cycle that 
places an unrelenting demand on pancreatic β-cell function. 
2.3. Skeletal muscle insulin signaling 
 The initial step in skeletal muscle glucose metabolism involves activation of the glucose 
transport system, which allows an influx of glucose into insulin target tissues. In both skeletal 
muscle and adipose tissue, insulin stimulates glucose transport into the cells through the 
activation of a complex signaling cascade. Integral to the mechanism of insulin signaling and 
action is the insulin receptor, which is expressed in insulin-responsive tissues, like the liver, 
adipose, β-cells and skeletal muscle, in addition to sites of diabetic complications. Mice with a 
global insulin receptor deletion show no obvious impairments at birth, however, develop early 
postnatal diabetes (Kitamura 2003). While tissue-specific deletion of the insulin receptor in 
pancreatic β-cells causes insulin secretion impairments comparable to what is observed in human 
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T2DM (Kulkarni 1999), deletion within skeletal muscle does not cause the development of 
hyperglycemia or overt diabetes (Brüning 1998). This result is likely due to both normal 
functioning of the insulin receptor in other insulin-sensitive tissues, and adaptive glucose uptake 
in peripheral organs mediated by glucose transporter (GLUT4) upregulation (Higaki 1999).  
 Once insulin binds to the insulin receptor, found in muscle, liver and adipose tissue, 
tyrosine phosphorylation of the insulin receptor is initiated, which causes movement of the 
insulin receptor substrate (IRS)-1 to the cell membrane. Tyrosine phosphorylation of IRS-1 
causes an activation of the p85 regulatory subunit of phosphatidylinositol (PI)-3 kinase (PI3K) 
which activates the p110 catalytic subunit, increasing phosphatidylinositol-3,4,5 triphosphate. 
Abnormalities of IRS proteins or within second messengers, such as PI3K, can affect docking 
and subsequent downstream insulin signaling . The interaction of PI3K with the IRS proteins 
ultimately regulates cellular glucose uptake through a series of phosphorylation events (Gual 
2005) and dysregulation of this interaction has been established as an important event in the 
development of the progressive defects in insulin secretion, insulin resistance and eventually 
overt T2DM development (Dominguez 2011). The resulting activation of protein kinase B (Akt) 
and phosphorylation of Akt substrate 160 (AS160), facilitates the translocation of GLUT4, an 
insulin-responsive glucose transporter, to the sarcolemma, which allows glucose to enter the cell 
(Taniguchi 2006). Changes in GLUT4 expression can occur in patients with vascular 
complications from diabetes mellitus, and decreased GLUT4 expression specifically, has been 
associated with impaired insulin receptor signaling (Friedman 1992). Furthermore, mice with a 
heterozygous deletion of the gene that encodes GLUT4 develop insulin resistance and T2DM 
(Stenbit, 1996), while skeletal muscle biopsies from T2DM patients show impaired intracellular 
GLUT4 translocation to the cell membrane (Kennedy 1999). Upon entry into the cell, glucose is 
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rapidly phosphorylated by hexokinase II to glucose-6-phosphate and shuttled to oxidative or non-
oxidative pathways. As skeletal muscle is the predominant site of glycogen synthesis under 
physiologic conditions, almost two-thirds of all glucose-6-phosphate is converted to glycogen, 
while one-third enters glycolysis. Maintenance of the IRS-1/PI-3 kinase/Akt pathway is essential 
for normal, insulin-mediated glucose uptake within the skeletal muscle. 
2.4. Mitochondrial oxidative phosphorylation  
 Mitochondria play a very important role in energy metabolism and ATP production in a 
number of tissues, including skeletal muscle, cardiac muscle, brain and liver. ATP generation 
occurs through tricarboxylic (TCA) cycle activity and the associated electron transport chain 
(ETC) of the inner mitochondrial membrane. Once the reducing equivalents (NADH and 
FADH2) are produced, they are reoxidized via a process that involves the transfer of electrons 
through the ETC and associated translocation of protons across the inner membrane, ultimately 
creating the transmembrane electrochemical gradient. The electrochemical potential from this 
gradient generates ATP from ADP and Pi, through proton movement back through the ATP 
synthase complex. Under normal conditions, this proton gradient is also reduced by H+ 'leak' to 
the matrix, which occurs via non-protein membrane pores, protein/lipid interfaces (H+ leak) or 
though proton channels called uncoupling proteins (UCPs) (Newsholme 2012). Howwever, 
during normal oxidative phosphorylation, mitochondria can produce considerable reactive 
oxygen species (ROS) and reactive nitrogen species such as superoxide anions (O2-), 
peroxynitrite and other reactive species which are very powerful chemical oxidants (Turrens, 
2003). To manage the potentially toxic levels of reactive species, cells require antioxidant 
systems to neutralize ROS. Enzymes such as manganese-superoxide dismutase (MnSOD), 
glutathione (GSH) and catalase are key antioxidants responsible for accepting unpaired electrons 
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to produce a stable product (Evans 2002; Evans 2004a). Although cells possess these different 
antioxidant systems, it is still possible for ROS to elude these defence mechanisms, resulting in a 
slow accumulation of chronic damage as the antioxidant network and repair systems become 
overwhelmed (Maiese 2007). 
2.4.1. Fatty acid-induced mitochondrial dysfunction 
 Obesity is commonly associated with insulin resistance and T2DM development, and one 
of the most harmful effects of obesity is lipid deposition in non-adipose tissues such as skeletal 
muscle, cardiac muscle and liver. It has been suggested that the accumulation of lipids within 
skeletal muscle can directly interfere with insulin signaling, possibly contributing to the 
generation of insulin resistance. In agreement with this hypothesis is the strong association 
observed between lipid accumulation in the skeletal muscle (and liver) and insulin resistance in 
men (Mcgarry, 2002). There is also an established association between elevations in IMCL 
levels and muscular insulin resistance in T2DM patients (Goodpaster, 2004) and in high-risk 
non-diabetic patients with a family history of diabetes (Perseghin 2003). However, elevations in 
IMCL accumulation do not automatically cause insulin resistance, as high levels of IMCL can 
also be present in skeletal muscle from endurance-trained athletes, who are very insulin-sensitive 
(Goodpaster 2001b). The general concept is that elevations in lipid accumulation can become 
harmful when an increase in the availability or supply of lipids to the skeletal muscle is not 
compensated for through increased oxidative pathways, which results in the generation of toxic 
intermediates like ceramides and diacylglycerol (DAG), which then accumulate within the cell 
and subsequently interfere with the insulin signaling machinery (Shulman, 2000). Controversy 
remains as to how excess ROS production contributes to the induction of diabetes mellitus, 
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especially since there is data demonstrating that ROS signaling is actually required for normal 
insulin secretion  (Macmillan-Crow 2001).  
 Excessive levels of ROS can damage cells by oxidizing DNA, protein and lipids as well 
as indirectly damaging cells through activation of a number of stress-sensitive intracellular 
signaling pathways such as NF-kB, p38 MAPK, JNK/SAPK and others. Stimulation of these 
pathways causes an increase in expression of various gene products that can cause cellular 
damage and have been established in the etiology of diabetic complications (Newsholme, 2012).   
 Mitochondria are the primary organelles that oxidize fatty acids, and there is evidence 
showing that fat oxidation is reduced in both T2DM patients and obese insulin-resistant 
nondiabetic individuals (Kelley, 2005), which suggests that skeletal muscle mitochondrial 
oxidative capacity is impaired. Evidence also shows that short-term increases in FFA, at fasting 
insulin levels, can induce insulin resistance in skeletal muscle, but does not impair mitochondrial 
activity (Chavez 2010), and highlights that physiological insulin resistance, in association with 
prolonged fasting, does not involve irregular mitochondrial activity. Additional data has 
demonstrated a reduction in the expression of key mitochondrial genes involved in the regulation 
of oxidative metabolism in the skeletal muscle of children of T2DM parents (Mootha 2003). 
Mitochondria isolated from the myotubes of T2DM patients demonstrate reduced ATP 
production when compared to lean controls (Minet 2010). Also, impaired TCA cycle flux has 
been shown in both insulin resistant offspring of T2DM patients (Befroy 2007) and exercising 
T2DM patients in vivo (Schrauwen and Hesselink 2008). Mitochondria, isolated from skeletal 
muscle biopsies of insulin-resistant individuals, was found to have reduced levels of mRNA for 
certain mitochondrial genes (Mootha, 2003) and lower protein expression of respiratory chain 
subunits (Heilbronn 2007).   
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2.5. Inflammatory signaling within the skeletal muscle  
Expansion of adipose tissue as a consequence of a sedentary lifestyle and excess energy 
intake can also result in a local inflammatory response in the visceral adipose tissue, infiltration 
of immune cells and local and systemic increases in proinflammatory cytokines and adipokines 
(Eckardt 2014). Thus, obesity, which is considered the most common cause of insulin resistance 
and T2DM are associated with chronic low-grade, systemic tissue inflammation (Lumeng 2011; 
Olefsky 2010). In obesity, there is an established increase in M1-like-macrophages, adipose 
tissue macrophages that exert potent proinflammatory signals, and secrete a number of different 
cytokines including tumor necrosis factor a (TNFa), interleukin-1b (IL-1b) and others. These 
cytokines then act through both paracrine mechanisms, to directly inhibit insulin action in target 
cells, like skeletal muscle myocytes (Fève 2009), and endocrine mechanisms through activation 
of stress kinases including S6K, IKKb, JNK1 and PKCF, which subsequently phosphorylate 
IRS1 on the inhibitory serine residues, impairing downstream insulin action (Hotamisligil, 2006). 
Inhibition of insulin action by cytokines can also occur through transcriptional mechanisms, 
ultimately reducing the expression of certain insulin signaling proteins, in addition to enhanced 
ceramide formation, which directly inhibits Akt activation (Holland 2011).  
There is clearly a close relationship between chronic inflammation, fatty acid metabolism 
and insulin resistance within the skeletal muscle in T2DM (De Luca, 2008). Biopsies from 
T2DM patients show evidence of infiltration of inflammatory cells into the skeletal muscle as the 
result of chronic inflammation in addition to elevations in inflammatory molecules/cytokines, 
including TNFa, IL-6, CRP and others (Marette, 2002). Additionally, skeletal muscle is capable 
of producing and secreting several inflammatory myokines, including a number of interleukins 
(IL-6, IL-8, IL-15) and TNFa, usually as the result of contraction (Bruunsgaard, 2005; Pedersen 
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2007). The effect of these contraction-mediated myokines on diabetic development is unclear, 
however, especially since regular exercise itself is protective against diabetes development (see 
section 2.6 below). However, skeletal muscles also possess a number of other immune system 
components, like cytokine receptors and TLRs (Lang 2003) which makes them a key 
immunomodulatory tissue.  
2.6. Exercise and diabetes; skeletal muscle effects 
 Regular physical activity, both endurance and resistance exercise, has numerous health 
benefits for healthy individuals and patients living with diabetes. More effective than 
pharmacologic agents, regular physical activity can reduce T2DM development in humans at risk 
for the disease by as mush as 68% (Group, 2002). The health benefits of regular exercise include 
improved cardiovascular function, insulin sensitivity, muscle metabolism, body weight and lipid 
profile (Myers, 2003; Santos 2012) among numerous other physiological and psychological 
adaptations. As maintenance of daily euglycemia and lipid content are important areas of 
treatment in T2DM, exercise has proven to be a vital therapy as studies suggest that exercise 
could diminish the intake of high caloric foods, which would subsequently improve the 
metabolic profile (Benite‐Ribeiro 2014) in addition to the fact that skeletal muscle contraction 
can improve glucose uptake independent of insulin stimulation. In contrast to the effects of 
insulin on stimulating skeletal muscle glucose disposal, exercise and contraction have no effect 
on tyrosine phosphorylation of IR and IRS-1, or PI3K activity (Goodyear 1995), and 
pharmacological inhibition of PI3K activity with wortmannin does not inhibit glucose transport 
in isolated rat muscles contracted in vitro (Hayashi 1998). Additionally, exercise is capable of 
increasing the activity of the insulin receptor and IRS proteins within the skeletal muscle, which 
further enhances the cellular uptake of glucose at rest (Christ-Roberts 2003). These results prove 
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that there are different signals leading to glucose transport by insulin and exercise in skeletal 
muscle which, either through individual or additive means, allow skeletal muscle contraction to 
ultimately override any established insulin resistance, causing increased glucose uptake and 
improved hyperglycemia. 
Elevated insulin-independent glucose uptake during exercise is mostly reversed ~2–3 h 
postexercise, whereas enhanced skeletal muscle and whole body insulin sensitivity can persist 
for up to 24 – 48 h postexercise (Cartee 1990; Perseghin  1996). This substantially elevated 
skeletal muscle insulin-stimulated glucose uptake after acute exercise was first identified by 
Richter et al. (Richter 1982) using the perfused hindlimb model. This response was confirmed 
using in the euglycemic hyperinsulinemic clamp in humans (Mikines 1988; Sharoff 2010). 
Additional work established that prior exercise can directly regulate subsequent insulin-
stimulated glucose transport in isolated muscles, and it is possible that prior exercise can also 
influence other processes that enhance in vivo glucose uptake, including elevated muscle blood 
flow and hexokinase activity (Fueger 2005; Richter 2013). More recent findings have examined 
the effects of an acute bout of exercise within insulin-resistant individuals and determined that a 
single bout of exercise can increase insulin-stimulated glucose uptake in insulin-resistant 
individuals (Perseghin 1996; Sharoff, 2010). However, when both insulin-resistant and healthy 
groups complete similar exercise protocols, exercise is consistently unable to equalize insulin-
stimulated glucose uptake between groups (Castorena 2014; Pehmøller 2012). 
 Contractile activity also changes the fuel status of the skeletal muscle, causing varied 
decreases in both phosphocreatine and ATP levels, which can subsequently stimulate the AMP-
activated protein kinase (AMPK) signaling pathway. AMPK is considered the master regulator 
of cellular energy homeostasis and can be activated in situations where cellular ATP 
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concentrations are depleted such as low cellular glucose availability, hypoxia and ischaemia 
(Winder 2000). In skeletal muscle, AMPK activation stimulates glucose uptake, fatty acid 
oxidation, GLUT4 translocation and mitochondrial biogenesis, while inhibiting protein and 
glycogen synthesis (Coughlan 2013), ultimately improving insulin sensitivity and glucose 
homeostasis, which makes it a possible target for therapeutic intervention in T2DM.  
Regular exercise can also reduce inflammation as there is a strong inverse relationship 
between the level of physical activity and systemic low-grade inflammation (King 2003). As 
mentioned, regular physical activity leads to reductions in body weight and visceral adiposity, 
which is a key source of proinflammatory cytokines, and could be  the reason behind reductions 
in C-reactive protein (Stewart 2007) and Toll-like receptor (TLR) expression (TLR2 and 4) in 
immune cells and skeletal muscle following long-term exercise. Additional benefits of exercise 
encompass the exercise-induced release of adrenaline (epinephrine), cortisol and other factors, 
like myokines, that have immunomodulatory effects ultimately acting on immune system 
function (Gleeson 2011).  
The skeletal muscle is now identified as a secretory organ, able to synthesize and release 
proteins, termed myokines, capable of communicating systemically or locally within the muscle 
(Pedersen, 2011). Contraction stimulates the muscles' release of various myokines, including IL-
6, IL-8 and IL-15 (Broholm, 2010), which have been suggested to mediate the acute and chronic 
adaptations induced with exercise. Muscle-derived IL-6 was the first identified myokine 
(Hiscock, 2004; Steensberg 2000), and is established as having the ability to affect other organs 
like the liver, brain and adipose tissue, as well as acting on muscle itself, as IL-6 induces glucose 
uptake (Saini 2014) and fatty acid β-oxidation (Pedersen, 2012) in muscle and can stimulate 
hepatic gluconeogenesis and lipolysis in adipose tissue. The plasma concentrations of the other 
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contraction induced myokines, IL-8 and IL-15 do not seem to increase proportionally to exercise 
(Broholm 2008; Nielsen 2007), suggesting that these factors may actually exert their actions 
locally. IL-15 is thought to be involved in muscle-adipose crosstalk (Pedersen 2008), while high 
concentrations of IL-8 might be involved in exercise-induced angiogenesis and capillarization 
(Pedersen, 2008). Enhanced glucose availability has been shown to attenuate IL-6 plasma 
concentrations after exercise, suggesting that fitness level can regulate IL-6 secretion (Pederson, 
2005 ) similar to what is observed with cortisol after exercise training. Additionally, elevated 
levels of IL-6 have also been suggested to exert a protective effect on individuals with low levels 
of chronic inflammation, as myokines could mediate the suppression of proinflammatory signals 
at both the level of the skeletal muscle and peripheral tissues, like the liver (Bruunsgaard, 2005).  
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Glucocorticoids and diabetes; effects within skeletal muscle 
3.1. Glucocorticoids, obesity and diabetes development 
 Glucocorticoids (GCs) are endogenous, steroid hormones responsible for mediating 
crucial and adaptive responses to stress. There is significant evidence that the 
glucocorticoid/glucocorticoid receptor (GC/GR) axis plays a critical role in maintaining overall 
glucose homeostasis, as maintenance of systemic carbohydrate metabolism requires complex 
regulation between various peripheral organs in addition to the central nervous system.  It has 
been suggested that subtle alterations in both cortisol secretion and tissue-specific action is a 
possible link between insulin resistance, the metabolic syndrome and T2DM development 
(Björntorp 1999). Endogenous overproduction or exogenous elevations (Di Dalmazi 2012) in 
cortisol are associated with metabolic disturbances resulting in abdominal obesity, insulin 
resistance, β-cell dysfunction, hepatic steatosis, all of which can lead to T2DM development 
(Hwang 2014) (Figure 1). Typically, these effects are not the result of elevations in circulating 
GCs alone, as some studies have found cortisol concentrations to be near normal in obese 
patients (Hautanen 1997). There is data showing increased responsiveness of the hypothalamic-
pituitary-adrenal (HPA) axis, which is responsible for the secretion of GCs, to different stimuli, 
like food intake (Korbonits 1996), in patients with abdominal obesity, establishing a possible 
attenuation of negative feedback within the HPA axis (Pasquali 2002) subsequently affecting the 
diurnal secretion pattern of cortisol. A positive relationship in overweight/obese women between 
urinary free cortisol concentrations, waist circumference and caloric intake, when compared to 
normal women (Vicennati 2011) has been found. Additionally, increased adiposity itself has the 
capacity to alter cortisol concentrations as it contains the enzyme 11β-hydroxysteroid 
dehydrogenase (11β-HSD1), which converts inactive cortisone to active cortisol, and is 
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subsequently increased in conjunction with increases in abdominal obesity (Bujalska 1997). 
Elevations in 11β-HSD1 activity have also been found within the skeletal muscle (Zhang 2009b), 
suggesting the importance of understanding the regulation of GC action  
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Figure 1.1. Pathophysiology of diabetes development.  
The development of overt diabetes occurs through a number of mechanisms, all of which work 
together to affect elevations in blood glucose ultimately causing hyperglycemia. Glucocorticoids 
(GC), free fatty acids (FFA), diacylglycerol (DAG). 
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at the tissue level. As mentioned above, a new model of GC-induced diabetes has been 
developed (Shpilberg, 2012), but the effects of regular exercise in this mode are only now being 
investigated, as part of this thesis. As such, additional background on glucocorticoid metabolism 
is provided below in this thesis introduction. 
3.2. Glucocorticoid synthesis and secretion 
GCs are secreted by the adrenal cortex and their regulation is controlled by a 
neuroendocrine feedback system, the HPA axis (Stranahan 2008). Activation of the HPA axis 
occurs with the secretion of corticotrophin-releasing hormone (CRH) which stimulates the 
release of adrenocorticotropic hormone (ACTH) and initiates the synthesis and subsequent 
release of GCs from the adrenal cortex (Rose 2010). Cortisol is the predominant GC released in 
humans, while in rodents it is termed corticosterone, and its release is pulsatile and follows a 
circadian rhythm that is sensitive to light, sleep, stress and disease. Cortisol levels are highest 
during the early waking hours, and as the afternoon progresses, levels tend to decline; the normal 
range of cortisol in healthy humans is 60-230ng/ml (Chung 2011). Endogenous, hyper-secretion 
of GCs, the result of a benign pituitary or adrenal tumor, causes Cushing’s disease and is 
characterized by visceral adiposity, hyperglycemia and peripheral muscle wasting (Juszczak 
2013). In addition to endogenous cases, chronic pharmacological administration of synthetic GC 
analogs can also generate negative side effects which mirror the clinical pathology observed in 
patients with endogenous overproduction of GCs, termed Cushings syndrome. As steroid 
hormones, GCs are lipophilic and usually bound to carrier proteins (cortisol-binding globulin and 
albumin) (Chung, 2011). Up to 10% of total plasma cortisol circulates unbound and is considered 
the free fraction, which constitutes biologically active cortisol (Chung, 2011). Localized tissue 
metabolism contributes to the variation of physiological actions of GCs through the isoforms of 
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the enzyme 11β-HSD, which are responsible for regulating the active to inactive concentrations 
of cortisol. 11β-HSD type 1 (11β-HSD1) converts cortisone to its active form, cortisol, and is 
predominately expressed in liver and adipose tissue (Cooper 2009). Converting active cortisol to 
inactive cortisone occurs primarily in the kidney and is mediated by 11β-HSD type 2 (11β-
HSD2). In a classic negative feedback loop, GCs act on the hypothalamus and pituitary to turn 
off neuroendocrine activity, restoring a steady state (Stratakis, 1995). In contrast to cortisol, 
synthetic GCs do not bind to CBG and are not classically metabolized by the IIβ-HSD2 isoform, 
which ultimately deactivates active cortisol to inactive cortisone (Oakley 2013).   
3.3. Glucocorticoid signalling and the glucocorticoid receptor 
 The majority of the multi-systemic, physiological effects of GCs are mediated through 
cell-specific actions of the intracellular glucocorticoid receptor II (GR), a ligand-induced 
transcription factor belonging to the nuclear transcription superfamily (Rose, 2010) (Figure 2). 
Virtually all cells express the GR, and GR knockout mice do not survive (Rose, 2010) which 
further highlights the ubiquitous actions that GCs have throughout the body. The GR consists of 
two isoforms, GRα and GRβ, GRα is the subunit that binds active cortisol and translocates to the 
nucleus, while GRβ is expressed in lower levels and exerts a negative effect on GRα (Lee 2013). 
Active cortisol passively diffuses into the cell and binds to the cytosolic, intracellular GR 
complex, made up of the receptor, two molecules of hsp90 and some additional proteins (Oakley, 
1996). Binding stimulates a conformational change, dissociating hsp90 and the associated 
proteins, and the new complex translocates into the nucleus where it can up- or down-regulate 
the expression of target genes (Kumar 2005). Once inside, the first mode of transcriptional 
regulation is through the binding of the liganded and dimerized GR to glucocorticoid response 
elements (GREs), found in the promoter regions of target genes (Oakley, 1996). Binding of the 
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GR to GREs increases chromatin remodelling and the rate of gene transcription through histone 
acetyltransferase activity from recruited coactivators, and is termed transactivation. Various 
transactivated genes have been associated with adipogenesis, muscle wasting and hyperglycemia, 
which are some side effects of GC treatment (Tomlinson 2006; Van Raalte 2009).  
 The second mode of transcriptional regulation is independent of GR dimerization and 
DNA binding, termed transrepression. Transrepression involves the interference of the GR 
monomer with other transcription factors. Transrepression of the proinflammatory transcription 
factors activator protein-1 (AP-1) and nuclear factor-B (NF-kB), for example, causes inhibition 
of the inflammatory signalling cascade and is considered a primary mechanism of the anti-
inflammatory actions of GCs (Busillo 2013; Van Raalte, 2009). 
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Figure 1.2. Molecular mechanisms of glucocorticoid receptor action. 
GCs regulate proteins through both genomic and non-genomic actions. Transactivation, or 
positive gene regulation, is mediated by binding of a ligand-activated glucocorticoid receptor 
(GR) to a GRE (GC response element). The ligand-activated GR can also bind to negative GREs 
resulting in repression of gene transcription. Inhibition of target genes can also occur through 
interaction of GCs with other transcription factors through protein-protein interactions, termed 
transrepression. (adapted from van Raalte et al. 2009). 
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3.4. Glucocorticoid effects on skeletal muscle 
 As previously mentioned, skeletal muscle is responsible for ~80% of postprandial 
glucose uptake from the circulation (Van Raalte, 2009), contains the body’s largest glycogen 
stores, and is essential for optimal glucose metabolism. Skeletal muscle glucose uptake is reliant 
on insulin secretion, and is therefore termed insulin-stimulated glucose uptake (ISGU). 
Impairments in ISGU have been observed after GC exposure (Buren 2008; Dimitriadis, 1997) 
and highlight the significant effect that GCs can have on metabolism. GCs can affect ISGU 
directly, by causing insulin resistance via inhibition of insulin signalling proteins (Ruzzin 2005; 
Weinstein, 1998) or indirectly through effects on both fat (Elks, 1990) and protein metabolism 
(Krebs, 2002) (Figure 3).  
3.4.1. Glucocorticoids and skeletal muscle insulin signaling 
 Elevated GCs have been shown to induce skeletal muscle insulin resistance, ultimately 
suppressing glucose uptake, primarily through the inhibition of GLUT4 translocation to the cell 
membrane (Weinstein, 1998). GC treatment can also impair glycogen synthesis through 
suppressed glycogen synthase activity (Buren, 2008; Dimitriadis, 1997; Weinstein, 1998), which 
suggests that abnormal activation of GC signaling within skeletal muscle may explain a part of 
dysfunctional glucose metabolism in the insulin resistant and/or diabetic state. This is especially 
true as GR mRNA levels in the skeletal muscle of diabetic patients correlate with the degree of 
insulin resistance, with a normalisation of GR expression following treatment to improve insulin 
sensitivity (Whorwood 2002).   
 Previous research has established that treatment of rats with dexamethasone (Dex), a GR 
agonist, causes a reduction in IR phosphorylation within skeletal muscle (Giorgino 1993) and 
subsequent inhibition of Akt phosphorylation/activity in both rat muscles after insulin 
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administration (Long 2003) and cultured C2C12 myotubes (Sandri 2004). Chronic elevations in 
GCs have also been found to induce both a decrease in IRS-1 protein content, responsible for 
transmitting signals from both insulin and insulin like growth factor-1 (IGF-1) through the 
activation of the PI3K and MAP kinase pathways, and decreased tyrosine phosphorylation of 
IRS-1 (Brown 2007; Girogino, 1993). GCs can also induce a reduction of PI3K activity (Saad, 
1993), as the GR seems to compete with IRS-1 for association of PI3K subunits p110 and p85, 
which, when they are associated with the GR, causes a reduction in IRS-1 associated PI3K 
activity and subsequent Akt phosphorylation at both serine and threonine sites (Buren, 2008; 
Buren, 2002). The down-regulated Akt activity can affect GLUT4 translocation (Weinstein, 
1998), glycogen synthesis and the muscle growth pathway, through decreased mammalian target 
of rapamycin (mTOR) activity ultimately decreasing protein synthesis and increasing protein 
degradation. 
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Figure 1.3. Glucocorticoid and intramuscular lipid-induced effects on skeletal muscle. 
Insulin stimulates glucose uptake in skeletal muscle cells by mobilizing glucose transporter 
(GLUT4) receptors to the surface of the cell membrane. Once bound to the insulin receptor, 
insulin initiates GLUT4 translocation through activation of a cascade of cytosolic proteins: 
insulin receptor-1(IRS-1), PI3-K and Akt/protein kinase B although the entire pathway is not 
completely understood. Once glucose is transported across the membrane, it can be used for 
glycogen synthesis. Insulin inhibits glycogen synthase kinase (GSK)-3, an in activator of 
glycogen synthase. Elevated FFA’s and GC’s impair nutrient delivery in addition to several steps 
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of the insulin signaling pathway which decreases glucose uptake and glycogen synthesis, GCs 
also increase muscle protein catabolism and decrease protein synthesis.  
(-) inhibition, (+) activation. 
 41 
3.4.2. Glucocorticoid-induced skeletal muscle dyslipidemia 
 Cushing's syndrome patients are characterized by a redistribution of body fat from 
peripheral subcutaneous depots, to more central abdominal regions (Arnaldi 2010). This over 
activity of the HPA axis, which is also seen with obesity, could be causally related to insulin 
resistance and diabetes development through ectopic lipid deposition and the underlying effects 
of both whole body and tissue-specific lipid metabolism. GC exposure in wild-type mice causes 
inhibition of adiponectin receptor gene expression within skeletal muscle (De Oliveira 2011), 
possibly affecting positive downstream consequences of adiponectin signaling in skeletal 
muscle, like fatty acid oxidation and the prevention of IMCL accumulation. GCs increase whole 
body lipolysis which leads to elevated levels of nonesterified fatty acids (NEFA) and 
triglycerides (TG) (Wajchenberg, 2000). Elevations in NEFA concentrations increase the risk of 
accumulation of IMCL, like fatty acyl CoA, DAG, and ceramide which have emerged as 
important contributors to insulin resistance, through the inhibition of select proteins along the 
insulin signalling pathway (Bosma 2012; Singh 2003). IMCL may activate various serine 
kinases, like c-Jun amino-terminal kinase (JNK) and IkB kinase (IKK), which phosphorylate 
serine residues on IRS-1, causing a decrease in insulin signaling (Perseghin, 2003). Ceramide is 
thought to be a key mediator of many of the pathological events associated with GC-induced 
myopathy, like insulin resistance, atrophy and apoptosis (Dirks-Naylor 2009), and is capable of 
directly inhibiting Akt phosphorylation after high fat feeding (Chavez 2003).  
3.4.3. Glucocorticoid-induced myopathy 
GCs are one of the most common medications known to induce myopathy, especially 
when taken chronically at a high dose (Owczarek 2005). Individuals’ prescribed long-term GC 
immunotherapy can have an incidence of muscle weakness as high as 50% (Bowyer 1985). GC-
 42 
induced myopathy is generally associated with muscle atrophy and weakness, insulin resistance, 
mitochondrial dysfunction and is proximal, symmetrical and can involve both upper and lower 
extremities (Dirks-Naylor, 2009). Steroid-induced atrophy has been shown to preferentially 
target fast, glycolytic muscle fibers (particularly type IIx and IIb) with almost no effect in type I 
fibers (Wang 2013). With acute atrophy there is an increase in the main degradation pathways, 
including the ubiquitin-proteasome system and the autophagy-lysosome pathway (Schiaffino 
2013). The reduction of skeletal mass by GCs occurs through both decreased protein synthesis 
and increased protein breakdown (Goldberg Al, 1980; Schakman 2008a). Protein synthesis is 
inhibited through reduced amino acid transport and prevention of the anabolic effects of both 
insulin and IGF-1, particularly through decreased activation of eIF4E-binding protein 1 (4E-
BP1) and ribosomal protein S6 kinase 1 (S6K1). The resulting elevation in circulating amino 
acids can interfere with insulin signaling through the inhibition of insulin-stimulated IRS-1 
tyrosine phosphorylation and activation of PI3K, and have also been shown to impair ISGU and 
glycogen synthesis in human muscle biopsies (Löfberg 2002). While increased proteolysis can 
occur through elevations in Muscle Ring Finger (MuRF)-1 and Atrogin-1 transcription (Gomes 
2001), two important ubiquitin-proteasome system proteins (Bodine 2001), with subsequent up 
regulation of Forkhead box O (FoxO) 1 and 3. The combination of the atrophy-related decrease 
in total muscle area, and increased circulating amino acid levels, ultimately contribute to the 
attenuated ISGU observed with hypercortisolemia.  
GCs have also been found to alter mitochondrial function (Du 2009), as defects in 
mitochondrial function are associated with GC-induced skeletal muscle wasting (Martens 1991). 
Although these mitochondrial alterations are usually the result of supraphysiological GC 
concentrations, as lower concentrations have actually been found to induce mitochondrial 
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biogenesis (Weber 2002). The general consensus is that, under physiological conditions, GCs 
work to enhance mitochondrial functions allowing the increased provision of energy to cells to 
adapt to acute stress challenges (Duclos 2004). However, chronic stress, which could lead to 
long-term elevations in GCs, has been shown to reduce mitochondrial function, through enlarged 
mitochondrial volume, decreased mitochondrial number and substrate utilization in addition to 
increased uncoupling of oxidative phosphorylation (Du, 2009; Martens, 1991).  
3.5. Skeletal muscle-targeted therapeutic options 
 GCs are the number one prescribed immunosuppressive medication to combat 
rheumatoid arthritis (Andre 2011), COPD, asthma and lupus (Luijten 2013), in addition to being 
used in combination cancer treatment (Kfir-Erenfeld 2014) there are also patients who suffer 
from endogenous GC overproduction (Cushing’s disease). Patients who are using exogenous 
GCs, like dexamethasone, do not want to limit GC action as they require the potent anti-
inflammatory and immune suppressive properties that GCs possess which points to therapeutic 
strategies that can modulate the peripheral effects of GCs. Some options include physical activity 
or IIβ-HSD1 inhibition. While GRII antagonism, typically using mifepristone, is administered to 
Cushing’s disease patients to combat the naturally high GC levels, as for these patients the goal 
is to block GC action. Both patient populations will experience the side effects associated with 
GC elevation, but each requires a different therapeutic focus.      
3.5.1. Physical activity and GC metabolism 
 Exercise is widely used to control and/or treat several diseases because of its 
compensatory and regulatory actions on organisms as reviewed here (Pedersen 2015). 
Interestingly, exercise is itself a common form of metabolic stress which stimulates the HPA axis 
(Campbell 2009) causing increased circulating GCs to mobilize fuel sources and subdue the 
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immune system during exercise-induced muscle damage. While elevations in circulating GC 
levels induce insulin resistance, regular exercise enhances insulin sensitivity and causes 
reductions in both GR and IIβ-HSD1 expression within the skeletal muscle, adipose and liver 
(Coutinho 2006), ultimately reducing tissue-specific GC exposure. Regular exercise before and 
during two weeks of dexamethasone treatment improved glycogen loss (Barel 2010; Jung 2010), 
hyperinsulinemia and muscular atrophy (Barel, 2010) in some muscles, as well as increasing 
physical capacity. While others have found chronic exercise down regulates MuRF1 and atrogin-
1 in atrophy induced through elevations in circulating GCs (Al-Nassan 2012; Hickson, 1981 ). 
Voluntary exercise is well known to improve skeletal muscle ISGU (Holten, 2004) and insulin 
resistance (Jung, 2010), induced by GC exposure, through attenuation of reductions in specific 
insulin signaling proteins, including Akt and IRS-1 activity and expression. Exercise also lowers 
ceramide content, while at the same time improving insulin sensitivity, possibly by directing 
lipids into the triglyceride pool (Amati 2011; Chavez 2012; Dube 2011). However, exercise 
training is not typically able to improve the extreme weight loss seen with dexamethasone or 
corticosterone treatment (Dionísio 2014) or some of the reductions observed in angiogenesis 
specifically decreased vascular endothelial growth factor (VEGF) expression (Barel, 2010). 
3.5.2. Glucocorticoid receptor modulation and diabetes-related metabolism. 
 Mifepristone (RU486) is a non-selective GRII antagonist that competitively blocks the 
GRII and the progesterone receptor, but not the mineralocorticoid receptor (Johanssen 2007). 
RU486 has been extensively studied in the literature, from cell culture (Menconi 2008) to human 
trials, where it is primarily prescribed to Cushing’s disease patients to aid in GC overproduction 
and hyperglycemia (Shibli-Rahhal 2006) as it has been shown to clinically improve glucose 
tolerance in these patients (Goldberg 1998). RU486 has also been studied in regards to GC-
 45 
induced skeletal muscle impairments and has been found to improve muscle atrophy (Bitar, 
2001), in addition to attenuating the decreased Akt phosphorylation associated with GC-
treatment.(Zhao 2009). However, RU486 administration requires constant patient observation as 
it can cause a number of side effects such as hypokalemia and aborted pregnancy due to the non-
selectivity of its antagonism (Johanssen, 2007). The creation of more specific antagonists, 
selective for only the GRII, are in development and a few studies have been completed in rodent 
models (Beaudry 2014) analysing their therapeutic effectiveness. Overall, selective GII 
antangonists seem to be beneficial in improving whole-body steady state glucose metabolism and 
body mass gains in rodent models (Beaudry, 2014). 
3.5.3. IIβ-HSD1 inhibitors and diabetes-related metabolism. 
 Elevations in GC activity within both the liver and adipose tissue have been implicated in 
the development of obesity and the metabolic syndrome (Staab 2010), and increased atrophy 
within the skeletal muscle (Schakman 2013), which sets the stage for inhibition of IIβ-HSD1 as a 
possible treatment strategy. Improving altered GC metabolism through the specific inhibition of 
IIβ-HSD1, especially within adipose tissue, has been proposed to result in favourable effects on 
body composition and the metabolic profile. Transgenic mice selectively overexpressing IIβ-
HSD1 within white adipose tissue, developed visceral adiposity, dyslipidemia and insulin 
resistance in addition to elevations in local corticosterone levels (Masuzaki 2001), while IIβ-
HSD1 null mice after being fed a HFD gained less weight and preferentially stored lipids in 
peripheral fat depots (Morton 2004). Pharmacological inhibition of IIβ-HSD1 activity in obese 
rodents improved glucose tolerance, insulin sensitivity and lipid profile (Kershaw 2005), while 
inhibition within C2C12 skeletal muscle cells abolished the effect of GCs on protein degradation 
and E3 ubiquitin ligases. There is additional evidence that IIβ-HSD1 inhibition restores IRS1 
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protein levels, decreased serine IRS-1 phosphorylation and enhanced Akt activation all of which 
contribute to augmented skeletal muscle insulin sensitivity (Morgan, 2009). 
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Role of the microvascular system within skeletal muscle  
Alterations in skeletal muscle vasculature may help drive diabetes development, a phenomenon 
known to be influenced by both GCs and regular exercise. As such, this thesis introduction also 
highlights what is known about the effects of diabetes and GCs on the muscle vasculature.  
4.1. Overview of the microvasculature in skeletal muscle 
 The microvasculature refers to the smallest systems of the body’s blood vessels and can 
include, arterioles, which are small diameter blood vessels branching out from an artery, 
capillaries, which are the smallest blood vessels, metarterioles, which are vessels that link 
arterioles to capillaries and venules, which are blood vessels that allow deoxygenated blood to 
return from the capillaries to the larger veins (Krogh, 1919). Within the skeletal muscle, the 
microvasculature is the final interface from which circulating nutrients, hormones, gases and 
electrolytes must pass when moving to and from the systemic circulation (Wagner, 2000). These 
blood vessels have numerous structural and flexible adaptations to ultimately fulfill the 
optimization of muscle function and there is significant evidence that vascular function and 
skeletal muscle metabolic activity are closely linked, as alterations in blood flow and distribution 
can modulate nutrient delivery to the muscle and trans-endothelial transport can regulate the 
exchange of hormones and metabolites between plasma and the myocyte (Kolka 2012). Both 
regular exercise (Egginton, 2009; Hoier 2014; Karimian 2015) and circulating insulin levels 
(Akerstrom 2014; Egginton, 2011) have been well documented in the regulation of 
microvascular augmentation. A number of pathological conditions, including obesity (Bakker 
2009; Gavin 2005), diabetes (Bakker, 2009; Roberts 2013), and hypercortisolemia (Halaby 2002; 
Shikatani 2012; Short 2004) negatively influence blood flow, muscle perfusion and new 
capillary formation.     
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4.1.1. Skeletal muscle structure 
 The architecture of the vascular network within the skeletal muscle is highly organized 
(Krogh, 1919) with arterioles branching off of primary arteries, down to terminal arterioles, 
which are perpendicular to the muscle fibres and work to supply them at regular intervals. 
Generally, the supply capacity of each terminal arteriole is ~15-20 capillaries which form a 
network around the muscle fibres. This is referred to as a microvascular unit and forms the 
smallest unit of control for capillary perfusion (Emerson 1997). The venules are found between 
two terminal arterioles and lymph vessels typically originate with the skeletal muscle and have 
the capacity to interact with both arterioles and venules. Within mammalian skeletal muscle, the 
organization of arterioles and venules is very similar, as the major differences in vascular 
structure are between aerobic and anaerobic skeletal muscles. Aerobic muscles require enhanced 
gas and nutrient exchange, in comparison to anaerobic muscles, which means they have 
generally more capillaries, larger capillary length and more capillary branches per fibre 
(Kubínová 2001) in addition to deeper microvessel situation within the sarcolemma and possibly 
greater perivascular mitochondria (Glancy 2015). Moreover, aerobic muscles typically have 
more mitochondria which rely on both nutrient and oxygen provision to generate energy for the 
cell. The proximity between muscle fibers and capillaries is a key factor in this process, as tissue 
delivery of oxygen, through passive diffusion, is actually limited to a distance of several 
micrometers (Hudlicka, 1992b), and recent findings have shown capillaries embedded in 
sarcolemmal grooves, which ultimately expands the contact area between the myocyte and the 
endothelial cells. Additional evidence shows mitochondria can be clustered within these grooves, 
which can reduce the distance that oxygen and fatty acids will require to diffuse into the myocyte 
(Glancy, 2015).  
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4.1.2. Exercise and muscle perfusion 
The regulation of fuel fluxes into and out of skeletal muscle has been well studied in vivo 
in animals (Hellerstein, 2003; Weber 2004) and humans (Hawley 2011; Juel 1990) and 
subsequently it is understood that tissue perfusion delivers oxygen, FFA, glucose, triglycerides 
and amino acids to and removes metabolites (amino acids, lactate, carbon dioxide) from the 
skeletal muscle. During exercise there is an increase in bulk blood flow which is stimulated both 
by local factors including, potassium, adenosine, lactate, hydrogen ions, nitric oxide and 
prostaglandins (Clifford 2004; Mortensen 2009)  which are released from the exercising muscle, 
and by neurovascular alterations that work to relax muscle vasculature. With very intense whole 
body exercise, the primary limiting factors are respiratory and cardiac function, while blood flow 
and oxygen delivery to the tissues are secondary factors (Mortensen 2005). When examined 
within isolated skeletal muscle, which removes the limitations to cardiorespiratory function, 
blood flow to the human quadriceps can actually increase >50-fold during short, intense exercise 
(Andersen 1985). Moreover, increasing the arterial oxygen content does not further enhance 
quadriceps oxygen extraction or peak work rate (Mourtzakis 2004). Both glucose and FFAs are 
important fuels during exercise, and during intense exercise, a >30-fold increase, from rest, in leg 
glucose uptake has been measured (Katz 1986) in addition to dramatic increases in glucose levels 
both within the muscle interstitium and the myocytes themselves. These results suggest that the 
delivery of glucose to the muscle microvasculature and trans-capillary transfer of glucose, are 
both fully capable of adapting to and subsequently meeting the glycemic metabolic demands 
during intense exercise.  
When examining the effect of light to moderate exercise on the skeletal muscle 
microvasculature, there is less data, and the results that have been found typically provide a more 
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mechanistic insight into exercise-induced vascular regulation versus possible performance based 
effects. With light exercise, blood flow remains relatively unaffected; however there is an 
increase in capillary perfusion (Inyard 2007). Any additional increase in contractile activity, or 
an increase in exercise intensity, causes a corresponding increase in total blood flow which is 
mediated by a number of factors including venous pO2, which promotes nitric oxide (NO) 
production and release (Stamler 1997) and hemodynamic forces, such as shear stress-induced 
NO production. Both of these responses are enhanced by prostaglandins to further increase 
exercise-induced tissue perfusion (Mortensen 2007).    
4.1.3. Insulin and muscle perfusion 
 Very early work examining the effect of insulin-stimulated glucose uptake in the forearm, 
saw an associated increase in forearm blood flow (Andres 1962). Additional work found that 
insulin-stimulated glucose uptake actually paralleled insulin's ability to increase total leg blood 
flow (Baron, 1994). Lower, more physiologic doses of insulin, in both healthy humans and 
animals, can increase microvascular perfusion, without an associated increase in total peripheral 
blood flow, while high physiological concentrations of insulin cause the relaxation of arterioles 
(vasodilation) and increased peripheral blood flow (Baron 1995). Further research has found that 
these effects are blunted in insulin resistant individuals with obesity (Laakso 1990), increased 
FFA levels (Steinberg 2000) and diabetes (Baron 1991). These pathological conditions impair 
insulin-stimulated peripheral blood flow and glucose uptake, and evidence suggests that impaired 
vasodilation in response to insulin could be a significant contributor to the metabolic 
complications associated with insulin resistance. Insulin is not the only hormone capable of 
stimulating the skeletal muscle microvasculature, as both GLP-1 (Subaran 2014) and adiponectin 
(Zhao 2013) increase microvascular volume through distinct biochemical pathways. Epinephrine 
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can increase skeletal muscle blood flow without altering microvascular perfusion volume, and 
corticosterone has been found to cause capillary rarefaction which ultimately reduces 
microvascular perfusion (Shikatani, 2012).  
 It is understood that there are differences in basal blood flow between different insulin-
sensitive tissues. The liver and the myocardium each have a very substantial basal blood flow (~1 
ml/min-1·g tissue-1), while the islets of Langerhans have an even greater blood flow that is 
estimated to be about 5–12 mL/min/g of tissue (Iwase 2001). By contrast, skeletal muscle and 
adipose tissue basal blood flow averages only 0.03–0.04 ml/min-1·g tissue-1 (Baron, 1994). As a 
result, in these tissues, blood flow (or for insulin and some other solutes, plasma flow) can 
become an important factor limiting nutrient delivery and solute exchange. As previously 
mentioned, there is an established link between the vascular action of insulin to enhance total 
limb blood flow and insulin’s metabolic action, however, contrary findings have also been 
reported. In particular, those reports raised the concern that increasing blood flow did not result 
in augmentation of insulin’s metabolic action in healthy or insulin-resistant individuals (Laine 
1998; Natali 1998) and that the time course for onset of insulin-induced increases in limb blood 
flow (particularly at physiological insulin concentrations) lagged behind insulin-induced 
increases in skeletal muscle glucose uptake (Yki-Järvinen 1998).   
 The movement of insulin from the vascular to the interstitial compartment within skeletal 
muscle is rate limiting for insulin’s metabolic action. Support for this argument is extensive and 
includes the early demonstration by Sherwin et al. (Sherwin 1974) that the disappearance 
kinetics of intravenously injected insulin indicated a rapid equilibration of injected insulin within 
plasma and visceral tissue compartments but a slow equilibration within skeletal muscle. 
Additional data notes that when the insulin concentration was increased muscle insulin clearance 
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declined, and suggests a saturable process for insulin transport. All of this evidence highlights 
the interesting relationship between insulin and microvascular recruitment. 
 The vasodilatory action of insulin occurs through its binding to the insulin receptor 
expressed on endothelial cells, which stimulates the PI-3K/Akt pathway into activating 
endothelial nitric oxide synthase (eNOS) (Jiang 1999) and induces NO-mediated vasodilation. 
Insulin can also activate the MAPK pathway in addition to enhancing the production of the 
vasoconstrictor endothelin-1 (Mather 2013). In pathological conditions like obesity and T2DM, 
there is an established endothelial dysfunction which is associated with increased inflammation, 
FFAs, oxidative stress and a significant reduction in perivascular adiponectin release. All of 
these factors have the capacity to inhibit the activation of the PI3K pathway within the 
endothelial cell, resulting in a reduced vasodilatory response, or sometimes even 
vasoconstriction in the face of hyperinsulinemia (Clerk 2006). There is additional evidence to 
support the idea that insulin exerts a physiological action at all levels of the arterial vascular tree, 
and that insulin resistance is accompanied by dysfunction at each level. At the level of conduit 
arteries, an extensive body of data indicates that metabolic insulin resistance, as seen in obesity, 
metabolic syndrome, and type 1 and type 2 diabetes, is accompanied by dysfunction that is 
manifested by increased vascular stiffness and/or impaired NO-mediated vasodilation 
(Stehouwer 2008; Webb 2010). Interestingly, in insulin-resistant individuals, pharmacologically 
increasing blood flow, through the use of prazosin, an α1-adrenergic antagonist that induces 
hyperaemia through enhanced shear stress (Dawson, 1989b), does not always improve insulin-
stimulated glucose uptake. It has been suggested that although peripheral tissue perfusion is 
augmented, insulin resistance within the myocyte remains and the acute correction of perfusion 
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is not enough to overcome that metabolic defect, however further understanding of this 
phenomenon is required.  
4.2. Skeletal muscle angiogenesis 
 In addition to blood flow and perfusion, the formation of new blood vessels from pre-
existing vessels, termed angiogenesis, is another level of skeletal muscle microvascular 
regulation. Angiogenesis is typically responsible for most, if not all, new blood vessel growth 
during adult development and disease. This process is in contrast to vasculogenesis, which is the 
de novo formation of blood vessels essential to the initial development of embryonic 
microcirculation (Olfert 2016). The growth of new blood vessels, or capillaries, occurs though 
endothelial sprouting, from the abluminal surface of endothelial cells, or non-sprouting 
(intussusceptive) microvascular growth (IMG) from the luminal surface of endothelial cells 
(Ribatti 2012), and is involved in tissue injury and wound healing (Arnold 1991; Billingham 
1955), the endometrial cycle (Gambino 2002) and skeletal muscle adaptation to stress and 
exercise (Egginton, 2009), among other physiological events. There are a number of important 
signals that induce skeletal muscle angiogenesis, including tissue hypoxia in both adult and 
embryonic capillary growth, increased contractile activity, as seen with endurance exercise 
(Bloor, 2005), and physiological or pathological reductions in contractile activity, such as hind 
limb unloading (Li 2004; Mariotti 2008) or in obesity (Gavin, 2005; Goodwill 2012) or diabetes 
(Bakker, 2009; Vessieres 2012).  
4.2.1. Capillary growth in adult skeletal muscles 
 The basic mechanisms of blood vessel growth and development have been established 
over the past couple decades (Folkman, 1997) and as such, angiogenesis can be divided into a 
number of specific phases, ultimately based upon the responses of the endothelial cells to certain 
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angiogenic stimuli, including 1) protease production, 2) migration or chemotaxis, 3) 
proliferation, 4) capillary morphogenesis, and 5) vascular maturation or stabilization.  
 In response to an angiogeneic stimulus (injury, hypoxia, mechanical stretch) endothelial 
cells become activated and attract and bind leukocytes and blood platelets that release a number 
of pro- and anti-angiogenic factors. Proteolysis is then required for the endothelial cells to pass 
through the basement membrane, which surrounds the capillary (Haas, 2002), and the secretion 
of these factors cause the stimulation of local endothelial cells which begin to produce proteases, 
including urokinase-type plasminogen activator and collagenase, to subsequently degrade the 
basement membrane which, once degraded, will allow the movement of the endothelial cells 
(Kalebic 1983). The basement membranes are composed of a scaffold of collagens, fibronectins 
and laminins, while the interstitial matrix contains fibrillar collagens. All of these matrix proteins 
are substrates for the matrix metalloproteinase (MMP) family of enzymes which influence cell 
adhesion through enhanced cell proliferation or migration through the release and/or activation 
of sequestered growth factors (Pepper, 2001). The endothelial cells then migrate out of the 
original vessel towards the source of the angiogenic stimulus, which produces nascent vascular 
sprouts. After which, the endothelial cells undergo mitosis, or proliferation, to align and form a 
capillary lumen in a process termed capillary morphogenesis (Kalebic, 1983). The cells then go 
through vascular maturation, or stabilization, which causes the formation of cell-cell junctions, 
the recruitment of supporting peri-endothelial cells (pericytes and smooth muscle cells) and the 
development of organ-specific endothelial characteristics which renders the endothelial cells 
quiescent.  
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4.2.1.a. Angiogenic factors 
 Physiological angiogenesis is controlled through equilibrium between both pro- and anti-
angiogenic factors. Presently, there are more than 40 stimulators and inhibitors of angiogenesis 
(Olfert 2011), and there are numerous examples within the literature demonstrating that an 
imbalance between the two contrasting factors causes either uncontrolled angiogenic growth or 
capillary rarefaction within various pathologies (Esemuede 2004). 
 There are a number of different factors that stimulate endothelial cell proliferation in 
vitro and mediate angiogenesis in vivo, however the major putative angiogenic factor, vascular 
endothelial growth factor (VEGF) and it's receptors, seems to increase to a greater extent, and 
more consistently than other measured angiogenic factors, including the fibroblast growth factor 
family (FGF), platelet derived growth factor (PDGF), the angiopoietins and TIE-receptors, the 
integrins and a number of others (Pepper, 1997; Yancopoulos 1998). These factors typically 
mediate their angiogenic actions through binding to specific cell-surface receptor tyrosine 
kinases, of which, the receptors for VEGF are expressed almost exclusively on endothelial cells. 
Receptor tyrosine phosphorylation stimulates signaling cascades that translate into specific 
endothelial cellular responses necessary for angiogenesis, like chemotaxis and proliferation.  
 While significantly less studied, endogenous inhibitors of angiogenesis are integral to the 
regulation of capillary growth. These angiostatic factors can be derived from within the 
extracellular matrix, such as thrombospondin, and they can also be from outside of the matrix, 
whether from other cells or within the blood such as angiostatin. There is still a significant 
amount of research required to fully ascertain the relationship between both angiogenic and 
angiostatic factors, however there is evidence implicating these anti-angiogenic factors in various 
pathologies, including ischemia-induced skeletal muscle injury (Milkiewicz 2011b; Silvestre 
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2002), diabetes (Krisp 2013; Simo 2006) and chronic obstructive pulmonary disease (Gouzi 
2012; Suzuki 2012). They have also been proposed as the 'brakes' of exercise-induced skeletal 
muscle angiogenesis, possibly in order to maintain precise angio-adaptive mechanisms (Olfert, 
2011).  
4.2.2. Exercising muscle 
 The growth of capillaries in response to exercising muscle is a complex, highly regulated 
process which is stimulated by increased blood flow and shear stress, mechanical stretch of the 
tissue in addition to the signals generated through increased metabolic demand or reduced 
oxygen delivery (Brown 2003). These signals modulate the activity of the pro-angiogenic and 
angiostatic factors previously described and many others, which act together to accurately 
regulate angiogenesis. Typically, capillarization within the skeletal muscle can be transformed in 
relation to the extent that the muscle is used, as aerobic (Andersen 1977), anaerobic (Egginton 
2000) and resistance training (Gavin 2007) can induce angiogenesis. Capillarization is associated 
with fibre size  and can be measured using the capillary-to-fibre (C:F) ratio. Generally, aerobic 
training can increase C:F either with or without a parallel change in fibre area, resistance training 
typically causes increased fibre area and matched alterations in C:F while inactivity causes a 
reduction in both fibre area and C:F (Musacchia 1990).  
4.2.2.a. Shear stress, mechanical stretch and metabolically related factors  
 When there is an increase in blood flow there is a corresponding increase in shear stress, 
which is a frictional force acting on the luminal side of the endothelial cells (Egginton 2014). 
The endothelial cells respond to this force through activation of signaling pathways which 
stimulate vascular growth factors and vasoactive compounds that alter blood flow. 
Vasodilatation, using chronic administration of the α1-adrenergic receptor antagonist prazosin, is 
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a widely used laboratory model of elevated shear stress, which has been shown to induce 
capillary growth in rat skeletal muscle (Dawson, 1989b), usually without modification of the 
metabolic activity of the skeletal muscle fibres. The use of this compound in rodents causes long 
term hyperaemia which stimulates the increased expression of angiogenic factors and increased 
endothelial cell proliferation resulting in angiogenesis, with the largest increases in capillarity 
occurring where the hyperaemic response was greatest (Egginton, 2001). Shear stress as a 
solitary, initial angiogenic stimulus is different from what is typically observed with contracting 
muscle, and subsequently causes a different pattern of capillary growth. Increased shear stress 
induces growth by longitudinal splitting, or intussusceptive microvascular growth (IMG) 
(Egginton, 2001). The process of intussusception is when the capillary network increases its 
vascular surface through invagination of the capillary wall allowing opposing endothelial cells to 
make contact across the lumen and form intercellular junctions. The new capillaries are 
subsequently formed by perforation and invasion of the region of contact by interstitial tissue 
(Burri 1990). This method of angiogenesis appears to be faster, less complex and possibly less 
energetic than sprouting angiogenesis, as it requires minimal degradation of the basement 
membrane and extracellular matrix, less endothelial cell proliferation, and capillary function 
seems to be uncompromised during growth (Prior 2004). However, the level of shear stress 
induced through pharmacological vasodilatation is probably much higher than what would be 
observed with functional hyperaemia induced by electrical stimulation in rodents. 
 Endothelial cells are tethered to myocytes through the extracellular matrix and connective 
tissue and contraction-induced alterations of the sarcomere, such as stretch or overloading 
(contraction), can stimulate the endothelial cells and induce capillary growth, primarily through 
sprouting angiogenesis (Egginton, 2011). Typically, alterations to blood flow are minimal, and in 
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contrast to endothelial detection of shear stress, muscle stretch or overload actually affects all 
cells within the skeletal muscle (myocytes, satellite cells, interstitial fibroblasts, vascular smooth 
muscle cells, pericytes and endothelial cells) (Haas, 2002). During both shear stress and muscle 
stretch, tensile forces are generated that stimulate mechanotransduction signaling pathways by 
activating integrin receptors. Protein and mRNA analysis of angiogenic factors within 
contracting skeletal muscle, demonstrate that factors associated with matrix remodelling, which 
primarily occur in sprouting growth, are upregulated in response to muscle stretch but not shear 
stress (Milkiewicz 2005). The growth factor VEGF is important for both luminal splitting and 
sprouting angiogenesis (Williams 2006b). 
 It is not only elevations in blood flow, shear stress and mechanical contraction that are 
important for the initiation of angiogenesis, alterations in metabolism and oxygen utilization and 
supply are other very important physiological stimuli. In an exercising model, it is difficult to 
elucidate the exact role of metabolism in angiogenesis, as changes in metabolic flux generally 
induce corresponding alterations to blood flow. It is well known that pro-angiogenic compounds 
are released from the exercising muscle during contraction, like the vasodilators adenosine and 
prostacyclin (Egginton, 2001), although the exact signal for this release, whether it is coupled 
with enhanced metabolism, alterations in oxygen levels or the mechanical aspects of contraction 
are not fully understood.   
4.2.3. Angiogenesis during diabetes mellitus 
Alterations in skeletal muscle capillarity can have a significant impact on metabolism, the 
endocrine system and muscle function. Typically, elevations in capillary density (CD) or C:F, 
suggest capillary growth or angiogensis and are associated with functional improvements, while 
decreased CD or C:F (capillary rarefaction) are associated with many chronic diseases including 
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diabetes (Kivela 2006), peripheral artery disease (Kikuchi 2014), cachexia  and chronic 
obstructive pulmonary disorder (Bašić, 2014).  
 Diabetes is associated with both micro- and macrovascular disorders which can result in 
adult-onset blindness, limb amputations, stroke and peripheral artery disease (Kilpatrick 2006; 
Olfert, 2016), among a host of others. There is evidence that capillarity in skeletal muscle is 
altered in both T1DM (Hansen 2002; Raskin  1983) and T2DM (Rasio 1992), typically in the 
form of endothelial dysfunction resulting in capillary rarefaction. Endothelial dysfunction 
encompasses a number of different functional changes in the vascular endothelium, including 
impaired vasodilation, angiogenesis, inflammatory activation and elevations in plasma levels of 
endothelial products (Bakker, 2009). Endothelial dysfunction is an early and significant event in 
the pathogenesis of micro- and macrovascular pathologies in both forms of diabetes, and is 
primarily due to chronic hyperglycemia, although insulin resistance, pro-inflammatory signaling 
and oxidative stress have also been implicated. Impaired endothelial function tilts the 
physiological balance towards vasoconstrictive and angiostatic effects which accelerate the 
development of atherosclerosis, a major complication of diabetes (Landmesser 2004).  
4.2.4. Effect of exercise on skeletal muscle capillary rarefaction in diabetes mellitus 
 Exercise training is a viable therapeutic option to improve the capillary rarefaction 
associated with insulin resistance (Hansen 2010), as it has been shown to stimulate local 
microvascular adaptations within the skeletal muscle in addition to systemic adaptations due to 
improved glycemia. In both humans and rodent models of insulin resistance and T2DM, exercise 
mediates local and systemic improvements in endothelial (Milkiewicz 2011a) and smooth 
muscle function which is typically evident through enhanced vasodilator signaling. Additionally, 
regular exercise promotes increases in NO synthesis and bioavailability while simultaneously 
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lowering levels of ROS which otherwise would counteract NO activity (Fuchsjäger-Mayrl 2002), 
other possible mechanisms which could ameliorate the endothelial dysfunction associated with 
diabetes. To date, there are limited studies examining the effect of exercise within the skeletal 
muscle in T1DM, although there is evidence that chronic T1DM causes capillary rarefaction and 
decreased skeletal muscle perfusion (Kindig 1998b; Laakso 1992; Tibiriçá 2007). Kivela et al. 
(Kivela, 2006)  is one of the few published works examining the effect of T1DM on skeletal 
muscle angio-adaptive molecules, capillarization, and the potentially therapeutic role of exercise 
training. The authors did find that 5 weeks of regular exercise caused a partial restoration of the 
diabetes-induced reduction in VEGF mRNA, however, further characterization of exercise-
induced alterations within the skeletal muscle microvasculature are required. 
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Summary of Intent 
Overall Purpose 
The overall purpose of the studies presented in this thesis was to investigate the 
relationship between elevations in glucocorticoids and diabetes development on skeletal muscle 
insulin resistance and angiogenesis, using two different rodent models of diabetes; T2DM and 
exogenous elevations in GCs combined with a HFD (ROD model) and T1DM using 
streptozotocin to induce β-cell destruction. 
 
Specific Purpose 
The specific purposes of the experiments conducted were to: 
1) Examine the effect of elevations in exogenous GCs combined with a HFD on insulin-
stimulated glucose disposal and other markers of skeletal muscle insulin resistance 
(chapter 2). 
2) Determine whether voluntary exercise is a viable therapeutic strategy to combat the 
significant diabetogenic and atrophic side effects associated with elevations in GCs and a 
HFD (chapter 3). 
3) Investigate whether prazosin administration, a potent pharmacologic stimulant of muscle 
angiogenesis, improves glucose intolerance, insulin sensitivity and other skeletal muscle 
specific defects associated with hypercortisolemia (chapter 4). 
4) Explore the induction of, and possibly enhancement in, angiogenesis from the 
combination of prazosin and voluntary exercise on the capillary rarefaction associated 
with untreated, chemically-induced, insulin-dependent diabetes. 
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Overall Hypothesis 
The overall hypothesis for these studies was that elevations in glucocorticoids would 
cause skeletal muscle insulin resistance, atrophy and capillary rarefaction and correlate with 
diabetes development. A secondary hypothesis is that both exercise and prazsoin would help 
ameliorate the diabetogenic effects of hypercortisolemia.  
Specific hypotheses 
The specific hypotheses for the studies listed above were that: 
1) Exogenous glucocorticoids and high-fat feeding synergistically cause skeletal muscle 
insulin resistance through decreased insulin stimulated glucose transport, impaired insulin 
signaling and glycolytic atrophy. 
2) Voluntary exercise will improve whole body glucose metabolism, normalize glycolytic 
fibre atrophy, and skeletal muscle insulin signaling without altering circulating 
glucocorticoid concentrations. 
3) Improved skeletal muscle capillary rarefaction, using prazosin administration, will 
enhance insulin sensitivity through increased skeletal muscle perfusion. 
4) The combination of three weeks of voluntary exercise and prazosin administration will 
lead to a magnified improvement in hyperglycemia and skeletal muscle capillary 
rarefaction, associated with untreated streptozotocin-induced diabetes. 
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Chapter 2 
Severe skeletal muscle metabolic impairments occur in response to concurrent high-fat 
feeding and glucocorticoid treatment in male Sprague Dawley rats 
 
Author Contributions: I designed the study and wrote the paper along with input from Dr. 
David Dyck, Dr. Ian Ritchie and my supervisor Dr. Michael Riddell. I performed all animal 
handling, including pellet surgeries, oral glucose tolerance tests and blood draws. Dr. Ian Ritchie 
and I completed the ex vivo glucose transport analysis, with input from Dr. David Dyck. I 
completed all plasma analysis (insulin ELISA, corticosterone RIA) and histochemistry (CSA, 
SDH, ORO). Western blotting of insulin signaling proteins was completed by myself and 
Deanna Porras; while GR and 11β-HSD1 was completed by myself. Carbonylated protein 
assessment was perfomed by Sofhia Ramos, with input from Dr. Christopher Perry. Dr. Michael 
Riddell oversaw the entire study and assisted in manuscript preparation. 
 
Rationale: It was well established that combining elevations in GC concentrations 
(pathophysiological) with a diet high in fat (ROD model) caused significant metabolic and 
tissue-specific side effects. The liver, pancreas and adipose tissue of this rodent model had been 
extensively investigated, although the exact mechanism of the synergistic initiation of diabetes 
development was not fully elucidated. This study was undertaken to analyze the skeletal muscle, 
which is a major organ responsible for glucose metabolism, through the measurement of ex vivo 
insulin stimulated glucose transport, in addition to examination of the glycolytic fibre-specific 
atrophy, indicative of GC action. In executing this study, we were able to establish that the 
glycolytic (white) skeletal muscle of these ROD animals (Cort-HFD) demonstrated severely 
impaired insulin stimulated glucose uptake and atrophy, possibly due to greater 11β-HSD1 
protein content, which could cause increased tissue-specific exposure to GCs.  
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Preface  
 Glucocorticoids (GCs) are naturally occurring stress hormones that are frequently 
prescribed to treat immune and inflammatory conditions. The administration of GCs can promote 
skeletal muscle insulin resistance, hepatic steatosis, ectopic fat accumulation as well as β-cell 
dysfunction. We have previously shown that a high-fat diet (HFD) in combination with GC 
treatment amplifies these detrimental metabolic effects, but the effects of this co-treatment have 
not been examined within the skeletal muscle per se. Young, male Sprague-Dawley rats were 
subcutaneously implanted with corticosterone (Cort), the main GC in rodents, (400mg/rat) or 
wax pellets and provided with either a rodent standard diet (SD) or a HFD (n=5/group). As 
expected, two weeks of HFD/Cort treatment resulted in profound 
hyperinsulinemia/hyperglycemia. Muscle insulin resistance was assessed in situ through direct 
measurement of insulin-stimulated glucose uptake (ISGU) in both the extensor digitorum longus 
(EDL) and soleus muscles. Cort-HFD-treatment resulted in ~50% less ISGU compared to the 
control-HFD within the EDL, with surprisingly no impairment observed within the soleus. Cort-
SD treatment caused ~4-fold decrease in IRS-1 protein within the EDL, while Cort-HFD animals 
had ~2-fold increase in AS160 protein, an adaptation that was unable to compensate for the 
decreased ISGU. Concurrent Cort-HFD treatment also resulted in greater type IIb/x fibre atrophy 
within the tibialis anterior and elevations in 11β-HSD1 protein within the EDL. These findings 
emphasize the significant adverse effects that combining Cort-treatment with a HFD can cause 
within the skeletal muscle, particularly in white muscle, which likely contributes to the 
development of insulin resistance. 
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Introduction  
 Synthetic glucocorticoids (GC) are commonly prescribed as anti-inflammatory and 
immunosuppressant medications for auto-immune diseases such as rheumatoid arthritis and 
lupus, (Rhen, 2005) and are also used in combination with cancer treatments (Walsh, 1992). 
Chronic or high dose GC administration is associated with numerous side effects such as: steroid 
myopathy (Owczarek, 2005), peripheral insulin resistance (Stojanovska 1990), visceral adiposity 
(Asensio 2004) and diabetes development (Pivonello 2010). These metabolic disturbances occur 
because GCs are inherently catabolic and can liberate fuel substrates and promote ectopic lipid 
accumulation (Peckett 2011). Increased exposure to GCs in rodents (Dallman, 2010; Dallman 
2005) or chronic stress in humans (Tomiyama 2011) have been shown to stimulate the desire for 
energy dense ‘comfort’ foods (high fat, simple sugars) and are often associated with excessive 
weight gain (Zakrzewska, 1999). Independently, chronically elevated GCs and high-fat feeding 
cause dysregulated lipid metabolism in the skeletal muscle of both rodents and humans 
(Koyama, 1997; Pan, 1997), specifically through accumulation of intramyocellular triglycerides 
(IMTGs), diacylglycerides (DAGs) and ceramides. Accumulation of these fatty acid 
intermediates in skeletal muscle can induce a reduction in insulin signaling through direct 
inhibition of insulin signaling proteins (IRS-1, Akt/PKB) (Ruzzin, 2005) and can alter insulin 
stimulated glucose uptake through inhibition of GLUT4 receptor translocation (Buren, 2008; 
Dimitriadis, 1997).  
 Previous work from our lab has shown that combining exogenous GCs (corticosterone in 
rodents; Cort) with a high-fat diet (HFD) drastically augments these metabolic impairments, 
rapidly inducing severe, whole body glucose intolerance, hepatic steatosis and a type 2 diabetes 
mellitus (T2DM) phenotype within days of treatment in young male Sprague-Dawley rats 
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(Beaudry, 2013; D'souza, 2011; Shpilberg, 2012). With exogenous Cort treatment only, or with 
just a HFD, the animals do not develop a diabetic phenotype in this same time-frame, suggesting 
a synergistic effect occurs with the combination of the two metabolic insults. In this paper, we 
examine the impact of these two metabolic stresses (diet, exogenous GCs) separately and in 
combination on skeletal muscle, which is a key determinant of whole body insulin sensitivity and 
T2DM development. We further determine if there are any muscle-specific differences between 
predominantly glycolytic and oxidative muscle groups.  Our findings clearly demonstrate that 
fast-twitch, glycolytic muscle fibres are a key target for the induction of atrophy and insulin 
resistance in response to the combination of high fat feeding and exogenous GC treatment. 
Methods 
This study was carried out in accordance with the recommendations of the Canadian 
Council for Animal Care guidelines and was approved by the York University Animal Care 
Committee (2013-5).  
Experimental Design and Animals: Male Sprague-Dawley rats (Charles River 
Laboratories, initial mass of 225-250 g, six weeks post-weaned, n=15) were individually housed 
(lights on 12 hour: lights off 12 hour cycle) after one week of acclimatization to room 
temperature (22-23°C) and humidity (50-60%) controlled facilities. An overview of the 
experimental design is depicted in Figure 2.1. Briefly, on day 0, basal (AM) Cort was measured 
and then animals were randomly divided into one of three groups: corticosterone-treated with a 
rodent standard diet (Cort-SD), corticosterone-treated with a high-fat diet (Cort-HFD), or 
placebo-treated with a high-fat diet (Control-HFD). Each rat received a subcutaneous 
implantation of either corticosterone (the major GC found in rodents) (Cort) pellets (4 x 100 mg; 
Sigma-Aldrich, Canada, Cat# C2505) or wax pellets (Control), as previously described 
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(Shpilberg, 2012). Following recovery from surgery, rats were placed into standard sterile cages 
and were maintained on either a rodent standard diet (14% fat, 54% carbohydrate, 32% fat; 3.0 
calories/g) or a HFD (60% total calories from fat; 5.1 calories/g). All animals were fed ad libitum 
during the treatment period, which lasted for 15 days. Body mass and food intake were measured 
daily for each rodent using an electronic scale (Mettler Toledo, Canada) and any changes in the 
rodents' health were noted and monitored.  
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Figure 2.1. Schematic of experimental design. 
Saphenous vein measurement of pre-treatment corticosterone (Cort, AM) occurred on day 0, 
immediately prior to pellet implantation (wax/Cort). A second saphenous vein Cort measurement 
was taken on day 7. An oral glucose tolerance test (OGTT) was administered on day 12, after an 
overnight fast. Animals were fasted overnight and then euthanized on day 14 or 15, following 
ex-vivo analyses of insulin-stimulated glucose transport.  
 70 
 Cort sampling: On day 0 and day 7, at ~0800 hour (AM), blood samples were collected 
from each animal via saphenous vein for Cort concentration measurements. A small area of hair 
on the lateral upper hind limb was shaven with an electric razor and wiped with a thin layer of 
petroleum jelly. Once the saphenous vein was located, a sterile 25-gauge needle was used to 
puncture the vein and whole blood was collected in lithium-heparin coated microvette capillary 
tubes (Sarstedt, Canada, Cat# 16.443.100) and centrifuged at ~ 9, 500 x g (Eppendorf Mini-Spin 
Plus, Brinkman Instruments Inc., USA) for 5 minutes, transferred into polyethylene tubes and 
stored at -80°C until further analysis of Cort concentrations using a radioimmunoassay kit (MP 
Biomedical, USA).  
Oral glucose tolerance test: Animals were fasted overnight (~12-14 hours) on day 11 and 
were then administered an oral glucose tolerance test on day 12 (OGTT, 1.5 g/kg body mass), as 
previously described (Shpilberg, 2012). Each animal’s fasting whole blood glucose concentration 
was measured (time 0) via saphenous vein bleed (~10 μl) using a sterile needle (25G) and 
glucometer (Bayer One Touch). Plasma was also isolated (~50 μl) from saphenous bleed 
collection at this same time point for subsequent analysis of insulin concentrations via an ELISA 
96-well kit (Crystal Chem, USA, Cat# 90060). Whole blood glucose was also measured and 
recorded from saphenous vein bleed at T=5, 15, 30, 60, 90 and 120 minutes post oral gavage. 
Glucose area under the curve (AUC) was calculated for each animal and these data were 
expressed for each group, relative to the fasting glucose levels of the control animals.  
 Basal and insulin-stimulated glucose transport: After an overnight fast, following 14 or 
15 days of treatment (as not all animals could be studied on the same day for practical purposes), 
basal and insulin-stimulated glucose transport and protein activation were assessed in paired, 
isolated soleus and EDL strips (~25 to 30 mg each). As previously published (Ritchie, 2011), a 
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27-gauge needle was used to carefully strip the soleus and EDL longitudinally, from tendon to 
tendon, into three sections, which were incubated under their respective condition. Pre-gassed 
(95% O2-5% CO2) Medium 199 containing 0.1% BSA and heated to 30oC was used as a base 
for all glucose uptake buffers. Insulin (10 mU/ml) (Humulin R; Eli Lilly, Toronto, Ontario, 
Canada) was added to all buffers for the insulin-stimulated condition. Immediately following 
excision, the soleus or EDL strips were placed in 20-ml glass vials containing pre-incubation 
buffer for 30 min in the presence or absence of insulin (10mU/ml; concentration maintained in 
following buffers). The pre-incubation buffer was a base buffer containing 8 mM glucose and 32 
mM mannitol. Both the soleus and EDL strips were washed in two glucose-free buffers, 
containing 4 mM pyruvate and 36 mM mannitol, for 10 min each, then the muscles were 
incubated in base buffer with 4 mM pyruvate, 8 mM 3-O-[3H]methyl-D-glucose (0.5 µCi/ml; 
American Radiolabeled Chemicals, St. Louis, MO), and 28 mM [14C] mannitol (0.2 µCi/mmol; 
American Radiolabeled Chemicals, St. Louis, MO) for 20 min (insulin-stimulated) or 40 min 
(basal) conditions. Soleus and EDL muscles were then removed, thoroughly blotted to remove 
extra buffer, and had their tendons removed. Muscles were then weighed and subsequently 
digested for 10 min in 1 ml of 1 M NaOH at 95oC. Muscle digest from each sample (200 µl) was 
sampled in duplicate and analyzed by liquid scintillation counting, from which glucose transport 
was calculated. 
Histology: Skeletal muscle (tibialis anterior, TA) tissues from animals euthanized after ~ 
2 weeks of treatment were embedded in tissue freezing medium, frozen in liquid nitrogen and 
cryosectioned (10 µm thick). The TA was stained for fiber type and SDH activity as previously 
described (Beaudry 2015). 
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Fibre Type, SDH and Oil Red O Analysis: To identify skeletal muscle fibre type a 
metachromatic myosin ATPase stain was performed on cross-sections of the TA muscle using a 
modified protocol (Ogilvie 1990). Sections were pre-incubated in an acidic buffer (pH = 4.25) to 
differentially inhibit myosin ATPases within the different fibre types. In this protocol, type I 
fibres appear dark blue, type IIa appear very light blue and type IIb and IIx are not apparent from 
each other and are thus classified as IIb/x. These fibres appear bluish-purple. A representative 
image of the TA for each group was acquired for analysis. The distribution of the CSA in a fiber 
population was assessed and depicted as a histogram.  
Succinate dehydrogenase (SDH) activity was then assessed using histochemical analysis 
(Shortreed, 2009) and expressed as total optical density. The same muscle regions of the TA that 
were used for fibre typing were used for SDH activity determination. Serial sections were used to 
directly compare levels of SDH in each fibre with each fibre type. SDH activity was assessed 
with Adobe Photoshop CS6, converted to grayscale, and reported as the average optical density 
(sixty fibers were counted per muscle section). The grayscale is evaluated on a range of 
completely black (set a zero) to white (set at 225).  
TA sections were fixed with 3.7% formaldehyde for 1 hour at room temperature while an 
ORO solution composed of 0.5 g ORO powder (Sigma-Aldrich, Canada) and 100 ml of 60% 
triethyl phosphate (Sigma-Aldrich, Canada) was mixed and filtered. Following fixation in 3.7% 
formaldehyde, slides were immersed in filtered ORO solution for 30 minutes at room 
temperature. Slides immediately underwent five washes with ddH2O, were allowed to dry for 10 
minutes and were sealed with Permount (Sigma-Aldrich, Canada). All images were acquired at 
10 x magnifications, using a Nikon Eclipse 90i microscope (Nikon, Canada) and Q-imaging 
MicroPublisher 3.3 RTV camera with Q-capture Software.  
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Western Blot Analysis: All procedures for derivatization of protein carbonyls with DNPH 
(2,4-dinitrophenylhydrazine) were conducted using the Oxy blot kit (Millipore, S7150). Briefly, 
10 μg and 15 μg of protein was loaded from EDL and soleus muscles respectively. Proteins were 
denatured with 12% SDS followed by derivatization for 20 min with gentle agitation at room 
temperature. Neutralization solution was then added to each sample to stop the derivatization 
reaction and samples were reduced with 2-mercaptoethanol (5%v/v). Proteins were separated on 
a 12% polyacrylamide gel and transferred onto a polyvinylidene fluoride (PVDF) membrane 
(Bio-Rad, Canada). Membranes were blocked in odyssey blocking buffer for 1 hour prior to 
overnight incubation with primary antibody provided with the kit (1:300, Rabbit Anti-DNP). On 
the following day membranes were washed with Tris-buffered saline with Tween 20 (TBST) and 
incubated with goat anti-rabbit IgG 680 (Licor, 926-68071) for 1 hour and imaged (Odyssey, 
Licor Bioscience). EDL and soleus muscles were homogenized and separated on a 10% (GR, 
11β-HSD1, GLUT4, total Akt, pSer473 and pTh308) or 6% (total PGC1-α, IRS-1, and AS160) 
SDS-page gel according to previously published work (Beaudry, 2015). Proteins were 
transferred to a PVDF membrane (Bio-Rad, Canada) and were blocked in 5% powdered milk 
and TBST at room temperature for 1 hour. Membranes were then incubated overnight at 4°C 
with their respective primary antibodies at a concentration of 1:1000 (GR, Cat#sc-12763, Santa 
Cruz Biotechnology, USA; 11β-HDS1, Cat#10004303, Cayman Chemical, USA; GLUT4, 
Cat#ab65267, Abcam, Toronto, ON; Akt, Cat#ab8805, Abcam, Toronto, ON; pSer473, 
Cat#ab28821, Abcam, Toronto, ON; pTh308, Cat#ab5626, Abcam, Toronto, ON; PGC1-α, 
Cat#4359, Cell Signaling, USA; total IRS-1, Cat#2382, Cell Signaling, USA; AS160, Cat 
#C69A7, Cell Signaling,  USA). The following morning, the membranes were washed with 
TBST and incubated with anti-mouse (1:10000, Cat#ab6789, Abcam, Toronto, ON) or anti-
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rabbit (1:10000, Cat#ab6721, Abcam, Toronto, ON) secondary antibodies for 1 hour at room 
temperature. Membranes were then washed and imaged. Images were detected on a Kodak In 
vivo FX Pro imager and molecular imaging software (Carestream Image MI SE, version 
S.0.2.3.0, Rochester, New York) was used to quantify protein content. GAPDH (1:10000, 
Cat#ab9484, Abcam, Toronto, ON) and α-tubulin (1:10000, Cat#ab7291, Abcam, Toronto, ON) 
were used as loading controls. 
 Statistical Analysis: All data are represented as means ± SE, with a criterion of P ≤ 0.05 
or P ≤ 0.01 and were assessed as stated using one-way ANOVAs as a means of statistical 
significance. Individual differences were calculated using Tukey post-hoc test (Prism4; 
Graphpad software Inc; La Jolla, CA, USA).  
Results 
 Body mass and food intake: Day 11 was used as a marker of body mass and food intake 
as the evening of that day the animals were fasted in preparation for the OGTT on day 12, which 
would alter their body composition. Cort-treatment resulted in a significant loss of total body 
mass (Table 2.1, P ≤ 0.01), regardless of diet, as measured on day 11 of the protocol. Absolute 
food intake (g/day) was higher in Cort-SD animals compared to the other two groups (P ≤ 0.01), 
while relative food intake (kcal/kg body mass/day) was higher in the two Cort-treated groups 
compared with the controls (both P ≤ 0.01). Cort-HFD had significantly lower relative EDL 
mass compared to the other two groups (P ≤ 0.01), while Cort-treatment in both groups (chow 
and HFD) caused an increase in relative soleus mass (Table 2.1, P ≤ 0.05), as has previously 
been shown by us (Beaudry, 2014). Interestingly, the addition of HFD to Cort treatment 
appeared to attenuate the rise in soleus mass compared to Cort treatment alone (Table 2.1, P ≤ 
0.01).  
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 Plasma cort, and fasted glucose and insulin concentrations: As expected, Cort levels 
measured at 0800, 7 days after pellet implantation, were elevated in both Cort groups (Table 2.1, 
P ≤ 0.05), similar to what we have previously reported in this model (Shpilberg, 2012). There 
was no significant effect of the HFD on Cort concentrations within either the Control or Cort-
treated groups (Table 2.1). Fasting blood glucose values were significantly elevated prior to the 
oral glucose challenge within the Cort-HFD group only (Fig. 2.2A, P ≤ 0.01). Fasting insulin 
values were 3-4 fold higher in the Cort-treated animals compared to controls, with the Cort-HFD 
group having the highest values, albeit not statistically different from the Cort-SD group (Fig. 
2,2B, P ≤ 0.05).  
 Oral Glucose Tolerance Test:  Cort-treatment resulted in elevated blood glucose values 
during the oral glucose challenge compared to the Control-HFD group (Fig. 2.2C), however, 
only Cort-HFD animals had significantly higher glucose AUC compared to controls when the 
AUC was adjusted for baseline values within each group (Fig. 2.2C`, P ≤ 0.05).   
 Skeletal muscle glucose transport (ex-vivo): Basal glucose transport in the EDL was ~40-
50% lower in the Cort-treated groups compared to control-HFD animals, although these 
differences failed to reach statistical significance. Basal glucose uptake was similar in all three 
groups within the soleus muscle.  Insulin stimulation significantly increased glucose transport 
within both the EDL and soleus in all treatment groups (Fig 2.3A, B; P ≤ 0.05). This effect was 
blunted within the EDL muscle only in the Cort-HFD animals (Fig. 2.3A`, (P ≤ 0.01). 
Intriguingly, insulin-stimulated glucose transport was unaffected by either diet or Cort-treatment 
in the soleus muscle, albeit the delta change from baseline was the lowest in the Cort-HFD group 
(Fig. 2.3B`).   
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Table 2.1. Corticosterone concentrations, body composition and food intake. 
 
 Control-HFD Cort-SD Cort-HFD 
Fasted body mass (g) 394.3 ± 6.0 301.6 ± 12.0* 298.3 ± 15.5* 
Absolute food intake (g/day) 22.4 ± 0.7 34.6 ± 3.3† 24.3 ± 2.5 
Relative food intake (kcal/g 
body mass/day) 
0.29 ± 0.01 0.4 ± 0.03* 0.42 ± 0.04* 
EDL mass (g/kg/BM) 0.46 ± 0.01 0.49 ± 0.04 0.38 ± 0.01# 
Soleus mass (g/kg/BM) 0.35 ± 0.03 0.48 ± 0.02† 0.41 ± 0.03# 
(AM) Plasma corticosterone 
(ng/ml) 
29.3 ± 18.0 426.1 ± 77.5* 485.7 ± 80.5* 
 
Notes: Body weight and food intake were measured every day, the data here is from day 11, one 
day prior to the OGTT. Plasma corticosterone values were measured 7 days after pellet 
implantation and high-fat diet administration. Body mass on day 11 with one-way ANOVA.  
*Significantly different from control-HFD p<0.001 with Tukey’s post Hoc, † significantly 
different from control and Cort-HFD p<0.001 with Tukey post Hoc, #significantly different from 
control-HFD and Cort-SD p<0.001 with Tukey post Hoc.
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Figure 2.2. Corticosterone and a high-fat diet cause severe hyperglycemia and glucose 
tolerance. 
Fasted glucose (A) and insulin (B) concentrations were measured at the onset of an oral glucose 
tolerance test (OGTT) (C, D); n=5. Bars that do not share similar letters denote statistical 
significance (P<0.05) using a one-way ANOVA with Tukey’s (A and D), (P<0.01) (B). All 
values are means ± SE. 
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Figure 2.3. Corticosterone and a high-fat diet impair glucose transport in the extensor 
digitorum longus but not in the soleus. 
Glucose transport was assessed in the EDL (A, A`) and the soleus (B, B`) at basal and insulin 
stimulated conditions; n=4. δ Significantly different from respective basal state (P ≤ 0.05) using 
an unpaired, two-tailed, T-test. Bars that do not share similar letters denote statistical 
significance (P ≤ 0.05) using a one-way ANOVA with Tukey post Hoc (A'). All values are 
means ± SE.  
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 Insulin signaling protein content: Within the EDL muscle, IRS-1 total protein was 
markedly lower in both Cort-treatment compared to control-HFD animals (Fig. 2.4A, P ≤ 0.01). 
In contrast, AS160 total protein was significantly increased in the Cort-SD group in comparison 
to the Control-HFD group, and even more elevated within the Cort-HFD group (Fig. 2.4B, P ≤ 
0.01). There were no significant differences in GLUT4 total protein concentration across all 
three treatment groups with the EDL muscle (Fig. 2.4C). Within the soleus, there was no effect 
of Cort-treatment on total IRS-1 or AS160 protein content (Fig. 2.4D-E). However, total GLUT4 
content was higher in the Cort-SD group compared to Control-HFD group, and paradoxically 
lower in the Cort-HFD group compared to the control-HFD group (Fig. 2.4F, P ≤ 0.01).  
 To determine whether there was an effect of insulin stimulation on components of the 
insulin signaling pathway, total and phosphorylated Akt was assessed both with and without 
insulin stimulation ex vivo, in both the EDL and soleus muscles. Within the EDL, there was an 
effect of insulin to increase pSer473 in all three treatment groups, with Cort-treatment blunting 
this effect (Fig. 2.5A, P ≤ 0.01). When the percent change in phosphorylation status from basal 
to insulin stimulated was measured relative to control-HFD, there was a greater impairment with 
Cort-HFD treatment compared to the other two groups (Fig. 2.5A`, p=0.0591).  Interestingly, this 
result was not found within the soleus (Fig. 2.5C, C`), as there was no difference in insulin 
stimulated pSer473 with either Cort-SD or Cort-HFD. While there was no effect of Cort-treatment 
to decrease pTh308 after insulin stimulation in the EDL (Fig. 2.5B), when the percent change in 
phosphorylation status was measured relative to control-HFD, there was a negative effect of 
insulin to stimulate pTh308 in the Cort-HFD group (Fig. 2.5B`, p=0.073), suggesting that pTh308  
is activated even before insulin administration. When measured in the soleus, there was no effect 
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of insulin stimulation to increase pTh308 phosphorylation within any treatment group (Fig. 2.5D, 
D`).    
 Muscle cross-sectional area, fibre frequency, succinate dehydrogenase and ORO 
content: To examine the effect of Cort-HFD-treatment within the skeletal muscle, the TA muscle 
of representative animals from each treatment group was stained for fibre type to measure CSA, 
SDH, and ORO content. CSA, indicating individual muscle fibre size, was lowest in type IIb/x 
fibres of Cort-HFD-treated animals (Fig. 2.6A, B, P ≤ 0.05). While the CSA of the type IIb/x 
fibres of the Cort-SD animals was also decreased, it did not reach statistical significance. A shift 
to smaller muscle fibres with Cort treatment, particularly in the Cort-HFD group, is displayed in 
the percent frequency histogram in the various fibre size categories shown (Fig. 2.6C). SDH 
staining, which correlates to oxidative capacity, was not significantly different among the three 
treatment groups (Fig. 2.6D, E). ORO staining of TA muscle sections was used to visually 
examine lipid accumulation in all treatment groups (Fig 2.6F). Lipid staining appeared to be 
highest in Cort-HFD-treated animals, which correlates with previous data examining the effect of 
Cort-HFD-treatment (Beaudry, 2015; Shpilberg, 2012). 
 Carbonylated protein and PGC1-α content: Total protein carbonylation was examined in 
both the EDL and soleus to determine whether there were any elevations in oxidative stress due 
to either a HFD or Cort-treatment. There were no significant differences in total protein 
carbonylation within either the EDL or soleus (Fig. 2.7A, C). Additionally, total PGC1-α 
content, a marker of mitochondrial biogenesis, was analyzed yielding no significant differences 
between groups within either the EDL or the soleus (Fig. 2.7B, D). 
 Glucocorticoid receptor and 11β-HSD1 protein content: GR protein content, within the 
EDL and soleus muscles, was unaffected by two weeks of Cort-treatment, regardless of diet (Fig. 
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2.8A). Overall, however, soleus muscle expressed ~2-fold higher GR concentration than EDL 
muscle, which was somewhat surprising since much of the selective effects on white muscle may 
have been explained by a higher GC receptor density. 11β-HSD1, the enzyme responsible for 
converting inactive 11-dehydrocortisone to active cortisol, protein content was highest in the 
EDL of the Cort-HFD group (Fig. 2.8B, P ≤ 0.05), but was not statistically different from that 
found within the EDL of the Cort-SD group. In contrast to the receptor expression, 11β-HSD1 
protein expression was higher in EDL than in the soleus in all three treatment groups.  
 82 
0
1
2
3
AS160
GAPDH
Control
HFD
CORT
SD
CORT
HFD
a
b
c
A
S
1
6
0
 A
.U
.
0.0
0.5
1.0
1.5
Control
HFD
CORT
SD
CORT
HFD
AS160
Alpha-Tubulin
A
S
1
6
0
 T
o
ta
l A
.U
.
EDL
0.0
0.2
0.4
0.6
0.8
Control
HFD
CORT
SD
CORT
HFD
IRS-1
GAPDH
Control
CORT
SD
CORT
HFD
a
b bIR
S
-1
 T
o
ta
l A
.U
.
0.0
0.5
1.0
1.5
2.0
Control
HFD
CORT
SD
CORT
HFD
IRS-1
Alpha-Tubulin
IR
S
-1
 T
o
ta
l A
.U
.
0.0
0.5
1.0
1.5
2.0
2.5
GLUT4
GAPDH
Control
HFD
CORT
SD
CORT
HFD
G
L
U
T
4
 A
.U
.
0.0
0.5
1.0
1.5
GLUT4
GAPDH
Control
HFD
CORT
SD
CORT
HFD
a
b
c
G
L
U
T
4
 A
.U
.
SoleusA)
B)
C)
D)
E)
F)
 
 
 83 
Figure 2.4. Insulin signaling proteins within the extensor digitorum longus are affected by 
corticosterone-treatment. 
Total IRS-1, AS160, and GLUT4 were measured in the EDL (A-C) and the soleus (D-F); n=5. 
Bars that do not share similar letters denote statistical significance (P ≤ 0.01) using a one-way 
ANOVA with Tukey post Hoc. All values are means ± SE. 
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Figure 2.5. Effect of corticosterone and a high-fat diet on Akt phosphorylation. 
Akt pSer473 was analyzed in the EDL (A, A’) and the soleus (C, C`) at basal and insulin-
stimulated conditions. Akt pTh308 was analyzed in the EDL (B, B`) and the soleus (D, D`) at 
basal and insulin-stimulated conditions; n=5. δ Significantly different from respective basal state 
(P ≤ 0.05) using an unpaired, two-tailed, T-test. Bars that do not share similar letters denote 
statistical significance (P<0.05) using a one-way ANOVA with Tukey post Hoc. All values are 
means ± SE. 
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Figure 2.6. Corticosterone and a high-fat diet cause glycolytic fibre atrophy. 
Representative images of the tibialis anterior (TA) depicting fiber type staining (A), 
measurement of individual muscle fiber cross-sectional area (CSA) (B) and assessment of 
individual fiber frequency (C) within each treatment group. Representative images of the TA 
depicting succinate dehydrogenase (SDH) staining (D), quantification of the intensity of SDH 
staining within all three treatment groups (E), and Oil Red O (ORO) neutral lipid staining (F); 
n=5. *Significantly different from control-HFD (P ≤ 0.05) using a one-way ANOVA with Tukey 
post Hoc. All values are means ± SE. 
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Figure 2.7. Corticosterone and a high-fat diet do not alter protein carbonyl or PGC1-α 
content. 
Protein carbonylation in EDL (A) and soleus (C). Relative total PGC1-α in EDL (B) and soleus 
(D); n=4-5. Analyzed by one-way ANOVA with Tukey post Hoc. All values are means ± SE. 
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Figure 2.8. Glucocorticoid receptor and 11β-HSD1 content are elevated in the soleus and 
extensor digitorum longus after corticosterone and high-fat diet treatment. 
Glucocorticoid receptor expression was assessed in both the EDL and soleus of all three 
treatment groups (A) at basal conditions. 11β-HSD1 total protein expression was measured in 
both the EDL and soleus of all three treatment groups (B) at basal conditions; n=5. *Significantly 
different from control-HFD (P ≤ 0.05) using a one-way ANOVA with Tukey post Hoc. All 
values are means ± SE. 
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Discussion 
 This study clearly demonstrates the deleterious effects of combining exogenous Cort-
treatment with a HFD can have on skeletal muscle, particularly in those muscle groups that 
expressed a high degree of glycolytic fibres.  Moreover, we show here that the combination of 
Cort and a HFD causes severe whole body glucose intolerance, muscle fibre type specific 
impairments in insulin signaling and glucose transport and considerable glycolytic muscle 
atrophy. The striking impairments observed, primarily in glycolytic (white) muscle, are not 
explained by a higher glucocorticoid receptor expression in that tissue compared with oxidative 
(red) muscle, but may be explained by a greater regeneration of intracellular GC via the 
increased expression of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) 
levels in the former muscle type.  
 The metabolic impairments caused by Cort-HFD-treatment have been previously 
examined by our lab in a number of other publications focusing on whole body glucose 
metabolism, liver and pancreatic tissues (Beaudry, 2013; Beaudry, 2015; Beaudry, 2014; 
D'souza, 2011; Shpilberg, 2012). The focus of this study was to determine whether skeletal 
muscle is a primary organ affected by this co-treatment, which would help to further explain the 
animals' severe hyperinsulinemic/hyperglycemic phenotype. To help determine if skeletal 
muscle was a primary organ of metabolic defect with GC and/or HFD treatment, we used an ex-
vivo glucose transport analyses that allows for more direct measures of muscle specific glucose 
transport under a standardized insulin exposure. This technique was advantageous since 
measuring insulin signaling and transport in vivo would have suffered from the inability to 
control for the markedly differing circulating insulin (and glucose levels) in these three animal 
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groups (Fig 2.2).  Using this technique also allowed us to determine if different muscle groups 
(i.e. white vs red) differ in their responses to prolonged GC-HFD treatment. 
 The combination of exogenous Cort and a HFD caused a novel and significant reduction 
in insulin-stimulated glucose uptake (ISGU) within the EDL but not within the soleus. The effect 
of dexamethasone, a synthetic GC, to impair skeletal muscle ISGU has previously been assessed 
in the epitrochlearis (glycolytic) and soleus muscles of male rats (11, 41). The authors found that 
both muscle types were significantly impacted after ~11 days of dexamethasone treatment, 
resulting in impaired ISGU. Here, we examined the addition of a HFD, as well as a lower ex-
vivo insulin concentration, on ISGU, also within both a glycolytic (EDL) and an oxidative 
(soleus) muscle. The insulin concentration used in this study was chosen to represent a lower, 
more physiological value, with the objective of elucidating the mechanism behind the 
impairments in glucose transport.  
 GCs are well-known stimulators of whole body lipolysis (Peckett, 2011), causing 
increased non-esterified free fatty acid (NEFA) and triglyceride levels. We have previously 
shown that Cort-HFD-treatment is capable of causing significant elevations in circulating 
triglycerides, with minimal effects on NEFA concentrations, in addition to intramuscular lipid 
accumulation (Shpilberg, 2012) which was improved with 2 weeks of Mifepristone 
administration (Beaudry, 2014). The reduction in insulin sensitivity and subsequent impairment 
to ISGU within the skeletal muscle induced by GC is thought to occur through direct 
perturbation of insulin signaling in combination with additional effects on protein and lipid 
metabolism. This suggests that the added variable of a HFD could compound the established 
impairments associated with GC treatment, especially since, in accordance with previously 
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published work (Beaudry, 2015; Shpilberg, 2012), we observed grater neutral lipid accumulation 
through ORO staining within the TA muscle (Fig. 2.6F). 
 GCs can affect muscle insuin signaling at several levels along the insulin signaling 
cascade, notably decreasing total IRS-1 content (Saad, 1993) while increasing Ser307 
phosphorylation (Morgan, 2009). Increased serine phosphorylation can subsequently decrease 
affinity of IRS-1 for the insulin receptor, increasing IRS-1 degradation (Aguirre, 2000; Aguirre 
2002), which could be the reason why both Cort-treated groups had deceased IRS-1 content 
within the EDL. Under basal conditions, AS160 is located within the vesicles that contain 
GLUT4 and controls the availability of guanosine triphosphate (GTP), which is required for 
vesicle translocation to the cell membrane, ultimately initiating glucose entry. Upon 
phosphorylation, initiated by Akt/PKB, AS160 dissociates from the vesicle, which allows the 
binding of GTP and subsequent vesicle translocation (Sano 2003). Previous research has 
established that GCs increase AS160 protein and GLUT4 mRNA content (Ewart, 1998; Morgan, 
2009) as a compensatory mechanism to preserve insulin sensitivity to compensate for inhibition 
of insulin signaling through decreased IRS-1. Additionally, the phosphorylation of AS160 by 
Akt regulates GLUT4 translocation which is the main mechanism that permits glucose entry into 
insulin-target tissues.  Intriguingly, we found that with Cort-HFD treatment there was an 
upregulation of AS160 total protein, yet there were still impairments in glucose transport within 
the EDL. We also observed a trend for increased GLUT4 protein due to Cort-treatment, within 
the EDL. Neither of these results were found within the soleus, however, possibly suggesting a 
protective effect of oxidative muscle on Cort-HFD treatment. Interestingly, the blockade of 11β-
HSD1, the major enzyme responsible for activation of GCs, in both human and rodent skeletal 
muscle (selective and nonselective) is able to restore IRS-1 levels similar to controls, improve 
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Akt/PKB activation and caused an insulin-sensitizing effect (Morgan, 2009). Moreover, selective 
inhibition of 11β-HSD1 caused a decrease in lipogenic gene expression (ACC1, DGAT, FAS) 
and increased free fatty acid (FFA) utilization (Berthiaume 2007) with the net effect being a 
decrease in intramuscular lipid accumulation, as well as a decrease in local FFA and DAG 
generation. These conclusions, added to the fact that we did not see any major differences 
between key insulin signaling proteins in either Cort-treated group, suggest that the added fat 
content from the diet did not have a substantial effect on insulin signaling machinery in this 2-
week treatment period.   
 Pronounced skeletal muscle atrophy is a common side effect of prolonged GC treatment 
with corticosteroids or with Cushing's disease (Khaleeli, 1983). There are a number of possible 
mechanisms explaining skeletal muscle atrophy with elevated GCs.  These steroids are known to 
be both catabolic, through stimulation of muscle proteolysis and anti-anabolic, through inhibition 
of insulin and IGF1-related muscle protein synthesis (Lofberg, 2002). The increase in circulating 
amino acids, caused by the inhibition of amino acid transport into the skeletal muscle by GC, in 
addition to the atrophy-related decrease in cross-sectional area (CSA), likely all contribute to the 
reduced ISGU associated with elevations in plasma GC. GCs are typically associated with the 
preferential targeting of glycolytic skeletal muscle for atrophy (Dekhuijzen, 1995; Fournier 
2003). While we did not measure protein synthesis or degradation, we did analyze the CSA and 
found that the Cort-HFD group had the lowest type IIb/x fibre CSA, which manifested as a 
possible fibre type shift when analyzed as a histogram. These results suggest that the skeletal 
muscle of the Cort-HFD group was more affected by the atrophic stimulus typically conveyed 
through elevations in GCs. This could be a contributing factor to the obvious glucose intolerance 
as there was less muscle available to take up the added plasma glucose. 
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 In addition to muscle size, alterations in muscle quality may be an important component 
in explaining the synergism associated with Cort-HFD-treatment. Excessive lipid accumulation 
within the skeletal muscle has been associated with sarcopenia (Tardif, 2014), in addition to 
chronic diseases such as diabetes (Goodpaster, 2004), and muscular dystrophy (Lott 2014) while 
also considered an important component of insulin resistance (Hegarty, 2003). Elevations in 
intramuscular lipid infiltration have been acknowledged as a contributor to declining strength 
and mobility, independent of muscle size (Goodpaster, 2001a), and in situations of reduced 
insulin action, it has been identified that irregular mitochondrial fatty acid metabolism is linked 
to intramuscular lipid accumulation (Kelley, 2002; Vladimir B. Ritov, 2005). Mice fed a HFD 
for ~2 months or less were found to have no impairments in basal skeletal muscle protein 
metabolism (Anderson 2008) but expressed whole body insulin resistance and impaired 
mitochondrial function (Boudina 2012). GCs have also been implicated in mitochondrial 
dysfunction, as long-term corticosteroid treatment causes mitochondrial damage (Mitsui 2002) 
and overproduction of ROS in human myogenic cells (Oshima 2004), while acute administration 
of Cort in broiler chickens was shown to augment lipid peroxidation, ultimately inducing 
oxidative stress (Lin 2009). To determine whether the mitochondria, or elevations in protein 
oxidation, could be contributing factors to the synergism we see with the Cort-HFD combination, 
we measured basic markers of mitochondrial biogenesis and reactive oxygen species (ROS) 
production. We did not find any statistically significant effects of Cort-HFD-treatment on SDH 
staining, a marker of oxidative capacity, although the Cort-HFD group did appear to have lighter 
staining intensity. Additionally, PGC1-α protein expression, a marker of mitochondrial content, 
was unaffected by Cort-HFD-treatment, as was total protein carbonylation. Protein carbonylation 
was tested as a measure of protein modification (Antunes 2014), and is not considered specific to 
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ROS produced within either the mitochondria or cytosol. As such, it is possible that while we 
were unable to detect any differences in total protein carbonylation, future measurement of 
protein nitrosylation or lipid membrane peroxidation, or other cellular ROS accumulation 
measurements, could link ROS elevations within the skeletal muscle to the major metabolic 
effects induced by the combination of Cort-treatment with a HFD. 
 There is much interest in the management of local GC action as a therapeutic strategy, as 
while it is known that excessive GC levels can play a role in the pathogenesis of obesity and 
T2DM development (Tomlinson 2007; Walker 2006), circulating plasma GC concentrations are 
not always elevated in obese individuals. It is possible that an increase in local reactivation of 
GC in a tissue-specific manner could be the driving force behind the associated metabolic 
dysregulation. The enzyme responsible for modulating the tissue-specific effects of circulating 
GC is 11β-HSD1, which activates inactive GCs (i.e. cortisone in humans and 11-
dehydrocortisone in rodents) in muscle, liver and adipose tissue so that they can then bind and 
activate the glucocorticoid receptor (GR) (Tomlinson 2004). Other studies have examined the 
effect of both deleting and over-expressing 11β-HSD1 in metabolism, showing that the high 
expression of this enzyme in adipose tissues drives the development of the metabolic syndrome 
(Drake 2005; Livingstone 2003; Wamil, 2011). In our study, both Cort-treated groups had 
elevations in 11β-HSD1 expression, particularly in EDL muscle of the Cort-HFD group (Fig. 
8B). In humans, increased muscle 11β-HSD1 has been linked to reduced insulin sensitivity 
(Whorwood, 2002) and cortisone itself has been shown to induce insulin resistance via 
upregulation of 11β-HSD1 in C2C12 cells (Park 2014). We have previously found there to be 
increased 11β-HSD1 mRNA and protein expression in the subcutaneous and visceral fat of these 
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animals (Beaudry, 2014; Shpilberg, 2012), indicating that this treatment causes a widespread up 
regulation of this enzyme, which likely worsens the metabolic phenotype in a number of tissues. 
 In summary, we show that Cort-HFD-treatment causes a more severe reduction in ISGU 
within glycolytic muscle, a consequence that appears to be linked to a greater glycolytic atrophy 
than Cort treatment alone.  Furthermore, Cort-treatment decreases total IRS-1 content and 
pSer473 phosphorylation within glycolytic muscle, a result that was not paralleled within the 
soleus nor affected by HFD. Interestingly, 2 weeks of Cort-HFD-treatment seemed to have the 
highest increase in 11β-HSD1 total protein, again within glycolytic muscle, but surprisingly 
showed no effects to induce elevations in protein oxidation. This study underscores the 
significant adverse effects that combining Cort-treatment with a HFD can have within the 
skeletal muscle, particularly in white muscle, which likely contributes to the diabetic phenotype. 
These findings also underscore the importance of a low fat diet when individuals are given a 
course of GC treatment.  
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Chapter 3 
Voluntary exercise improves metabolic profile in high-fat fed glucocorticoid treated rats  
 
This chapter is an original published article. It is presented in its published format. 
 
This research was originally published in the Journal of Applied Physiology. Jacqueline L. 
Beaudry*, Emily C. Dunford*, Erwan Leclair, Erin R. Mandel, Ashley J. Peckett, Tara L. Haas 
and Michael C. Riddell. Voluntary exercise improves metabolic profile in high-fat fed 
glucocorticoid treated rats. 
doi: 10.1152/japplphysiol.00467.2014.  
 *Co First Author 
 
Author Contributions: Dr. Jacqueline Beaudry and I designed the study and wrote the paper 
along with input from our supervisor Dr. Michael Riddell. Dr. Jacqueline Beaudry and I 
performed all animal handling, including pellet surgeries, oral glucose tolerance and insulin 
tolerance tests, and plasma analysis (insulin ELISA, corticosterone RIA, NEFAs, GIP, GLP-1). 
Dr. Erwan Leclair assisted with measuring GIP and GLP-1. Dr. Jacqueline Beaudry completed 
all islet analyses. I sectioned and stained all skeletal muscle samples for measurement of CSA 
and SDH, Ashley Peckett assisted with SDH analysis, while Erin Mandel completed the capillary 
to fibre analysis, with input from Dr. Tara Haas. I performed western blotting of all skeletal 
muscle proteins with assistance from Dr. Erwan Leclair. Dr. Michael Riddell oversaw the entire 
study and assisted in manuscript preparation. 
 
Rationale: Regular exercise is well known to induce considerable physiological improvements 
in a number of pathological situations. Chapter 3 focussed on the application of voluntary wheel 
running, as a more practical exercise stimulus, to the ROD model (elevated GC and HFD). The 
completion of this study demonstrated the viability of aerobic exercise as a possible therapeutic 
strategy for individuals who suffer from endogenous GC overproduction or are taking exogenous 
GC therapy and indulge in poor diet choices.
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Preface 
  Diabetes is rapidly induced in young male Sprague-Dawley rats following treatment with 
exogenous corticosterone (CORT) and a high-fat diet (HFD). Regular exercise alleviates insulin 
insensitivity and improves pancreatic β-cell function in insulin resistant/diabetic rodents, but its 
effect in an animal model of elevated glucocorticoids is unknown. We examined the effect of 
voluntary exercise (EX) on diabetes development in CORT-HFD treated male Sprague-Dawley 
rats (~ 6 weeks old). Animals were acclimatized to running wheels for 2 weeks, then given a 
HFD, either wax (placebo) or CORT pellets and split into 4 groups: placebo-SED or -EX and 
CORT-SED or -EX. After 2 weeks of running combined with treatment, CORT-EX animals had 
reduced visceral adiposity, increased skeletal muscle type IIb/x fibre area, oxidative capacity, 
capillary to fibre ratio and insulin sensitivity compared to CORT-SED animals (all p<0.05). 
Although CORT-EX animals still had fasting hyperglycemia, these values were significantly 
improved compared to CORT-SED animals (14.3±1.6 vs. 18.8±0.9 mM). In addition, acute in 
vivo insulin response to an oral glucose challenge was enhanced ~ 2-fold in CORT-EX vs. 
CORT-SED (p<0.05) which was further demonstrated ex vivo in isolated islets. We conclude that 
voluntary wheel running in rats improves, but does not fully normalize, the metabolic profile and 
skeletal muscle composition of animals administered CORT and HFD.   
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Introduction 
 Sustained elevations in circulating glucocorticoids (GCs) cause major physiological 
consequences to the body including severe insulin resistance (Shibli-Rahhal, 2006) central 
obesity (Peckett, 2011) non-alcoholic fatty liver disease (D'souza, 2011) and hyperglycemia 
(Lansang 2011). Both rodent (Campbell 2010; Király 2008) and human (Cameron 1984; 
Chiodini 2006; Lansang, 2011) studies of type 2 diabetes mellitus (T2DM) show a strong 
correlation between hypercortisolemia and the development of T2DM. Examination of possible 
therapeutic options to ameliorate GC-induced metabolic conditions is of utmost importance as 
exogenous GCs are among the most commonly prescribed anti-inflammatory and 
immunosuppressive medications (Rosen 2005).  
 Our laboratory has developed an animal model of rapid-onset diabetes induced through 
treatment with exogenous corticosterone, (CORT, the primary active GC in rodents) and a high-
fat diet (HFD, 60% calories from fat) (Beaudry, 2013; Beaudry, 2014; Shpilberg, 2012). We 
found that modest elevations in CORT, comparable to peak diurnal levels observed in healthy 
rodents, when combined with a HFD, result in severe hyperglycemia and hyperglucagonemia, 
despite hyperinsulinemia and increased pancreatic β-cell mass. These results are largely due to 
extreme whole-body insulin insensitivity and impaired insulin responsiveness to oral glucose 
challenge (Beaudry, 2013). Recently, we have also demonstrated that this diabetic phenotype can 
be corrected by the administration of a nonspecific GC receptor II antagonist, RU486, without 
modification to the animal’s diet (Beaudry, 2014). However, RU486 is also highly selective for 
the progesterone receptor (Johanssen, 2007) and may present complications with pregnancy and 
other undesirable side effects. To date, other more selective GR antagonists have failed to 
completely reverse the diabetic phenotype in GC-treated animals (Beaudry, 2014). Thus, 
alternative therapies for reducing the metabolic effects of hypercortisolemia are needed. 
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 Regular exercise in diabetic prone rats can improve glucose homeostasis by increasing 
whole body insulin sensitivity (Király 2010), β-cell function (Király, 2008) and by lowering 
circulating basal (non-stimulated) GC levels (Campbell, 2010; Király 2007). Interestingly, in 
Zucker Diabetic Fatty (ZDF) rats, the prevention of hyperglycemia with regular exercise 
coincides with the prevention of basal hyperglucocorticoidemia (Campbell, 2010). This may 
indicate that some of the metabolic advantages of exercise in diabetes prevention and treatment 
occur through a reduction in chronic GC elevation thereby limiting the GC action at the tissue 
level. Little is known about the effect of voluntary exercise on a model of exogenously 
administrated GCs, as acute exercise would not be expected to lower GC concentrations (Fediuc 
2006). Interestingly, dexamethasone-treated Wistar rats that underwent treadmill training for 8 
weeks, showed restoration of muscle glycogen levels and improved muscular atrophy, despite 
sustained insulin resistance (Barel, 2010), thereby suggesting exercise training may offer some 
protection against hyperglucocorticoidemia.  
 Voluntary exercise normalizes glucose tolerance and islet glucose sensitivity (Beaudry 
2012) through up-regulated mechanisms of skeletal muscle glucose uptake, i.e. GLUT4 
translocation (Burr 2012; Van Raalte, 2009), oxidative capacity (Nagatomo 2012) and pancreatic 
islet function (Delghingaro-Augusto 2012). In this rodent model of elevated GCs and high fat 
feeding, we hypothesized that voluntary exercise would alleviate hyperglycemia, impaired 
muscle insulin signalling and skeletal muscle wasting while helping to preserve β-cell function. 
As elevated GCs are caused by exogenous treatment in our model, voluntary exercise would not 
be expected to lower GC concentrations sufficiently to promote full metabolic recovery. To 
examine the metabolic effects of exercise in this rodent model, we compared the effects of ~2.5 
weeks of voluntary wheel running with sedentary behaviour on various markers of energy 
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metabolism including: 1) whole-body glucose homeostasis, 2) body composition and skeletal 
muscle tissue histology, 3) in vivo and ex vivo islet responsiveness to glucose challenge and 4) 
skeletal muscle atrophic/insulin signalling proteins.  
Methods 
 This study was carried out in accordance with the recommendations of the Canadian 
Council for Animal Care guidelines and was approved by the York University Animal Care 
Committee (2013-6).  
 Animals: First cohort of animals consisted of forty (40) male Sprague-Dawley rats 
(Charles River Laboratories, initial mass of 225-250 g, six weeks post-weaned) were individually 
housed (lights on 12 hour: lights off 12 hour cycle) after one week of acclimatization to room 
temperature (22-23°C) and humidity (50-60%) controlled facilities. Animals were initially 
divided equally into either sedentary (SED) or wheel running exercise (EX) groups (day -14) for 
a two week habituation phase, and then further subdivided into either CORT or placebo treated 
groups (i.e. 4 groups in total with 10 in each subgroup). Thus, the four experimental groups 
consisted of two sets of EX animals; one group received wax pellets (placebo-EX) and the other 
group received CORT pellets (CORT-EX) and two sets of SED animals; one group received wax 
pellets (placebo-SED) and the other group received CORT pellets (CORT-SED). A second 
cohort of animals (n=20) were utilized to measure incretin levels, muscle histology and western 
blot data. All animals were placed on an ad libitum HFD (see below) following the two-week 
habituation period and were killed between days 17-22 to accommodate for islet isolation 
experiments. 
 Experimental Design: A timeline of the experimental protocol is shown in Fig 3.1. Each 
EX animal was placed into specialized rodent cages with 24-hour access to a running wheel 
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(Harvard Apparatus), while SED animals were housed in standard cages. Each wheel was 
equipped with a magnet and sensor that was wired to an electronic counter. Wheel revolutions 
were counted each time the magnet passed the sensor and the numbers on the counters were 
recorded and reset to zero daily. The wheel revolutions were collected daily and were multiplied 
by the wheel circumference (106 cm) to estimate the running distances of each animal 
(previously reported in (Campbell, 2009). During the two-week cage habituation period, rodents 
were given standard rodent chow (Purina chow #5012) and water ad libitum.   
 102 
 
Figure 3.1. Schematic of experimental groups and design. 
Experimental treatment groups (A) and schematic of experimental design (B). On day -14, all 
animals were individually housed and divided into one of four groups; placebo-EX, CORT-EX, 
placebo-SED and CORT-SED (EX, exercise and SED, sedentary). At this time, all EX animals 
were introduced to running wheels in their cages and allowed 2 weeks to acclimate to the 
experimental conditions. On day 0, either wax or CORT pellets were subcutaneously implanted 
into the animals according to the assigned experimental group and all animals were given a HFD 
(60%) ad libitum. Seven days post pellet implantations (~ 0800 hour), blood samples were taken 
to measure plasma CORT and blood glucose levels. On day 11 animals were fasted overnight (~ 
16 hour) and the following day (12) were administered an oral glucose tolerance test. On day 14 
(~ 0800 hour), blood samples were taken again to measure plasma CORT and blood glucose 
levels. On the evening of day 15, animals were fasted and on day 16 animals were administered 
an insulin tolerance test. All animals were euthanized between days 17-22 of the experimental 
protocol. 
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 Pellet Surgeries: On day 0, each rat received a subcutaneous implantation of either 
corticosterone (CORT) pellets (4 x 100 mg; Sigma-Aldrich, Canada, Cat# C2505) or wax pellets 
(placebo), as previously described (Shpilberg, 2012). Immediately following surgery, rats were 
placed into standard sterile cages with chow and water for 24 hour to recover and then placed 
back in their home cages and were given ad libitum access to a high-fat diet (HFD) and water as 
previously described (Shpilberg, 2012).This diet consisted of 60% of the total calories from fat 
and 5.1 kcal per gram (D12492, Research diets); this diet was maintained until the end of the 
experimental protocol.  
 CORT sampling: As in previously published protocols (Beaudry, 2013; D'souza, 2011; 
Shpilberg, 2012). On day 7, at ~0800 hour, blood samples were collected from each animal via 
saphenous vein for CORT concentration measurements. A small area of hair on the lateral upper 
hind limb was shaven with an electric razor and wiped with a thin layer of petroleum jelly. Once 
the saphenous vein was located, a sterile 25-gauge needle was used to puncture the vein and 
whole blood was collected in lithium-heparin coated microvette capillary tubes (Sarstedt, 
Canada, Cat# 16.443.100) and centrifuged at ~ 9, 500 x g (Eppendorf Mini-Spin Plus, Brinkman 
Instruments Inc., USA) for 5 minutes, transferred into polyethylene tubes and stored at -80°C 
until further analysis of CORT concentrations using a radioimmunoassay kit (MP Biomedical, 
USA). Fed blood glucose concentrations (mM) were measured on day 7 using a single drop of 
blood (2 µl) with a handheld glucometer (Bayer Contour, USA), after blood was collected for 
CORT measurements. This sampling was repeated on day 14 so that CORT concentrations could 
be assessed two weeks after pellets were implanted.  
 Oral glucose and intraperitoneal insulin tolerance test: Animals were fasted overnight 
(16 hour) on day 12 and were administered an oral glucose tolerance test (OGTT, 1.5 g/kg body 
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mass) as previously described in (Shpilberg, 2012). Each animal’s fasting blood glucose (time 0) 
was measured via saphenous vein bleed (~ 50 μl) using a sterile needle (25G) and glucometer 
(Bayer One Touch) and plasma was also collected for later analysis of insulin concentrations via 
an ELISA 96-well kit (Crystal Chem, USA, Cat# 90060). Blood glucose was also measured and 
recorded for time 5, 15, 30, 60, 90 and 120 minutes post oral gavage. Blood was collected to 
measure plasma insulin for time 15, 30, 60 and 120 minutes post oral gavage. In separate 
experiments, total GIP and GLP1 levels were measured at time 0 and 10 min post glucose 
gavage and analyzed using ELISA kits (Millipore, USA, Cat #EZRMGIP-55K) and (Meso Scale 
Discovery, MD, USA Cat #K150JVC-1, version 2), respectively. An insulin tolerance test (ITT) 
was performed on day 16 after an overnight fast by intraperitoneal insulin injection (0.75 
units/kg body mass) as previously reported (Shpilberg, 2012). For these tests, ~ 50 μl of blood 
was collected to measure glucose concentrations were measured with a glucometer at time 0, 5, 
10, 20 and 30 minutes post insulin injection. Non-esterified fatty acid (NEFAs) concentrations 
were measured from overnight fasted plasma collections, collected before OGTT (NEFA kit, HR 
Series NEFA-HR, Wako Chemicals, USA). Glucose and insulin area under the curve (AUC) was 
measured relative to the lowest fasting glucose and insulin levels of a placebo-SED animal. The 
acute insulin response (AIR) was determined between the difference in basal plasma insulin 
(fasting insulin levels) and 15 minutes following the oral glucose gavage (previously reported in 
(Beaudry, 2013; Holness 2005)). This measurement represents the secretion of insulin in 
response to an exogenous glucose load (Rafacho 2011) Homeostatic Model Assessment for β-
cells (HOMA-β) as previously reported in (Beaudry, 2013; Shpilberg, 2012) was calculated 
based on the following equation: 20 x Insulin (μ units·L)/Glucose (mM)-3.5 (Wallace 2004).  
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 Glucose stimulated insulin secretion (GSIS) experiments: All animals were killed by 
decapitation between days 17 to 22 of the experimental protocol, in a counterbalanced fashion, 
and islet isolations were carried out as previously reported (Shpilberg, 2012). Collagenase 
pancreas digestion was followed by Histopaque-1077 (H8889, Sigma-Aldrich, Canada) pellet 
suspension followed by re-suspension in KREBs buffer (125 mM NaCl, 4.7 mM KCl, 1.2 mM, 5 
mM NaHCO3, 2.5 mM CaCl2, 2.4 mM MgSO4, 10 mM Hepes, 0.5% BSA, pH-7.4). Islets were 
hand selected and cultured in filtered RPMI buffer (Wisent) overnight (24 h) at 37°C, 5% CO2.  
Islets were separated into a 12-well culture plate (6-10 islets/well in 3 batches) and given a 30-
minute pre-incubation period as previously described (Shpilberg, 2012). Islets were given fresh 
KREB’s buffer with 2.8 mM glucose + 0.1% BSA for 1 hour at 37°C, 5% CO2. Media was 
changed to KREBs buffer with 16.7 mM glucose + 0.1% BSA for 1 hour at 37°C, 5% CO2.  
Immediately following each incubation period, media was collected, centrifuged and stored at -
20°C for further analysis. At the termination of experiments, islets were placed in 1 ml cold lysis 
buffer (acid-ethanol solution), sonicated (15 s), and centrifuged at ~ 13,500 x g at 4°C for 10 
minutes. Supernatant was collected and stored at -20°C until further analysis of insulin content. 
All insulin secretion data was normalized to total insulin content. Insulin was measured using 
radioimmunoassay kit (Millipore, USA).  
 Histology: Liver and skeletal muscle tissue (tibialis anterior, TA) from euthanized 
animals were embedded in tissue freezing medium, frozen in liquid nitrogen, cryosectioned (10 
µm thick) and stained with Oil Red O (ORO) for neutral lipid content as previously described 
(Koopman 2001). Staining for fibre type, SDH activity and capillary to fibre ratio (Ogilvie, 
1990) was also completed. 
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 ORO staining: Liver and TA sections were fixed with 3.7% formaldehyde for 1 hour at 
room temperature while an ORO solution composed of 0.5 g ORO powder (Sigma-Aldrich, 
Canada) and 100 ml of 60% triethyl phosphate (Sigma-Aldrich, Canada) was mixed and filtered. 
Following fixation in 3.7% formaldehyde, slides were immersed in filtered ORO solution for 30 
minutes at room temperature. Slides immediately underwent five washes with ddH2O, were 
allowed to dry for 10 minutes and were sealed with Permount (Sigma-Aldrich, Canada). Liver 
and TA images were acquired at 20 x and 10 x magnifications respectively, using a Nikon 
Eclipse 90i microscope (Nikon, Canada) and Q-imaging MicroPublisher 3.3 RTV camera with 
Q-capture Software.  
 Fibre Type and SDH Analysis: To identify skeletal muscle fibre type a metachromatic 
myosin ATPase stain was performed on cross-sections of the TA muscle using a modified 
protocol (Ogilvie, 1990). Sections were pre-incubated in an acidic buffer (pH = 4.25) to 
differentially inhibit myosin ATPases within the different fibre types. In this protocol, type I 
fibres appear dark blue, type IIa appear very light blue and type IIb and IIx are not apparent from 
each other and are thus classified as IIb/x. These fibres appear bluish-purple. A representative 
image of the TA for each group was acquired for analysis. Succinate dehydrogenase (SDH) 
activity was then assessed using histochemical analysis and expressed in relative optical density 
to placebo-SED (Shortreed 2009). The same muscle regions of the TA that were used for fibre 
typing were used for SDH activity determination. Serial sections were used to directly compare 
levels of SDH in each fibre, to each fibre type. SDH activity was assessed with Adobe Photoshop 
CS6, converted to greyscale and reported as the average optical density (sixty fibres were 
counted per muscle section). The greyscale is evaluated on a range of completely black (set as 
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zero units) to white (set at 255 units). All images were acquired with a Nikon Eclipse 90i 
microscope and Q-Imaging MicroPublisher with Q-Capture software at 10x magnification. 
 Capillary-to Fibre Analysis: To determine capillary-to-fibre ratio, TA sections (10 µm 
thick) were fixed with 3.7% para-formaldehyde prior to being stained with fluorescein 
isothiocyanate-conjugated Griffonia simplicifolia isolectin B4 (1:100; Vector Laboratories, 
Canada). Sections were viewed using a Zeiss M200 inverted microscope with a 20x objective 
and images were captured using a cooled CCD camera using Metamorph imaging software. 
Capillary-to-fibre counts were averaged from 5-7 independent fields of view per animal by a 
blinded observer.  
 Western Blot Analysis: We quantified protein expression for key determinants of skeletal 
muscle insulin signalling including total IRS-1, total AKT, pAKT (T308), GLUT4, FOXO1 and 
PGC1α to assess the atrophic and mitochondrial biogenesis pathways. Western blot analysis was 
carried out according to previously published work (Shpilberg, 2012). In brief, 50 μg of protein 
lysate from the TA was run on a 10% (total AKT, pAKT (T308), GLUT4, FOXO1) or 6% (total 
IRS-1 and PGC1α) SDS-page gel and proteins were transferred to a PVDF membrane (Bio-Rad, 
Canada). Membranes were blocked in 5% powdered milk and Tris-buffered saline with Tween 
20 at room temperature for 1 hour. Membranes were then incubated overnight at 4°C with their 
respective primary antibodies (total AKT, 1:1000, ab47610, Abcam, Toronto, ON; T308, 1:1000, 
ab5626, Abcam, Toronto, ON; GLUT4, 1:1000, ab65267Abcam, Toronto, ON; FOXO1, 1:1000, 
Cat #2880, Cell Signaling, USA; PGC1α, 1:1000, Cat #4259, Cell Signaling, USA; total IRS-1, 
1:1000, Cat #2382, Cell Signaling, USA). The following morning, the membranes were washed 
with TBST and incubated with anti-mouse (1:10000, Cat#ab6789, Abcam) or anti-rabbit 
(1:10000, Cat#ab6721, Abcam) secondary antibodies for 1 hour at room temperature. 
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Membranes were then washed and imaged. Images were detected on a Kodak In vivo FX Pro 
imager and molecular imaging software (Carestream Image MI SE, version S.0.2.3.0, Rochester, 
New York) was used to quantify protein content. GAPDH (1:10000, ab9484, Abcam, Toronto, 
ON) was used as a loading control for all proteins. 
 Statistical Analysis: All data are represented as means ± SE, with a criterion of p<0.05 
and p<0.001 and were assessed as stated using two-way ANOVAs as a means of statistical 
significance. Individual differences were calculated using Bonferroni’s post-hoc test unless 
stated as using a Duncan’s post-hoc test (Statistica 6.0 software).  
Results 
 Body mass. Relative body mass was reported between 0-10 days as metabolic profiling 
(OGTT, ITT) of these animals in a fasted state was performed on days 11-17. All animals had 
similar body mass prior to pellet surgery (day 0, ~ 350 g). Both placebo-treated groups gained 
mass after pellet surgery from day 0 to 10 (Fig. 3.2A). However, on experiment termination day 
(days 17-22) placebo-SED animals tended to weigh more than placebo-EX animals (472.7±14.4 
vs. 438.7±31.5 g). Similar to previously reported findings (Beaudry, 2013; Beaudry, 2014; 
D'souza, 2011; Shpilberg, 2012), both CORT-treated groups lost body mass after pellet surgery 
compared to placebo animals (p<0.01, Fig. 2A). No differences were found in relative body mass 
between CORT-EX and -SED animals on day 10; however, CORT-EX animals had heavier 
absolute body mass than CORT-SED animals by the termination of treatment (333.5±16.2 vs. 
265.9±13.0 g, p<0.05).   
 Running Distances. On average, CORT-treated runners ran longer distances than placebo 
runners (6541.7±467 vs. 3308.4±260 m, p<0.05, Fig. 3.2B). However, this difference was also 
noted prior to pellet implant surgery; thereby suggesting that these two groups of rats differed 
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slightly in their preference for wheel running prior to the experimental treatment (CORT vs. wax 
implantation). When running distances were expressed relative to day -2 (i.e. before surgery), 
CORT treatment, per se, did not appear to influence running distances significantly (Fig. 3.2C).   
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Figure 3.2. Corticosterone-treatment caused reductions in body mass with no effect on 
running distances. 
Body mass relative to pre-surgery mass during pellet treatment (A), absolute daily running 
distances during pellet treatment (B) and daily running distances relative to pre-surgery running 
distances (day 2) (C). CORT-treated animals experienced ~ 10-15% reduction in relative body 
mass throughout the pellet treatment period while placebo-treated animals continuously gained 
mass from day 2 onward (p<0.05). CORT-EX animals ran further distances per day than 
placebo-EX animals (p<0.05), however, CORT-EX animals ran more prior to surgery. Pellet 
implants had no impact on relative running distances. n=7-12. All values are means ± SE.   
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Plasma CORT, fasting NEFAs, glucose and insulin concentrations. As expected, CORT 
levels measured at ~ 0800 hour on day 7 were higher in all CORT treated groups as compared to 
placebo treated animals (p<0.05, Table 3.1) and similar to our previously published results (64). 
Placebo-SED animals had the lowest CORT levels compared to all other animal groups (p<0.05). 
Levels measured at ~ 0800 h on day 14 were also higher in CORT-treated groups compared to 
placebo-SED and not significantly impacted by exercise in the CORT treated groups. On day 14, 
CORT levels in placebo-EX animals were higher than in placebo-SED animals, and similar to 
what was observed in the CORT-SED group, but still lower than the CORT-EX animals (p<0.05, 
Table 3.1). Fasted NEFA levels were higher in CORT-treated animals compared to placebo 
animals (p<0.05, Table 3.1), while CORT-EX animals tended to have lower fasting NEFAs than 
CORT-SED animals. Placebo-SED animals tended to have higher fasting NEFAs than placebo-
EX animals, although this difference failed to reach statistical significance. 
 Fasting blood glucose levels prior to oral glucose challenge were ~ 4-fold higher in 
CORT-SED animals than in placebo-SED (p<0.05, Table 3.1). CORT-EX animals had lower 
fasting blood glucose levels compared to CORT-SED animals, although concentrations were still 
significantly higher when compared to placebo-treated groups (p<0.05, Table 3.1). CORT-SED 
animals had ~ 5.4-fold increase in fasting plasma insulin levels compared to placebo-SED and 
CORT-EX animals had ~ 8-fold increase in fasting plasma insulin levels compared to placebo-
EX animals (p<0.05, Table 3.1). CORT-EX animals also tended to have higher fasting plasma 
insulin levels than CORT-SED animals, although these values did not achieve statistical 
significance.  
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 Table 3.1. Corticosterone, fasted non-esterified free fatty acidss, glucose and insulin 
concentrations. 
 
Note: All values are means ± SE in ng/ml for CORT and insulin. Values are in mM for glucose 
and NEFAs. The * indicates the mean was statistically significant from placebo-SED, the ** 
indicates significance from CORT-SED and the # indicates significance from placebo-EX. All 
analysis was carried out by a two-way ANOVA with a Tukey’s post-hoc, where p<0.05. n=7-12.   
 
 Placebo CORT 
 SED EX SED EX 
Day 7 CORT 66.0±17.1 271.3±42.9* 566.2±65.6*,# 548.2±45.0*,# 
Day 14 CORT 70.6±12.3 375.0±44.7* 468.6±38.3* 504.9±38.7*,# 
Fasted NEFAs 0.45±0.1 0.39±0.9 1.0±0.1* 0.85±0.1* 
Fasted Glucose 4.9±0.3 5.1±0.2 18.8±0.9* 14.3±1.6*,**,# 
Fasted Insulin 1.24±0.3 1.1±0.5 6.8±0.6* 8.9±1.2* 
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 Oral glucose tolerance test. CORT-SED animals had markedly elevated blood glucose 
levels before and during the oral glucose tolerance challenge compared to all other treatment 
groups (p<0.05, Fig. 3.3A). CORT-EX animals had improved glucose tolerance compared to 
CORT-SED animals (p<0.05); however, they still were glucose intolerant when compared to the 
two placebo groups (p<0.001, Fig. 3.3A’). Interestingly, placebo-EX rats had similar fasting 
glucose and glucose tolerance as placebo-SED rats, suggesting that exercise failed to improve 
glucose homeostasis in these high-fat fed animals. Plasma insulin concentrations were highest in 
CORT-EX animals before and during the oral glucose tolerance challenge compared to all 
treatment groups (p<0.001, Fig. 3.3B). CORT-SED animals also had increased levels of plasma 
insulin at baseline but levels failed to respond to oral glucose challenge (p<0.01, Fig. 3.3B’). 
Acute insulin response (AIR) to oral glucose gavage was measured to determine the islet 
sensitivity to exogenous glucose challenge (Fig. 3.3C). CORT-SED animals had a negative AIR 
to glucose challenge, indicating impaired islet responsiveness (p<0.05), as has been recently 
demonstrated in this model (Shpilberg, 2012). Voluntary wheel running in both placebo- and 
CORT-treated groups increased AIR by ~ 2-fold above placebo-SED animals (p<0.05). To 
determine the influence of basal blood glucose levels on plasma insulin concentrations in each 
treatment group, these parameters were plotted against each other (Fig. 3.3D). The r2 with all 
groups included was 0.47 and there was a significant correlation relationship (p<0.0001) 
suggesting that higher fasted blood glucose concentrations were driving higher insulin levels in 
the CORT-treated animals. It should be noted that fasting blood glucose and fasting plasma 
insulin values in the placebo animals did not deviate markedly, clustering at around 3.5-5.5 mM 
of glucose and less than 4 ng/ml of insulin, while the CORT treated animals had much higher 
(and wider) ranges in both fasting glucose and insulin levels (Fig. 3.3D). Total GIP and GLP1 
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plasma levels were measured at 0 and 10 min during a separate OGTT to determine differences 
in insulin secretion amongst treatment groups (Fig. 3.3E and F). Both incretins tended to be 
elevated in CORT-treated animals, compared to placebo animals. However, there were no 
differences found in GIP or GLP1 levels between CORT-EX and SED groups at 0 or at 10 min 
post gavage.    
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Figure 3.3. Effect of voluntary wheel running on glucose tolerance, insulin secretion and 
plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels. 
Glucose tolerance (A and A’), insulin secretion (B and B’), acute insulin responses (AIR, C and 
D), plasma GIP and GLP1 levels during 0 and 10 min of OGTT (E and F). Blood glucose levels 
were elevated with CORT-SED treatment (p<0.001) and voluntary wheel running decreased 
glucose intolerance in CORT-treated animals. Plasma insulin levels post oral glucose challenge 
were elevated with CORT treatment compared to placebo-treated animals and exacerbated with 
the addition of wheel running (p<0.01). n=7-12 for all above graphs. Acute insulin response 
(AIR) between basal and 15 minutes post exogenous glucose challenge was elevated with EX 
and reduced in SED-treated animals (n=6-12). Higher fasting plasma insulin concentrations were 
correlated with higher fasting blood glucose concentrations in both CORT-EX and SED groups 
(r2=0.47, p<0.0001). n=6-12. CORT animals had higher fasting and stimulated GIP and GLP1 
levels than placebo groups. n=4-5. The * indicates values are statistically significant from 
placebo groups and ** indicates significance from CORT-SED (p<0.05) using a two-way 
ANOVA with Bonferroni’s (A’, B’, E and F) and Duncan’s (C) post hoc tests. All values are 
means ± SE except in D, where values are individual.   
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 In vivo assessment of β-cell function. HOMA-β was used to calculate basal β-cell 
function where higher HOMA-β scores indicate greater β-cell function (Fig. 3.4A). No 
significant differences in HOMA-β levels were found between CORT-SED and placebo-SED 
groups, although values tended to be higher in the CORT-SED group compared to the placebo-
SED group (p=0.1481). Voluntary wheel running improved β-cell function in CORT animals by 
~ 2.5-fold compared to CORT-SED groups (p<0.05, Fig. 3.4A). It also increased β-cell function 
in placebo-EX animals compared to placebo-SED animals by a similar extent (p<0.05). 
 Islets were isolated from each animal upon euthanization (day 17-22) and challenged 
with low (2.8 mM) and high (16.7 mM) glucose containing media. We found that in both low 
and high glucose media, CORT-SED islets had higher relative glucose-stimulated insulin 
secretion (GSIS) than all the other groups (p<0.05, Fig. 3.4B). CORT-EX tended to have lower 
relative GSIS levels in low glucose media when compared to the CORT-SED group and had 
significantly lower GSIS in the high glucose media compared to the CORT-SED group.  
 An insulin tolerance test was conducted in vivo to measure insulin sensitivity primarily in 
the skeletal muscle (Fig. 3.4C). CORT-SED animals had the highest glucose AUC levels 
compared to all treatment groups (p<0.05, Fig. 3.4C’). Voluntary wheel running reduced glucose 
AUC in CORT-EX animals indicating improved peripheral insulin sensitivity (p<0.05).  
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Figure 3.4. Effect of voluntary exercise on β-cell function. 
β-cell function (A) as measured by HOMA-β, glucose stimulated insulin secretion (GSIS) (B) 
and insulin sensitivity (C and C’). HOMA-β, an indicator of β-cell function was increased with 
voluntary wheel running in placebo and CORT-treated animal groups. CORT-SED group had 
higher insulin secretion in low (2.8 mM) and high (16.7 mM) glucose media compared to 
placebo-treated groups. Voluntary exercise normalized GSIS in CORT-treated animals. n=3-7 
per group.  Insulin sensitivity measured by the response to an insulin bolus was improved with 
voluntary wheel running in CORT-treated animals (p<0.05). n=7-12. The * indicates statistical 
significance from placebo-SED and ** indicates statistical significance from CORT-SED 
(p<0.05) using two-way ANOVA with Duncan’s (B) and Bonferroni’s (C’) post hoc tests. All 
values are means ± SE.
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 Food intake and body composition. As expected, relative food intake tended to be slightly 
higher in placebo-EX animals than placebo-SED animals, although it was not significant 
(p>0.05, Table 3.2). There was no significant difference in relative food intake between CORT-
SED and -EX animals; however, there was a main effect of pellet treatment across groups with 
the CORT-treated animals having a higher relative food intake than placebo-treated animals 
(p<0.05). Visceral adiposity, as measured by relative epididymal fat pad mass, greatly increased 
in CORT-treated animals but was lower in CORT-EX compared to CORT-SED group (p<0.05, 
Table 3.2). There were no differences in visceral adiposity between placebo-SED and placebo-
EX groups. Relative liver mass was increased with CORT treatment compared to placebo-treated 
animals (p<0.05) but no differences were found with the addition of exercise in placebo or 
CORT-treated animals (Table 3.2). Relative gastrocnemius mass was lower with CORT-SED 
treatment compared to placebo-treated animals (p<0.05) and tended to be higher with CORT-EX 
treatment. No differences were found with relative TA mass between any treatment groups. 
Relative soleus mass, a marker of oxidative muscle mass, was higher in CORT-SED animals 
compared to CORT-EX animals and placebo-SED animals (p<0.05, Table 3.2). In contrast, 
relative epitrochlearis mass, a marker of glycolytic muscle mass, was significantly lower in 
CORT-SED animals compared to placebo-SED animals. CORT-EX animals had higher relative 
epitrochlearis mass in comparison to CORT-SED animals, with values similar to those observed 
in the placebo-treated groups (p<0.01, Table 3.2).  
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Table 3.2. Food intake and body composition.  
 
 
Note: Values are means ± SE in kcal/g of body mass per day for food intake and g tissue/kg of 
body mass. The * indicates the mean was statistically significant from placebo-SED, the ** 
indicates significance from CORT-SED and the # indicates significance from placebo-EX. All 
analysis was carried out by a two-way ANOVA with a Tukey’s post-hoc, where p<0.05. n=7-12.   
 
 Placebo CORT 
 SED EX SED EX 
Food intake 0.25±0.02 0.30±0.02 0.45±0.01* 0.44±0.02* 
Epididymal Fat 17.0±1.0 17.0±1.6** 26.9±1.1* 21.8±1.4*, ** 
Liver 37.4±1.6 37.7±1.6 69.7±2.4* 69.3±6.8* 
Gastrocnemius 4.7±0.2 5.4±0.5 3.7±0.1* 4.2±0.2# 
Tibialis Anterior 1.5±0.04 1.6±0.20 1.35±0.05 1.50±0.1 
Soleus 0.40±0.01 0.45±0.1 0.52±0.03* 0.43±0.02 
Epitrochlearis 0.14±0.01 0.17±0.02 0.11±0.01* 0.20±0.03*,** 
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  Muscle and liver lipid staining. ORO staining of TA muscle sections was used to visually 
examine lipid accumulation in all treatment groups (Fig 3.5 A). Lipid staining appeared to be 
higher in placebo-EX animals compared to placebo-SED animals, as expected since endurance 
exercise generally increase muscle lipid storage in healthy rats (Goodpaster, 2001b). CORT-
treated animals had increased lipid staining compared to placebo-treated animals, indicating 
more lipid accumulation in the muscle and no obvious differences were observed between 
CORT-SED and CORT-EX groups. CORT-treated animals increased liver ORO staining 
compared to placebo-treated animals, indicating more hepatic lipid accumulation (Fig. 3.5 B). 
There were no differences in ORO staining between CORT-SED and -EX groups as well 
between placebo-SED and -EX groups. 
 Muscle oxidative capacity, PGC1α protein, capillary to fibre ratio, cross-sectional area 
and FOXO1 protein levels. To determine the effects of exercise training, the TA muscle of 
representative animals from each treatment group was stained for SDH activity (Fig. 3.6 A and 
B). SDH is an oxidative complex bound to the inner mitochondrial membrane of skeletal muscle 
cells and is responsible for oxidizing succinate to fumarate in the citric acid cycle (Hederstedt 
1981). Strong SDH staining correlates with higher muscle fibre oxidative potential. The TA from 
both placebo-EX and CORT-EX treatment groups showed darker SDH staining compared to 
placebo-EX and CORT-SED muscles (p<0.001, Fig. 6A and B). In type I and IIa muscle 
sections, CORT-SED animals had lighter SDH staining than all other treatment groups (p<0.05, 
Fig. 3.6 A and B). PGC1α is a known protein marker for mitochondrial biogenesis (Wing 2011) 
and was measured to help explain the observations of impairments in SDH staining in CORT-
SED animals. Although data failed to reach statistical significance, PGC1α tended to be elevated 
in both EX groups compared to their respective SED groups (Fig. 3.6C).  
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 CORT-treatment alone causes significant reduction in capillary to fibre ratio within 
skeletal muscle (Shikatani, 2012). Capillary to fibre ratio was reduced in CORT-SED animals 
but normalized in CORT-EX animals compared to placebo-treated animals (Fig. 3.6 D and E). 
Cross-sectional area, indicating individual muscle fibre size, was lowered in type IIa and IIb/x 
muscle fibres from the TA in CORT-SED animals (Fig. 3.6 F and G) and tended to increase with 
CORT-EX treatment. CORT treatment is known to induce atrophic signalling pathway leading to 
muscle wasting (Lecker 1999). Therefore, FOXO1 protein levels were measured as an indicator 
of muscle degradation. CORT treatment alone increased FOXO1 protein content (Fig. 3.6 H, 
p<0.05); however, EX failed to normalize FOXO1 levels.    
 Insulin signalling and glucose metabolic protein levels. Regular exercise is known to 
stimulate skeletal muscle insulin signalling (Goodyear 1998b) therefore protein markers of these 
pathways were analyzed. Voluntary wheel running increased total IRS-1 protein content in 
placebo animals by ~2-fold and tended to increase total IRS-1 in CORT-EX animals compared to 
CORT-SED animals (Fig. 3.7A). Total AKT protein content was increased in CORT-EX animals 
compared to placebo-SED animals (p<0.05, Fig. 3.7B). However, no differences were found in 
phosphorylated AKT (T308) or GLUT4 protein expression between any of the treatment groups 
(Fig. 3.7C and D).  
 Running distance vs. blood glucose, plasma insulin and CORT. To determine if fasting 
blood glucose, plasma insulin and CORT are associated with individual running distances in the 
exercising rats, each value from each exercising animal in both treatment groups was plotted and 
a linear regression was calculated (data not shown). No significant correlations were found 
between running distances and fasting blood glucose levels (r2=0.083, p>0.05), fasting plasma 
insulin levels (r2=0.023, p>0.05), nor with plasma basal CORT levels (r2=0.003, p>0.05). 
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Figure 3.5. Voluntary exercise does not improve lipid deposition within either the skeletal 
muscle or liver. 
Muscle (A) and liver (B) lipid accumulation was completed through ORO staining. CORT 
treatment increased lipid deposition in both muscle (tibialis anterior) and liver. There was no 
effect of exercise to lower lipid accumulation in either tibialis anterior or the liver in CORT-
treated animals. Representative images are shown from an n=6.  
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Figure 3.6. Effect of voluntary exercise on skeletal muscle oxidative capacity, capillary 
content and glucocorticoid-induced atrophy. 
Muscle oxidative capacity as measured through succinate dehydrogenase (SDH) histology (A 
and B), PGC1-alpha protein content (C), capillary to fibre ratio (D and E), cross-sectional area 
(CSA) in I, IIa, and IIb/x muscle fibre types (F and G) and FOXO1 protein content (H). Muscle 
oxidative capacity was increased in all placebo- and CORT-EX muscle types. n=6. In type I and 
IIa muscle sections, CORT-SED had lower oxidative capacity. PGC1-alpha tended to be higher 
in EX treated animal groups compared to SED groups. n=5. CORT-SED treatment resulted in a 
significant reduction in capillary to fibre ratio compared to all treatment groups and CORT-EX 
animals exhibited greater capillary-to-fibre ratio compared to CORT-SED animals (p<0.05, n=6-
9), demonstrating that CORT-induced capillary rarefaction is prevented by volitional exercise. 
This assay stained for capillaries via Griffonia Simplicifolia isolectin-fluorescein and image 
color was inverted to enhance muscle fiber visualization. CSA tended to normalize with exercise 
in CORT treated animals in IIb/x muscle fibres. FOXO1 protein content increased with CORT-
SED and EX treatment. n=4-5. The * indicates statistical significance from placebo-SED and ** 
indicates statistical significance from CORT-SED (p<0.05) using two-way ANOVA with 
Bonferroni’s post hoc test. All values are means ± SE. 
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Figure 3.7. Effect of voluntary exercise on insulin signaling protein content. 
IRS-1 (A), AKT Total (B), AKT phosphorylated T308 (C) and GLUT4 protein content (D) in 
tibialis anterior (TA) muscle. Exercise tended to increase IRS-1 protein content in placebo and 
CORT animals. CORT-EX animals had higher AKT Total protein content compared to CORT-
SED animals but no differences in AKT phosphorylated T308 protein content were found 
amongst groups. No differences were found in GLUT4 protein content between the treatment 
groups. n=4-5. The * indicates statistical significance from CORT-SED (p<0.05) using two-way 
ANOVA with Bonferroni’s post hoc test. All values are means ± SE. 
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Discussion 
 The effect of voluntary wheel running was assessed to determine if exercise has the 
ability to reduce, or offset, the detrimental metabolic outcomes typically observed in rodent 
models of exogenous GC treatment. In this study, we demonstrate that voluntary exercise (for ~ 
2.5 weeks) reduced visceral adiposity, glucose intolerance, insulin insensitivity and impaired 
glucose responsiveness. Furthermore, many skeletal muscle specific abnormalities such as 
oxidative capacity, atrophy and capillary rarefaction associated with sustained GC treatment 
were improved with voluntary exercise. These novel findings suggest that regular exercise is able 
to promote healthier metabolic function, even in situations of hypercortisolemia, i.e. Cushing’s 
syndrome or patients treated with exogenous GCs.   
 Generally, GCs decrease absolute body mass but increase relative fat mass, an outcome 
that appears to be dependent upon animal model/type, dosing and duration of treatment (Coderre 
2007; Kaasik 2007; Karatsoreos 2010; Menezes 2007; Rafacho 2009; Yau 2012). Much of the 
loss in total mass is speculated to be due to reductions in skeletal muscle mass, although body 
length (or height) is also reduced if GCs are elevated in young growing animals (Shpilberg, 
2012) or in human adolescence (Abad 2001). In this study, and in our previously published 
studies (Beaudry, 2013; Beaudry, 2014; Shikatani, 2012; Shpilberg, 2012), we found that CORT 
treatment induces a dramatic (~ 50%) reduction in total body mass when compared to placebo-
treated animals and this effect was not mitigated by a high fat diet. Normally, voluntary wheel 
running in healthy young animals lowers body mass gain (Campbell, 2009; Fediuc, 2006; Yau, 
2012) and reduces adiposity in obesity prone animals (Bi 2005; Patterson 2008). However, in our 
study, voluntary exercise did not cause a further reduction in body mass nor did it prevent the 
body mass loss that is typically observed in CORT-treated animals. Indeed, both CORT-SED 
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and -EX-treated groups had similar body masses throughout the 10 days of treatment (Fig. 3.2A).  
Although, it was obvious that the exercising animals had much less adipose mass and greater 
skeletal muscle mass (i.e. altered body composition) compared to the CORT-SED animals (Table 
3.2). Some evidence indicates that the lower body mass observed in GC-induced models is the 
result of reduced food intake (Rafacho 2008). Others suggest that GCs increase the preference 
for foods with high-fat content, overriding the anorexigenic effects of insulin (Dallman 2007) 
and leading to larger fat accumulation. We found that CORT-treated animals, regardless of being 
SED or EX, consumed more calories relative to body mass than the placebo-treated animals (~ 
1.5-fold change, Table 3.2). Although exercise improved body composition (decreased adiposity 
and increased skeletal muscle mass) in the CORT treated animals, possibly due to greater 
running distances than placebo animals (Fig. 3.2), the growth impairments and changes in eating 
behaviour accompanying CORT treatment were seemingly unaffected by exercise.  
 Exercise training and adaptations to restraint stress reduce hyperglucocorticoidemia and 
prevent diabetes development in ZDF rats (Bates 2008; Király, 2008) and in other insulin 
resistant rodent models (Linden 2014). In this study, and in our previously published work 
(Beaudry, 2013; Shpilberg, 2012), we show that elevated GCs induce severe glucose intolerance, 
hyperinsulinemia, impaired β-cell function and severe insulin resistance. Here, we show that 
daily voluntary wheel running, for ~2.5 weeks, improves glucose intolerance and insulin 
responsiveness to oral glucose challenge in GC-treated high-fat fed rats (Fig. 3.3). However, 
increased fasting and stimulated insulin levels were observed. In comparison to other published 
work on dexamethasone treatment and treadmill exercise (Barel, 2010), we found that CORT-EX 
animals had elevated fasted and stimulated insulin levels during the glucose challenge compared 
to all other treatment groups (Fig. 3.3B).  
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 In an attempt to explain the higher levels of circulating insulin in CORT-treated animals, 
we measured plasma incretin hormone (GIP and GLP1) levels, which are known to stimulate 
insulin secretion upon glucose ingestion (Campbell 2013) and are also known to be elevated with 
CORT treatment (Jensen 2012). In our study, CORT treatment increased GIP and GLP1 levels in 
both the basal and glucose stimulated states but there were no definitive distinctions found 
between SED and EX treatments. As such, we conclude that the improvements in insulin 
responsiveness to oral glucose feeding in the CORT-exercising animals cannot be attributed to 
differences in incretin secretion. However, similar to our observation of increased GIP and GLP-
1 with CORT treatment in general, others have shown increased fasting insulin levels after 11 
weeks of swim training in ZDF rats compared to SED and lean controls, results which were 
paralleled by increases in β-cell mass, through increased β-cell proliferation (hypertrophy and 
hyperplasia) mechanisms (Király, 2008). Although β-cell mass was not measured directly in this 
study, we do demonstrate greater AIR and HOMA-β levels with CORT exercise treatment 
(Fig.4.), suggesting that our exercise model was sufficient to improve β-cell function possibly 
via proliferation or β-cell specific pathways.  
 We have recently shown that CORT-SED treatment impairs β-cell responsiveness to 
glucose in vivo but not ex vivo (Beaudry, 2013). Regardless of exercise protocol, endurance 
training (swimming, voluntary wheel running, treadmill running), results in reduced insulin 
release in isolated healthy rodent islets (Almeida 2012; Galbo 1981; Tsuchiya 2013; Zawalich 
1982; Zoppi 2011) and more specifically in the β-cell itself (Farrell 1992). Our findings are in 
line with these previous observations, since placebo-EX animals tended to have lower GSIS 
compared to placebo-SED islets (Fig. 3.4). In addition, voluntary wheel running (6 weeks) 
improves GSIS in ZDF rat islets as well as prevents complete depletion of insulin stores within 
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the islet (Delghingaro-Augusto, 2012). Our study is the first to show that voluntary exercise 
lowers relative GSIS in CORT-treated animals; however, it does not normalize to that of 
placebo-treated SED animals. Our results differ somewhat from those found in active ZDF rats, 
as GSIS was elevated in high glucose and palmitate media compared to inactive ZDF rat islets 
(Delghingaro-Augusto, 2012). This may be because ZDF rats have larger compensatory β-cell 
mass in response to exercise causing higher insulin levels.  
 GCs help to regulate adipose tissue by promoting mechanisms of differentiation and 
ectopic fat distribution (Peckett, 2011). In this model of elevated GCs and HFD, there is an 
excessive accumulation of visceral fat that is ~ 1.5-fold higher in CORT-SED animals when 
compared to placebo treatment (Table 3.2), which parallels previous work (Björntorp, 2001; 
Chandola 2006; Rebuffe-Scrive 1992; Shpilberg, 2012). Exercise is known to help reduce fat 
mass gain (Danielsen 2013; Gollisch 2009; Stiegler 2006) even in instances of high-fat feeding 
(Gauthier 2004; Gollisch, 2009). In the present study, we demonstrate that voluntary wheel 
running is sufficient to attenuate visceral fat accumulation in CORT/HFD-treated animals, but 
not muscle nor hepatic neutral lipid accumulation (Fig. 3.5A and B, respectively). Perhaps this 
may explain why we demonstrate some relief from GC-induced abnormalities with exercise but 
not complete reversal of the various features of insulin resistance and glucose intolerance.  
 GCs are well known to induce muscle atrophy (Menezes, 2007), likely through negative 
protein balance due to increased protein degradation and decreased protein synthesis 
(Hasselgren, 1999). Both GCs and diabetes advance muscle atrophy by targeting fast-twitch 
(type II), glycolytic muscle (Schakman, 2013) and reducing muscle mitochondrial content 
(Lewis 1992). In this model of CORT/HFD, we found lower skeletal muscle oxidative capacity, 
as measured by SDH staining, in type I and type II fibres of the CORT-SED animals (Fig. 3.6 A 
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and B). This impaired oxidative capacity, along with the obvious muscle atrophy and capillary 
rarefaction, likely contributes to the poor glycemic control and skeletal muscle lipid 
accumulation in these animals. Similar to previous findings (Nagatomo, 2012), we found that 
regular exercise improved muscle oxidative capacity in all fibre types of the TA muscle. We 
suspected that these exercise-mediated improvements could be caused by up-regulation of 
PGC1α, a transcription factor that turns on oxidative metabolic proteins that contribute to greater 
mitochondrial biosynthesis (Puigserver 2003) and slow-twitch (i.e. type I) muscle fibre 
formation (Lin 2002). We found that EX treatment tends to increase PGC1α protein levels in the 
TA muscle indicating that greater levels of oxidative capacity may be due to elevated 
mitochondrial biosynthesis and possibly more slow-twitch fibre recruitment, helping to utilize 
higher levels of plasma glucose. In addition, it is a continued observation in our model that 
relative soleus muscle mass increases with CORT and HFD treatment (Table 3.2). The soleus 
muscle is composed of slow-twitch fibres that are less sensitive than fast-twitch fibres under 
conditions of atrophy (reviewed in (Schiaffino 2011) and increased compensation by the soleus 
muscle may result. Interestingly, CORT-EX treatment normalized soleus muscle mass, 
indicating decreased compensation, possibly elicited by the activation of oxidative muscle fibre 
types with voluntary exercise. 
 One of the most novel aspects of this study was the finding that CORT-EX treatment was 
able to induce angiogenesis by increasing the number of capillaries in a given area of muscle 
thereby evading CORT-induced capillary rarefaction, which is a hallmark of GC treatment 
(Shikatani, 2012). The increased capillarization suggest that exercise improves nutrient and 
insulin delivery to skeletal muscle in GC treated animals, and that this adaptation may contribute 
to the augmentation in glucose tolerance and muscle insulin sensitivity detected in these animals. 
 133 
In line with this, we also observed a tendency for improved cross sectional area in the type IIb/x 
fibres of the TA muscle with regular exercise and CORT treatment. While it is still not known 
why GCs target type IIb/x fibres, higher GC receptor expression in these fibres may be a likely 
mechanism (Shimizu 2011). Indeed, skeletal muscle specific GC receptor knockout animals are 
resistant to GC-induced muscle atrophy (Watson 2012). However, these knockout studies are not 
entirely conclusive, as they do not allow determination of exact mechanisms of GC-induced 
atrophy. Therefore, it remains that either genomic (atrophic genes, i.e. FOXO1) or non-genomic 
(inhibition of insulin signalling) pathways are likely contributors to muscle wasting with GC 
treatment. In this study, we confirm increases in FOXO1 protein levels in CORT-treated animals 
(Fig. 6H); however, unlike previous literature (Yuan 2011) regular exercise was unable to 
normalize FOXO1 levels. It is possible that although these FOXO1 levels were not normalized in 
the CORT-EX animals, voluntary wheel running was sufficient to stimulate increase protein 
synthesis mechanisms (i.e. IGF-1 or mTOR signalling) independent of elevated FOXO1 levels 
(reviewed in (Atherton 2012). Although IGF-1 was not measured in this study, we have 
previously measured and found lower plasma IGF-1 levels in CORT-SED animals (unpublished 
observations) indicating less activation of the growth pathways. We suggest that regular exercise 
in CORT treated animals may promote higher levels of IGF-1 overriding protein degradation 
pathways, such as FOXO1. Moreover, we recognize that we used whole muscle homogenates to 
measure FOXO1 protein levels and these methods may not have allowed us to specifically 
capture true nuclear FOXO1 translocation. The up-regulation of non-genomic signalling 
pathways, such as IRS-1 and AKT, may help to reverse GC-induced muscle atrophy mechanisms 
and improve glucose intolerance (Schakman, 2013). We demonstrate increased protein levels of 
total AKT, as well as the tendency to increase total IRS-1 protein levels, in CORT-EX animals as 
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compared to CORT-SED animals. GCs are known to inhibit P13K/AKT signalling, which down-
regulate protein synthesis pathways (Schakman 2008b) and increase muscle catabolism, in 
addition to propagating insulin resistance through impaired GLUT4 translocation (Goodyear, 
1998b). Together, we conclude that voluntary exercise is an adequate stimulus to improve 
skeletal muscle oxidative capacity, capillary to fibre ratio and shows tendencies to reverse 
muscle atrophy in type IIb/x fibres in situations of elevated GCs and HFD. These improvements 
in skeletal muscle composition are most likely mediated via the atrophic mechanisms beyond 
FOXO1 protein expression, as insulin-signalling proteins (i.e. GLUT4 and IRS-1) remained 
relatively unaffected.  
 In summary, we have shown that elevated CORT exposure, in conjunction with a HFD, 
induces severe hyperglycemia, hyperinsulinemia and muscle wasting along with impaired insulin 
response and islet glucose sensitivity; features that can all be attenuated with volitional activity.  
Our study shows that voluntary exercise attenuates symptoms of T2DM induced by elevated 
CORT and HFD and provides evidence that exercise can independently influence tissues even 
when the exercise-associated reductions in basal GC levels are prevented. Exercise intervention 
may be an ideal form of rehabilitation in individuals with hypercortisolemia or Cushing’s 
syndrome as these individuals suffer from hyperglycemia, insulin insensitivity, muscular atrophy 
and increased central obesity. Therefore, these individuals may benefit from the positive effects 
of regular exercise that may help to control or attenuate symptoms of diabetes development.  
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Chapter 4 
The metabolic effects of prazosin on insulin resistance in glucocorticoid-treated rats 
 
Author Contributions: I designed the study and wrote the paper along with input from Erin 
Mandel, Dr. Tara Haas and my supervisor Dr. Michael Riddell. Erin Mandel and I completed all 
animal anthropometry, including pellet surgeries, oral glucose tolerance tests, and some plasma 
analyses (insulin ELISA, corticoserone RIA). I performed the NEFA measurements, skeletal 
muscle IRS-1 and liver G-6-pase western blots and sectioned all skeletal muscle samples and 
stained them for measurement of CSA and SDH. Erin Mandel completed the capillary to fibre 
assessment and FOXO1 western blots. Sepideh Mohajeri performed liver sectioning and H and E 
assessment under my supervision, while I completed the ORO on the liver sections. Dr. Michael 
Riddell, with input from Dr. Tara Haas, oversaw the entire study and assisted in manuscript 
preparation. 
Rationale: Glucocorticoids have potent anti-angiogenic action, ultimately causing capillary 
rarefaction, especially within the skeletal muscle. There is additional information suggesting that 
alterations to the microvasculature can significantly impact insulin sensitivity. In Chapter 3, 
voluntary exercise enhanced insulin resistant skeletal muscle angiogenesis, with an associated 
improvement in glucose disposal and increased insulin secretion. The completion of this study 
(Chapter 4) allowed independent assessment of GC-induced capillary rarefaction (without HFD), 
and provides evidence that pharmacologically enhanced hyperemia, in insulin resistant skeletal 
muscle, can stimulate capillary growth which corresponds with improved insulin sensitivity. 
However, alterations in angiogenic capacity are unable to overcome the GC-induced pathologies 
caused within the myocyte itself.  
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Preface 
High dose usage of glucocorticoids (GC) induces skeletal muscle atrophy, insulin 
resistance and reduced muscle capillarisation. Identification of new treatments to prevent or even 
reverse the capillary rarefaction and metabolic deterioration that occurs in the presence of 
prolonged elevations in GCs would be of major therapeutic benefit. Chronic administration of 
prazosin, an α1-adrenergic antagonist, increases skeletal muscle capillarization, in both healthy 
rodents and recently, in a rodent model of elevated GCs and hyperglycemia. The purpose of this 
study was to determine whether prazosin administration would improve glucose tolerance and 
insulin sensitivity, as a result of prazosin mediated sparing of capillary rarefaction, in this rodent 
model of increased GC exposure. Prazosin was provided in drinking water (50mg/L) to GC-
treated or control rats (400 mg implants of either corticosterone or a wax pellet) for 7 or 14 days 
(n=5-9/group). Whole body measures of glucose metabolism were correlated with skeletal 
muscle capillarisation (C:F) at 7 and 14 days in the 4 groups of rats. Individual C:F was found to 
be predictive of insulin sensitivity (r2=0.4781), but not of glucose tolerance (r2=0.1601) and 
when compared with water only, prazosin treatment significantly decreased insulin values during 
oral glucose challenge by~1/3rd in the Cort-treated animals. Cort-treatment, regardless of 
duration, induced significant glycolytic skeletal muscle atrophy (P<0.05), decreased IRS-1 
protein content (P<0.05), and caused elevations in FOXO1 protein expression (P<0.05), which 
were unaffected with prazosin administration. In summary, it appears that α1-adrenergic 
antagonism improves Cort-induced skeletal muscle vascular impairments and reduces insulin 
secretion during an OGTT, but is unable to improve the negative alterations directly affecting the 
myocyte itself, including muscle size and muscle signaling protein expression. 
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Introduction 
 Glucocorticoids (GCs) are naturally occurring stress hormones, which are frequently 
prescribed for a number of immune and inflammatory conditions (Rhen, 2005) and in 
combination with cancer treatments (Walsh, 1992). Acute high dose or chronic usage of GCs has 
been shown to induce skeletal muscle atrophy (Menconi, 2008), insulin resistance (Buren, 2008; 
Schakman, 2013), capillary rarefaction (Shikatani, 2012), nonalcoholic fatty liver disease 
(D'souza, 2011) and the development of type 2 diabetes mellitus (T2DM) (Katsuyama 2015). 
GCs also have various effects on vascular function, inhibiting inflammation and cell proliferation 
(Shikatani, 2012), preventing endothelium dependent vasodilatation (Vogt 2001) and altering 
vasoconstrictor responses (Ullian, 1999). 
The profound metabolic deterioration caused by high GCs may be related, at least in part, 
to changes in the vascular network. Indeed, a key characteristic of both insulin resistance and 
T2DM is an inability for the peripheral vascular networks to sufficiently perfuse skeletal muscle 
during periods of elevated metabolic demand (Lind, 1993), ultimately leading to poor muscle 
oxygenation (Greene, 1992; Stainsby, 1988) and likely decreased hormone and nutrient 
provision (Kusters 2015b; Lillioja 1987). The relationship between insulin resistance within the 
skeletal muscle and microvascular perfusion continues to suggest an important role for the 
microvasculature as a target for insulin action, and that when impaired, insulin's vasodilatory 
action within the microvasculature can significantly affect glucose metabolism.   
 New capillary growth within the skeletal muscle occurs via existing capillaries through 
sprouting or nonsprouting angiogenesis (Egginton, 2011). Exercise training and mechanical 
loading triggers sprouting angiogenesis, while vasodilation through α-adrenergic antagonism 
promotes nonsprouting angiogenesis. The α1-adrenergic antagonist prazosin has been used in 
rodent studies (Dawson, 1989b; Ziada, 1989b), to selectively increase skeletal muscle capillary-
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to-fiber ratio, and very recent work from our lab has established that 14 days of prazosin 
treatment is enough to prevent capillary rarefaction associated with elevated GCs through 
maintenance of multiple aspects of shear stress signaling (manuscript under review). There is 
further evidence that α1-adrenergic blockade can enhance hepatic function (Dubuisson 2002; 
Oben 2003), insulin sensitivity and the lipid profile in hypertensive and non-insulin dependent 
diabetes mellitus patients (Hirano, 2001; Maruyama 1991a), in addition to decreasing blood 
pressure. Furthermore, subjects with T2DM, when compared to healthy lean and obese controls, 
have elevated resting sympathetic activation (Huggett 2005) and demonstrate an augmented 
plasma glucose response after a noradrenaline load, primarily due to elevated hepatic glucose 
output, suggesting these individuals could be more sensitive to sympathetic stimulation (Bruce, 
1992). 
 Recent work has established that the administration of prazosin to healthy rats results in 
enhanced insulin sensitivity (Akerstrom, 2014), while in aging adults at risk for T2DM 
development, augmented skeletal muscle capillarization due to aerobic exercise training caused 
improved insulin sensitivity which persisted even after 2 weeks of detraining (Prior 2015). To 
examine the relationship between improved microvasculature and insulin sensitivity in a model 
of skeletal muscle insulin resistance, we used the α1-adrenergic antagonist prazosin to increase 
skeletal muscle capillarization and measured markers of glucose metabolism and skeletal muscle 
atrophy. We hypothesized that the increased angiogenesis due to α1-adrenergic antagonism 
would increase peripheral tissue perfusion, enhancing insulin sensitivity and skeletal muscle 
glucose uptake. 
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Methods 
This study was carried out in accordance with the recommendations of the Canadian 
Council for Animal Care guidelines and was approved by the York University Animal Care 
Committee (2013-5).  
Animals:  Male Sprague-Dawley rats (Charles River Laboratories, initial mass of 225-250 
g, six weeks post-weaned, n=50) were individually housed (lights on 12 hour: lights off 12 hour 
cycle) after one week of acclimatization to room temperature (22-23°C) and humidity (50-60%) 
controlled facilities. After 7 days of acclimation, animals were randomly divided into one of four 
groups: corticosterone-treated or wax-treated (controls), with either regular drinking water (Cort-
water and Control-water), or drinking water containing prazosin hydrochloride (50 mg/L; P7791, 
Sigma Aldrich Canada) (Cort-prazosin and Control-prazosin). Animals were then randomly 
allocated to complete either 9 or 16 days of the protocol (7 or 14 days of water/prazosin 
treatment). All animals were fed a standard rodent chow diet (14% fat, 54% carbohydrate, 32% 
fat; 3.0 calories/g) ad libitum.  
Pellet Surgeries: On day 0, each rat received a subcutaneous implantation of either 
corticosterone (the major GC found in rodents) (Cort) pellets (4 x 100 mg; Sigma-Aldrich, 
Canada, Cat# C2505) or wax pellets (control), as previously described (Shpilberg, 2012). 
Immediately following surgery, rats were placed into standard sterile cages with chow and water 
for 24 hours to with ad libitum access to chow and water. Two days after Cort or wax pellet 
implantation, prazosin was administered to those groups allocated to receive it, a timeline of the 
experimental protocol is shown in Fig. 4.1.  
Blood sampling: On day 7 or 14, at ~0800 hour, blood samples were collected from each 
animal via saphenous vein for the determination of basal cort concentrations. For this, a small 
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area of hair on the lateral upper hind limb was shaven with an electric razor and wiped with a 
thin layer of petroleum jelly. Once the saphenous vein was located, a sterile 25-gauge needle was 
used to puncture the vein and whole blood was collected in lithium-heparin coated microvette 
capillary tubes (Sarstedt, Canada, Cat# 16.443.100) and centrifuged at ~ 9, 500 x g (Eppendorf 
Mini-Spin Plus, Brinkman Instruments Inc., USA) for 5 minutes, transferred into polyethylene 
tubes and stored at -80°C until further analysis of cort concentrations using a radioimmunoassay 
kit (Cat #07120102, MP Biomedicals, Solon Ohio). 
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Figure 4.1. Schematic of experimental design.  
Pellet implantation of either wax or cort pellets occurred on day 0, followed by prazosin 
administration on day 2. Saphenous vein measurement of plasma cort took place on day 7. An 
oral glucose tolerance test was administered on day 8 after on overnight fast to examine the 
effects of one week of concurrent cort and prazosin treatment. The first round of animals were 
euthanized on day 9 (endpoint 1). The second round of animals were administered their oral 
glucose tolerance test on day 12, followed by plasma cort measurement on day 14. The second 
round of animals were euthanized on day 16 (endpoint 2). 
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 Oral glucose tolerance test: Animals were fasted overnight (16 hour) on days 7 and 11 
and were administered an oral glucose tolerance test on the following day (OGTT, 1.5 g/kg body 
mass), as previously described (Shpilberg, 2012).  Each animal’s fasting blood glucose (time 0) 
was measured via saphenous vein bleed (~ 50 μl) using a sterile needle (25G) and glucometer 
(Bayer One Touch meter, Contour New York). Plasma was also collected from saphenous vein 
bleed (see above for this procedure) for subsequent analysis of insulin concentrations via 
enzyme-linked immunosorbent assay (ELISA kit, Cat# 90060, Crystal Chem, Downer's Grove, 
Illinois). Blood glucose was also measured from saphenous vein at 5-, 15-, 30-, 60-, 90- and 120- 
minutes post oral glucose gavage. In the four groups completing 16 days of the protocol, blood 
was collected to measure plasma insulin at 15-, 30-, 60- and 120- minutes post oral gavage. 
Insulin concentrations were not measured in the OGTT in the 9 day treated group for technical 
reasons. NEFA concentrations were measured from overnight fasted plasma collections, 
collected before OGTT (NEFA kit, Cat #999-34691, Wako Diagnostics, Richmond, Virginia). 
Glucose area under the curve (AUC) was measured relative to the lowest fasting glucose of a 
control-water animal, while insulin AUC was measured relative to each animals individual 
fasting insulin level. Homeostatic Model Assessment for β-cells (HOMA-β) and insulin 
resistance (HOMA-IR) as previously reported in (Beaudry, 2013; Shpilberg, 2012; Wallace, 
2004) was calculated based on the following equations: HOMA-β = 20 x Insulin (μ 
units·L)/Glucose (mM)-3.5, HOMA-IR = [Insulin (μUnits∙ml) x glucose (mmol∙L)]/22.5.  
 Histology: Skeletal muscle (tibialis anterior, TA) and liver tissue from euthanized 
animals were embedded in tissue freezing medium, frozen in liquid nitrogen and cryosectioned 
(10 µm thick). The TA was stained for fibre type, SDH activity and capillary-to-fibre ratio while 
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the liver was stained with Oil Red O (ORO) for neutral lipid content as previously described 
(Beaudry, 2015) and hematoxylin and eosin for structural assessments. 
Fibre Type and SDH Analysis: To identify skeletal muscle fibre type a metachromatic 
myosin ATPase stain was performed on cross-sections of the TA muscle using a modified 
protocol (Ogilvie, 1990). Sections were pre-incubated in an acidic buffer (pH = 4.25) to 
differentially inhibit myosin ATPases within the different fibre types. In this protocol, type I 
fibres appear dark blue, type IIa appear very light blue and type IIb and IIx are not apparent from 
each other and are thus classified as IIb/x. These fibres appear bluish-purple. A representative 
image of the TA for each group was acquired for analysis. Succinate dehydrogenase (SDH) 
activity was then assessed using histochemical analysis and expressed as total optical density. 
SDH activity was assessed with Adobe Photoshop CS6, converted to greyscale and reported as 
the average optical density (two 10x images were averaged per animal). The greyscale is 
evaluated on a range of completely black (set as zero units) to white (set at 255 units). All 
images were acquired with a Nikon Eclipse 90i microscope and Q-Imaging MicroPublisher with 
Q-Capture software at 10x magnification. 
Capillary-to Fibre Analysis: TA capillary-to-fibre measurements, as reported by Mandel 
et al (2016), were utilized in the current study to correlate with factors related to insulin 
sensitivity and glucose uptake. 
ORO staining: Liver sections were fixed with 3.7% formaldehyde for 1 hour at room 
temperature while an ORO solution composed of 0.5 g ORO powder (Sigma-Aldrich, Canada) 
and 100 ml of 60% triethyl phosphate (Sigma-Aldrich, Canada) was mixed and filtered. 
Following fixation in 3.7% formaldehyde, slides were immersed in filtered ORO solution for 30 
minutes at room temperature. Slides immediately underwent five washes with ddH2O, were 
 145 
allowed to dry for 10 minutes and were sealed with Permount (Sigma-Aldrich, Canada). Liver 
images were acquired at 20x magnification using a Nikon Eclipse 90i microscope (Nikon, 
Canada) and Q-imaging MicroPublisher 3.3 RTV camera with Q-capture Software.  
H&E staining: Liver sections were hydrated with ethanol, washed with running tap 
water, then stained with hematoxylin (Sigma-Aldrich, Canada), differentiated (0.1% HCl, 0.1% 
NH4OH) and stained with eosin. After staining was complete, the sections were dehydrated, 
allowed to dry, and then sealed with Permount (Sigma-Aldrich, Canada). Liver images were 
acquired at 20x and 10x magnifications respectively, using a Nikon Eclipse 90i microscope 
(Nikon, Canada) and Q-imaging MicroPublisher 3.3 RTV camera with Q-capture Software.   
Western Blot Analysis: We quantified protein expression for IRS-1 and FOXO1 to assess 
the insulin signaling and atrophic pathways in the skeletal muscle, and G6Pase to assess the 
gluconeogenic pathway in the liver. Western blot analysis was carried out according to 
previously published work (Beaudry, 2015). In brief, 20-40 μg of protein lysate from the TA or 
the liver was run on a 10% (FOXO1 and G6Pase) or 6% (total IRS-1) SDS-page gel and proteins 
were transferred to a PVDF membrane (Bio-Rad, Canada). Membranes were blocked in 5% 
powdered milk and Tris-buffered saline with Tween 20 at room temperature for 1 hour. 
Membranes were then incubated overnight at 4°C with their respective primary antibodies 
(FOXO1, 1:1000, Cat#2880, Cell Signaling, USA; G6Pase 1:1000, Cat#sc-25840, Santa Cruz 
Biotechnology, USA; total IRS-1, 1:1000, Cat#2382, Cell Signaling, USA). The following 
morning, the membranes were washed with TBST and incubated with anti-mouse (1:10000, 
Cat#ab6789, Abcam) or anti-rabbit (1:10000, Cat#ab6721, Abcam) secondary antibodies for 1 
hour at room temperature. Membranes were then washed and imaged. Images were detected on a 
Kodak In vivo FX Pro imager and molecular imaging software (Carestream Image MI SE, 
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version S.0.2.3.0, Rochester, New York) was used to quantify protein content. GAPDH 
(1:10000, ab9484, Abcam, Toronto, ON) was used as a loading control for all proteins. 
 Statistical Analysis: All data are represented as means ± SE, with a criterion of P<0.05 
and P<0.001 and were assessed as stated using two-way ANOVAs as a means of statistical 
significance. Individual differences were calculated using Bonferroni’s post-hoc test (Prism4; 
Graphpad software Inc; La Jolla, CA, USA).  
Results 
 Body composition and muscle mass: A significant reduction in body weight and in the 
relative muscle weight of hind limb muscles (TA, plantaris, and gastrocnemius) was observed 
after exogenous Cort-treatment at both time points (P<0.05, Table 4.1), consistent with the 
known influence of Cort on body mass and muscle atrophy (Schakman, 2013; Shpilberg, 2012). 
Prazosin did not modify body weight or relative muscle weights at either time point (P<0.05, 
Table 4.1). 
 Plasma Cort, fasting NEFAs, glucose and insulin concentrations: Cort levels measured at 
0800 on days 7 and 14 were elevated in both cort groups (P<0.05, Table 4.2), as expected and 
previously observed by our lab (Beaudry, 2014). There was no effect of prazosin on Cort 
concentrations within either the control or cort-treated groups. Fasted NEFA levels were similar 
in all groups at both day 7 (P<0.05, Table 2) and day 14 (P<0.05, Table 4.2).  
 Fasting blood glucose values were significantly elevated prior to the oral glucose 
challenge after both 8 (P<0.05, Table 4.2) and 12 days (P<0.05, Table 4.2) of cort treatment. No 
effect of prazosin to alter fasting blood glucose concentration was observed in either groups 
(Cort or controls). Fasting insulin values were ~ 4-fold higher after cort-treatment compared to 
placebo-treated groups regardless of treatment duration (P<0.05, Table 4.2). Prazosin treatment 
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of only 7 days caused a slight reduction in fasted insulin concentrations in the Cort-prazosin 
animals compared to the Cort-water animals (3.7±0.4 vs 5.3±0.6 ng/ml, P<0.05, Table 4.2), 
however this reduction was not maintained after 14 days of prazosin treatment (3.8±0.6 vs 
3.7±0.2, Table 4.2).  
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Table 4.1. Animal characteristics 
 1 Week 
 
Control-
Water 
Control-
Prazosin 
Cort-Water Cort-Prazosin 
Body weight 
(g) 
361.7±10 357.2±7.7 260.7±5.5# 251.3±2.3# 
TA relative weight 
(g/kg BW) 
1.77±0.06 1.85±0.04 1.71±0.05 1.71±0.08 
EDL relative weight 
(g/kg BW) 
0.5±0.02 0.52±0.01 0.52±0.02 0.51±0.01 
Plantaris relative 
weight (g/kg BW) 
0.87±0.75 0.93±0.04 0.84±0.04 0.87±0.03 
Soleus relative weight 
(g/kg BW) 
0.41±0.01 0.38±0.02 0.49±0.01# 0.50±0.02# 
Gastroc relative weight 
(g/kg BW) 
4.5±0.3 4.9±0.1 4.3±0.1 4.4±0.2 
 2 Weeks 
 
Control-
Water 
Control-
Prazosin 
Cort-Water Cort-Prazosin 
Body weight 
(g) 
373.4 ± 4.9 369.4±10 245.0±7.7# 254.9±8.5# 
TA relative weight 
(g/kg BW) 
1.88 ± 0.04 1.88±0.03 1.57±0.04# 1.58±0.05# 
EDL relative weight 
(g/kg BW) 
0.49 ± 0.01 0.52±0.01 0.48±0.02 0.47±0.02 
Plantaris relative 
weight (g/kg BW) 
0.91±0.04 0.92±0.02 0.82±0.03 0.81±0.03 
Soleus relative weight 
(g/kg BW) 
0.45±0.009 0.40±0.02 0.54±0.02# 0.51±0.02# 
Gastroc relative weight 
(g/kg BW) 
5.0±0.2 5.2±0.1 4.2±0.2# 4.3±0.1# 
 
Notes: All values are means ± SE. #Significantly different compared to respective control group. 
All analysis was completed by two-way ANOVA with Bonferroni’s post hoc, where P<0.05; 
n=5 for 1 week, n=7-9 for 2 weeks. 
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Table 4.2. Plasma and metabolic effects of corticosterone- and prazosin co-treatment. 
 1 Week 
 
Control-
Water 
Control-
Prazosin 
Cort-Water Cort-Prazosin 
Basal plasma 
corticosterone  (ng/ml) 
44.3 ± 17.6 61 ± 46.1 28 ± 17.5 37.6 ± 14.7 
Plasma corticosterone 
(ng/ml) 
17.5 ± 1.8 18.9 ± 7.1 583.1 ± 51.3* 485.5 ± 93.3* 
Capillary-to-fiber ratio 1.9 ± 0.1 2.0 ± 0.1 1.7 ± 0.2* 1.7 ± 0.1* 
Fasted glucose 
(mmol/L) 
4.8 ± 0.1 5.2 ± 0.2 6.56 ± 0.26* 6.6 ± 0.8* 
Fasted insulin (ng/ml) 0.39 ± 0.2 0.29 ± 0.2 5.3 ±0.6* 3.7 ± 0.4*# 
HOMA-IR 1.6 ± 1.3 1.9 ± 1.2 44.7 ±5.5* 36.3 ± 6.9* 
HOMA-β 222.6 ± 131.4 112 ± 74 1009.9 ± 94.9* 1136.8 ± 396* 
 2 Weeks 
 
Control-
Water 
Control-
Prazosin 
Cort-Water Cort-Prazosin 
Basal plasma 
corticosterone  (ng/ml) 
39.8 ± 25.1 47.3 ± 25.2 64.5 ± 20.6 51.6 ± 19.5 
Plasma corticosterone 
(ng/ml) 
16.2 ± 6.5 9.6 ± 0.6 296.3 ± 34.5* 284.7 ± 34.2* 
Capillary-to-fiber ratio 2.1 ± 0.1 2.3 ± 0.03† 1.6 ± 0.1* 2.0 ± 0.1*† 
NEFAs (mmol/L) 0.67 ± 0.1 0.66 ± 0.1 0.79 ± 0.1 0.65 ± 0.1 
Fasted glucose 
(mmol/L) 
5.5 ± 0.2 5.8 ± 0.2 6.7 ± 0.3* 8.1 ± 0.5* 
Fasted insulin (ng/ml) 0.9 ± 0.2 1.1 ± 0.2 3.8 ± 0.6* 3.7 ± 0.2* 
HOMA-IR 7.0 ± 1.8 8.6 ± 1.7 35 ± 4.7* 42.3 ± 4.2* 
HOMA-β 266.8 ± 55.6 294 ± 60 739.7 ± 83.4** 435.4 ± 81.0 
 
Notes: All values are means ± SE. †Main effect of prazosin consumption. #Mean was 
statistically significant from control-prazosin. *Main effect of cort-treatment. **Significantly 
different from all groups. All analysis was completed by two-way ANOVA with Bonferroni’s 
post hoc, where P<0.05, P<0.001 for HOMA- β; n=5 for 1 week, n=7-9 for 2 weeks.  
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 Oral Glucose Tolerance Test:  Cort, regardless of the duration of treatment, resulted in 
elevated fasting blood glucose values and deterioration in glucose tolerance when compared to 
the control groups (P<0.05, Fig. 4.2A, 2B).  Seven and 14 days of prazosin treatment did not 
improve glucose tolerance significantly, although AUC appeared to be slightly reduced with 
prazosin exposure and values at the 120-minute time point were normalized with prazosin 
treatment (P<0.05, Fig. 4.2A', Fig. 2B'). Plasma insulin concentrations were highest in the cort 
water-treated animals before and throughout the oral challenge (P<0.05, Fig. 4.2C). 
Interestingly, prazosin administration lowered the insulin AUC during oral glucose gavage at the 
2-week time point, primarily by restoring the insulin levels back to baseline by the 30-minute 
time point  (P<0.05, Fig. 4.2D'). HOMA-IR was used to determine the level of fasting insulin 
resistance, with both 9 and 16 days of cort-treatment causing significant insulin resistance when 
compared to both control groups, with prazosin not having any significant effect in either group 
(P<0.001, Table 4.2). HOMA-β was used to calculate basal β-cell function where higher 
HOMA-β scores indicate greater β-cell function. Cort-treatment, after 9 days, caused ~4-5-fold 
increase in HOMA- β compared to controls, with prazosin having no significant effect (P<0.001, 
Table 4.2). Two weeks of cort water treatment was also associated with higher HOMA-β score, 
while the cort-prazosin animals had an attenuated rise in HOMA-β (P<0.05, Table 4.2), 
suggesting that prazosin administration was able to release the demand on β-cell function. 
 Capillary-to-fibre ratio vs. glucose tolerance and insulin sensitivity: The C:F analysis 
was originally reported in Mandel et al (2016); a series of representative images (Fig. 4.3A) and 
reference C:F values (Table 2) were reported here to allow for regression analysis. To determine 
if glucose tolerance and insulin sensitivity are associated with C:F in the 14 day treatment 
groups, individual glucose AUC. Fasted insulin and insulin AUC values from each animal were 
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plotted and a linear regression was calculated for each variable (Fig. 4.3B, 3C, 3D). C:F was 
found to be predictive of  insulin sensitivity (r2= 0.5783, P<0.05, Fig. 3C; r2=0.4781, P<0.05, 
Fig. 3D) but not of glucose tolerance (r2=1.601, P<0.05, Fig. 4.3B).  
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Figure 4.2. Glucose tolerance and insulin secretion after corticosterone and prazosin co-
treatment. 
Glucose tolerance and insulin secretion after 8 (A and A') and 12 days (B, B', C and C') of 
corticosterone and prazosin treatment. An oral glucose tolerance test (OGTT) was administered 
after 8 and 12 days of cort-treatment. The cort-water animals were glucose intolerant after only 8 
days of treatment, (P<0.05); n=5. Both cort-treated groups were glucose intolerant after 12 days 
of cort-treatment, regardless of prazosin consumption (P<0.05); n=7-9. Insulin secretion 
throughout the OGTT was significantly elevated in the cort-water group, and was greatly 
improved with prazosin consumption (P<0.05); n=7-9. Bars that do not share similar letters, 
denote statistical significance (P<0.05) using a two-way ANOVA with Bonferroni’s (A', B' and 
C'). All values are means ± SE. 
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Figure 4.3. Capillary-to-fiber ratio (C:F) is predictive of insulin sensitivity but not glucose 
tolerance. 
Representative images depicting C:F within the TA muscle (A) after 2 weeks of co-treatmnt. 
Individual C:F, glucose area under the curve (AUC) (B), fasted insulin (C) and insulin AUC (D) 
values after two weeks of concurrent cort and prazosin treatment were plotted and a linear 
regression was calculated. C:F was found to have no relationship with glucose tolerance 
(r2=1.601, P<0.05), but was predictive of insulin sensitivity (r2= 0.5783, P<0.05; r2=0.4781, 
P<0.05); n=7-9. All values are individual. 
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 Muscle cross-sectional area and succinate dehydrogenase content: The TA muscle of 
representative animals from each treatment group was stained for CSA and SDH. CSA, 
indicating individual muscle fiber size, was lowest in type IIb/x fibers of cort-treated animals 
after both 9 and 16 days (Fig. 4.4A-D, P<0.01).  The control-prazosin animals had the largest 
muscle fibers across all three fiber types after 9 days (P<0.05), but this difference was 
unsustained by 16 days of treatment. SDH staining, which correlates with muscle oxidative 
capacity (Seick 1986), was not different among all treatment groups after both 9 and 16 days 
(Fig. 4.6 A-D).  
 FOXO1 and IRS-1 protein content: Cort-treatment is known to stimulate muscle atrophy 
and impair insulin signaling, therefore FOXO1 and IRS-1 protein concentrations were analyzed 
since these are considered critical signaling molecules in these two pathways. After 9 days of 
cort-treatment, there was a significant increase in FOXO1 protein content and ~2-fold decrease 
in total IRS-1 (Fig. 4.5A, 5B, P<0.05).  These changes were sustained after 16 days, regardless 
of prazosin treatment (Fig. 4.5C, 5D, P<0.05). 
 Liver histology and enzymatic content: H&E staining of liver sections was used to 
visually examine possible structural damage in all treatment groups after both 9 (Fig. 4.7A) and 
16 (Fig. 4.7B) days. Nuclei are visualized as purple (dark) and the cytosol is pink (light). Cort-
treatment appeared to cause damage to the liver, seen as vacuoles or holes in the cytosol, at both 
9 and 16 day end points, and 14 days of prazosin consumption seemed to have a small visual 
beneficial effect in reducing the number of vacuoles. Liver sections after 16 days of treatment 
were also stained for ORO, to examine lipid accumulation (Suppl. Fig. 4.1A). Lipid staining was 
highest in the Cort-water treated group compared with both control groups and the Cort-prazosin 
group. Cort-prazosin animals had visibly less lipid accumulation in comparison to Cort-water 
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animals, but when compared to both control groups the lipid droplets were still obvious. 
Glucose-6-phosphatase (G6Pase) protein content was measured to assess the gluconeogenic 
pathway in the 16 day treatment groups (Fig. 4.7C). There was an effect of Cort-treatment to 
significantly increase G6Pase content (P<0.05) in comparison to both control groups, with no 
obvious effect of prazosin treatment in either controls or Cort-treated groups. 
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Figure 4.4. Corticosterone treatment causes glycolytic fibre atrophy. 
Cross-sectional area (CSA) in I, IIa, and IIb/x fibre types of the tibialis anterior (TA) after 9 (A, 
B) and 16 days (C, D) of concurrent prazosin and corticosterone treatment. Cort-treatment, 
regardless of duration, resulted in significant atrophy of the IIb/x fibers (P<0.01). The control-
prazosin animals had the largest muscle fibers across all three fiber types after 9 days (P<0.05), 
which was not sustained after 16 days of co-treatment.; n=4-5. # Significantly different from all 
other groups (P<0.05), * significantly different from control groups (P<0.01), ** significantly 
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different from control-prazosin (P<0.05) using a two-way ANOVA with Bonferroni’s. All values 
are means ± SE.  
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Figure 4.5. The effect of corticosterone and prazosin on FOXO1 protein content. 
Effect of prazosin and corticosterone on FOXO1 (A,C) and IRS-1 (B,D) total protein content in 
the tibialis anterior (TA) after 9 (A,B) and 16 (C,D) days of co-treatment. Regardless of protocol 
duration, cort-treatment caused increased FOXO1 content and decreased total IRS-1 content, 
impairments which were unaffected by prazosin administration; n=5. Bars that do not share 
similar letters, denote statistical significance (P<0.05) using a two-way ANOVA with 
Bonferroni’s. All values are means ± SE.    
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Figure 4.6. The effect of corticosterone and prazosin co-treatment on succinate dehydrogenase content. 
Representative cross-sections of the tibialis anterior (TA) depicting succinate dehydrogenase 
(SDH) content after 9 (A, B) and 16 days (C, D) of concurrent prazosin and corticosterone 
treatment. Muscle oxidative capacity was unaffected by either cort- or prazosin- treatment at 
either time point; n=4-6. A two-way ANOVA was used. All values are means ± SE.  
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Figure 4.7. Liver structure and G-6-Pase content is unaffected by prazosin treatment. 
Representative images of the liver depicting hematoxylin and eosin staining after 9 (A) and 16 
(B) days and protein content of the gluconeogenic enzyme glucose-6-phosphatase (G-6-Pase) (C) 
after 16 days of co-treatment. Cort-treatment of both 9 and 16 days caused vacuole deposition in 
the liver, which appeared to be slightly improved with two weeks of prazosin consumption. Two 
weeks of cort-treatment caused a significant elevation in liver G-6-Pase protein content, which 
was unaffected by prazosin consumption; n=5. Bars that do not share similar letters, denote 
statistical significance (P<0.05) using a two-way ANOVA with Bonferroni’s. All values are 
means ± SE.     
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Supplementary Figure 4.1. Liver lipid content is unaffected by prazosin treatment. 
Representative images showing Oil Red O staining of the liver (A) after 16 days of co-treatment. 
Prazosin seemed to improve the fat accumulation observed in the liver after 16 days of cort-
treatment; n=5-9.  
 162 
Discussion 
 This study demonstrates, for the first time, that the improvement in skeletal muscle 
capillary number with prazosin treatment, observed in GC-treated rats, corresponded with a 
distinct improvement in whole body insulin sensitivity. However, in spite of the marked 
improvements in muscle capillarization and insulin sensitivity with prazosin treatment, GC-
induced muscle atrophy and severe glucose intolerance was still observed in this animal model. 
These findings suggest that simply promoting muscle capillarization might not translate to 
significant metabolic improvements in the Cushing’s like phenotype in this particular animal 
model.    
 Elevations in GCs for a two-week period in male rats negatively impacts ectopic fat 
deposition, glucose tolerance, insulin sensitivity and skeletal muscle growth and capillary 
number (Beaudry, 2014; D'souza, 2011; Shikatani, 2012; Shpilberg, 2012). Recently, we have 
established that regular exercise improves the metabolic profile and skeletal muscle phenotype in 
male Sprague-Dawley rats exposed to prolonged corticosterone treatment (Beaudry, 2015). 
Prazosin is an established method to increase skeletal muscle angiogenesis, through interference 
with peripheral sympathetic function, selectively blocking postsynaptic α-adrenoceptors 
(Graham, 1977), without any of the other metabolic and morphological adaptations that can 
occur with exercise training. Blockade of the α-adrenergic pathway with prazosin leads to 
angiogenesis and enhanced capillary flow in skeletal muscle in healthy rats, a phenomenon that 
is linked to improvement in whole body insulin sensitivity without apparent changes in skeletal 
muscle insulin signaling per se (Akerstrom, 2014). We have also established that prazosin 
administration is able to prevent the capillary rarefaction associated with pathophysiological 
elevations in GCs, through maintenance of multiple aspects in shear stress signaling (manuscript 
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in review). While muscle capillarization was improved by prazosin treatment, as was whole body 
insulin sensitivity, glucose tolerance and skeletal muscle size were unaffected. These findings 
suggest that an increase in skeletal muscle capillarization alone may not improve glucose 
tolerance or significantly alter the metabolic profile in organisms suffering from elevated GCs. 
We have previously shown that two weeks of Cort-treatment causes glucose intolerance 
and here we show that this response can also occur as early as 9 days of Cort-treatment. Early 
work examining the effect of prazosin in human hypertensive subjects found that 12 weeks of 
prazosin consumption was associated with altered carbohydrate metabolism, specifically 
improving both glucose uptake and insulin sensitivity (Pollare 1988). A number of studies have 
since been completed further verifying the beneficial effect that prazosin can have on glucose 
tolerance and insulin sensitivity in human subjects (Maruyama, 1991a; Swislocki, 1989). The 
relationship between insulin sensitivity and capillarisation was recently explored, also using 
prazosin to alter skeletal muscle angiogenesis, in sedentary, non-diabetic, male rats (Akerstrom, 
2014). The authors found that after 21 days of prazosin treatment there was an increase in 
capillarisation, accompanied by an improvement in insulin sensitivity and glucose uptake, but no 
effect on major insulin signaling proteins within the skeletal muscle. The authors attribute the 
improvement in insulin sensitivity to improved glucose diffusion due to enhanced surface area 
for exchange. In line with these observations, we also saw significant improvements in both 
insulin sensitivity and capillarisation after only 14 days of prazosin administration, but found 
only modest alterations in glucose tolerance, perhaps because hepatic glucose production was not 
improved or because the muscle atrophy was still apparent in this animal model. To further 
examine the link between capillarisation and insulin sensitivity, we analyzed individual 
capillary-to-fiber and insulin and glucose AUC values and found that the individual capillary-to-
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fiber ratio was predictive of insulin sensitivity but not of glucose tolerance. The lack of 
significant improvement to glucose tolerance could be due to the fact that Cort-treatment caused 
such pronounced skeletal muscle atrophy and hepatic insulin resistance that the modest 
improvements in skeletal muscle vasculature were unable to overcome these impairments. 
The alterations in glucose tolerance observed in the Cort-treated animals appear to be 
mediated by activation of the atrophic pathway identified by significantly decreased skeletal 
muscle cross-sectional area, specifically within the glycolytic (IIb/x) fibers and elevations in 
total FOXO1 protein content, an atrophic protein with a glucocorticoid response element (GRE). 
We also observed an obvious deficit in IRS-1 total protein content which was evident after just 9 
days of treatment. These results parallel the general findings of the effects of elevated Cort on 
the skeletal muscle machinery (Buren, 2002; Saad, 1993; Schakman, 2013). While we know 
prazosin was able to improve the capillary rarefaction observed after Cort-treatment and increase 
insulin sensitivity, the Cort-treated animals were still glucose intolerant, insulin resistant and 
were physically smaller than their placebo counterparts. In general, GCs decrease absolute body 
mass but increase relative fat mass, a result which is especially pronounced in young growing 
animals (Shpilberg, 2012) or in human adolescence (Abad, 2001). The loss in total mass is 
usually attributed to reduced skeletal muscle mass, but can also represent reductions in body 
length or height. While we did not expect α1-adrenoceptor antagonism to completely reverse 
these symptoms of GC excess, it was hypothesized that increasing the skeletal muscle capillary 
supply could in fact enhance nutrient and hormone provision, possibly attenuating some growth 
impairments within the muscle itself.  
We hypothesized that pharmacologically increasing the capillarisation of insulin resistant 
rodent skeletal muscle could subsequently impact its oxidative capacity. After basic 
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quantification of SDH staining within the TA, neither 7 nor 14 days of prazosin administration 
caused augmentation to SDH staining intensity within either the control or Cort-treated groups. 
These results suggest that the capillary supply to skeletal muscle can be enhanced independently 
of the metabolic profile, oxidative capacity and fiber size, an interesting finding also observed in 
the skeletal muscle of young men (Bosutti 2015). As such, it is likely that regular exercise, which 
can increase both muscle capillarisation and oxidative capacity as well as improve skeletal 
muscle insulin sensitivity, might be a preferred means to improve metabolic function in this 
particular animal model of sustained hyperglucocorticoidemia.   
 The promoter of the glucose-6-phosphatase (G6Pase) gene also has a GRE which 
suggests initiation of gene transcription by activated glucocorticoid receptors, stimulating an 
increased rate of gluconeogenesis (Yoshiuchi, 1998). Our results show increased G6Pase protein 
content in the liver of Cort-treated rats, suggesting elevated gluconeogenesis, which was 
unaffected by prazosin administration. Very early research determined that the glycogenolytic 
and gluconeogenic actions of epinephrine and norepinephrine in the rat liver were primarily 
mediated through an α-adrenergic, cAMP-independent mechanism (Chan, 1979), and that after 
adrenalectomy, there was a reduction in α-adrenergic action in rat livers. Additionally, hepatic 
triglyceride secretion rate was reduced in prazosin-treated rats (Chait, 1979), which correlated 
with reduced plasma triglyceride concentrations and points to a direct effect of α-adrenergic 
blockade on liver triglyceride secretion rate. Additionally, antagonism of the α-adrenergic 
pathway leads to increased availability of lipoprotein lipase, which also can decrease plasma 
triglycerides and triglyceride-rich lipoproteins (Nash, 1990). These are possible mechanisms for 
the improved lipid profile observed in multiple chronic α-adrenergic blockade studies , and also a 
reason why we measured NEFAs and lipids in the liver. While there was no effect of Cort to 
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increase NEFA concentrations, there was also no effect of prazosin to lower NEFA 
concentrations in either the control or Cort groups. Histochemical analysis of the liver shows 
slight improvements in both structural integrity and neutral lipid deposition after 14 days of 
prazosin administration in the Cort-treated rats. There was a fair amount of variability involved 
in the ORO analysis, as some Cort-treated rats given prazosin did not improve to the extent as 
others, a result that was additionally observed with both glucose tolerance and insulin sensitivity 
assessments. This is not uncommon with our model of elevated GCs, as some rats tend to 
respond to the Cort pellets much more aggressively than others, and points to a possible 
enhanced therapeutic action of prazosin if administered for a longer period of time, as here we 
only examined either 7 or 14 days of treatment. Interestingly, 9 days of Cort produced minimal 
visible defects within the liver. Furthermore, 16 days of Cort-treatment caused elevations in 
fasted glucose values, regardless of prazosin administration, which also points to the conclusion 
that two weeks of α1-adrenoceptor antagonism was unable to provide major functional 
improvements to the liver of Cort-treated rodents.    
The Cort concentration administered to the rats was a pathophysiological dose and could 
have been too high to allow for prazosin to reverse the key metabolic impairments, a possible 
reason why there were no major improvements observed after the significant increase in 
capillary-to-fiber ratio.  The fact that prazosin was able to influence insulin sensitivity and 
increase capillary number indicates that it did have an effect, but suggests that the systemic 
consequences of GC’s (skeletal muscle atrophy, increased liver gluconeogenesis, glucose 
intolerance and insulin resistance) were too aggressive for prazosin to have a substantial 
beneficial effect. This study also shows how the short-term correction in skeletal muscle 
capillarisation, specifically through α1-adrenergic blockade, in a model of Cort-induced insulin 
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resistance is insufficient to overcome the other metabolic and physiologic impairments 
associated with this condition. 
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Chapter 5 
The effects of voluntary exercise and prazosin on capillary rarefaction and metabolism in 
streptozotocin-induced diabetic male rats 
 
Author Contributions: Dr. Erwan Leclair and I designed the study and wrote the paper along 
with input from Erin Mandel, Dr. Tara Haas, Dr. Olivier Birot and my supervisor Dr. Michael 
Riddell. Dr. Erwan Leclair and I completed all animal handling, including STZ injections, blood 
glucose and exercise monitoring, and plasma analyses (NEFAs, corticosterone RIA). I performed 
all skeletal muscle sectioning, Erin Mandel completed the capillary to fibre analyses, Julian 
Aiken completed the western blot analyses. Dr. Michael Riddell, with input from Dr. Tara Haas, 
oversaw the entire study and assisted in manuscript preparation. 
 
Rationale: Diabetes is associated with both micro- and macrovascular complications, generally 
due to chronic hyperglycemia. Skeletal muscle capillary rarefaction, a microvascular 
complication, was shown to be attenuated in GC-induced insulin resistant rats through voluntary 
exercise in Chapter 3, and prazosin-induced hyperemia in Chapter 4. There is currently very 
limited research examining the effect of exercise on the microvasculature of diabetic skeletal 
muscle. The completion of this study highlights the importance of exercise on vascular 
complications associated with diabetes, through the use of a chemically-induced (STZ) rodent 
model of diabetes. Additionally, the apparent synergism of exercise and prazosin co-
administration on further angiogenic and glycemic enhancements, underscores the importance of 
combination therapies designed to target the vasculature.  
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Preface 
Type-1 diabetes mellitus causes impairments within the skeletal muscle 
microvasculature. Both regular exercise and prazosin have been shown to improve skeletal 
muscle capillarization and metabolism in healthy rats, through distinct angiogenic mechanisms. 
The aim of this study was to evaluate the independent and additive effects of voluntary exercise 
and prazosin treatment on capillary-to-fiber ratio (C:F) in streptozotocin (STZ)-treated diabetic 
rats. STZ (65mg/kg) was intraperitoneally administered to male Sprague-Dawley rats (n=36) to 
induce diabetes, with healthy, non-diabetic, sedentary rats (n=10) used as controls. The STZ-
treated rats were then divided into sedentary (SED) or exercising (EX, 24h access to running 
wheels) groups and then further subdivided into prazosin (Praz) or water (H2O) treatment 
groups: non-diabetic-SED-H2O, STZ-SED-H2O, STZ-EX-H2O, STZ-SED-Praz, and STZ-EX-
Praz. After 3 weeks, untreated diabetes significantly reduced the C:F within both the tibialis 
anterior (TA) and soleus muscles in the STZ-SED-H2O animals (P<0.05). Both voluntary 
exercise and prazosin treatment independently resulted in a normalization of C:F within the TA 
(1.86±0.12 & 2.04±0.03 vs 1.71±0.09, P<0.05) and the soleus (2.36±0.07 & 2.68±0.14 vs 
2.13±0.12, P<0.05). The combined STZ-EX-Praz group resulted in the highest C:F within the 
TA (2.26±0.07, P<0.05). Voluntary exercise volume was correlated with fed blood glucose 
levels (r2=0.7015, P<0.01), and when combined with prazosin, caused further enhanced 
glycaemic control (P<0.01). Additionally, exercise and prazosin reduced circulating NEFAs 
more than either stimulus alone (P<0.05). These results suggest that the distinct stimulation of 
angiogenesis, with both regular exercise and prazosin treatment, causes a cooperative 
improvement in the microvascular complications associated with type-1 diabetes. 
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Introduction 
 Type-1 diabetes mellitus is a chronic autoimmune disease targeting the pancreatic beta-
cells causing little to no insulin production, resulting in hyperglycaemia (Cryer, 2012). Despite 
exogenous insulin therapy, individuals with diabetes have an increased risk for long-term 
microvascular and macrovascular complications which can significantly impact their morbidity 
and mortality (Coleman 2015; Dawson 2008). Type-1 diabetes is associated with impaired 
angiogenesis in skeletal muscle (Abaci 1999; Rivard 1999). It is generally held that 
hyperglycaemia itself, or some metabolic byproduct of hyperglycaemia, induces remodeling of 
capillaries within the skeletal muscle, resulting in lower capillary-to-fiber ratio (C:F), and 
ultimately affecting regional hemodynamic regulation (Kindig 1998a; Sexton 1994). In addition 
to insulin therapy, regular exercise is an established management strategy for type-1 diabetes, 
improving glucose uptake and insulin sensitivity within both the skeletal muscle and adipose 
tissue (Galassetti 2013). Additional health benefits include increased cardiorespiratory fitness, 
improved endothelial function, increased vascular health and quality of life (Chimen 2012; 
Galassetti, 2013). Regular endurance exercise  has been shown to increase skeletal muscle 
capillarization in healthy individuals (Hudlicka 1992a). However, the effects of endurance 
training on changes in capillarization in diabetic animals and patients are contradictory 
(Henriksson, 1992a; Kivela, 2006; Leinonen 1982; Wallberg-Henriksson 1984). Vascular 
function has been shown to improve with physical activity in both animal models of diabetes 
(Kivela, 2006) and in patients with type-1 diabetes (Chimen, 2012), but these alterations were 
unable to fully restore the diabetes-induced defects (Fuchsjager-Mayrl 2002; Mason 2006).  
 New capillary growth within the skeletal muscle occurs via existing capillaries through 
two morphologically different, and separately inducible, forms of physiological angiogenesis 
termed sprouting or non-sprouting angiogenesis (Egginton, 2011). Exercise training and 
 172 
mechanical loading trigger sprouting angiogenesis, while vasodilation, such as through α-
adrenergic antagonism, promotes non-sprouting angiogenesis (Egginton 2001; Milkiewicz 2001). 
Prazosin, an α1-adrenergic antagonist, has been used in many rodent studies (Akerstrom, 2014; 
Dawson 1989a; Ziada 1989a), to selectively increase skeletal muscle C:F, but it has yet to be 
used as an agent to stimulate angiogenesis in an animal model of type-1 diabetes. However, 
chronic treatment with prazosin in streptozotocin (STZ)-induced diabetic rats reduces elevations 
in blood pressure and cholesterol levels and improves cardiac function (Goyal 1996). There is 
further evidence that α1-adrenergic blockade, using prazosin, enhances hepatic function 
(Dubuisson, 2002; Oben, 2003), insulin sensitivity and the lipid profile in hypertensive and type-
2 diabetic patients (Hirano 2001; Maruyama 1991b), in addition to decreasing blood pressure.   
 The aim of this study was to evaluate the independent and combined effects of exercise 
and prazosin administration on skeletal muscle capillary content in the STZ-induced rodent 
model of type-1 diabetes. 
Methods 
This study was carried out in accordance with the recommendations of the Canadian 
Council for Animal Care guidelines and was approved by the York University Animal Care 
Committee (2013-5). The Guide for the care and use of laboratory animals, Eighth edition (2011) 
was followed.  
Animals: Adult, male Sprague-Dawley rats (Charles River Laboratories, initial mass of 
225-250g, n=46) were individually housed (lights on 12 hour: lights off 12 hour cycle) after one 
week of acclimatization to room temperature (22-23°C) and humidity (50-60%) controlled 
facilities.  
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Experimental design: A timeline of the experimental protocol is shown in Fig. 5.1. All 
animals had access to voluntary running wheels for one week. Each exercising animal was 
placed into rodent cages with 24-hour access to a running wheel (Harvard Apparatus), while 
sedentary animals were housed in standard cages. Running distance was measured and reset 
daily. Seven days after wheel assignment, a single injection of streptozotocin (STZ) (65 mg/kg) 
was administered to induce diabetes. Animals were also provided with sugar water (20% 
sucrose) to assist with diabetes development, and any exercising animals had their wheels 
removed overnight to further promote diabetes induction. Two days after diabetes inducement 
animals were divided into one of five groups: Non-diabetic-SED-H2O (Control), STZ-SED-H2O, 
STZ-EX-H2O, all given regular water, STZ-SED-Praz and STZ-EX-Praz, all given drinking 
water containing prazosin hydrochloride (5 mg/kg; P7791, Sigma Aldrich Canada). Five days 
after diabetes induction, all animals had their food reduced to 30% of their total body weight, to 
improve glycaemia in the diabetic animals. Body mass, food intake and fluid consumption were 
measured daily for each rodent and any changes in the rodents' health were noted and monitored. 
Blood glucose, NEFA and corticosterone sampling: Blood glucose values were measured 
with a glucometer (AlphaTRAK, Abbott Laboratories, IL, USA) and 5ul of blood from the tip of 
the tail. Blood samples were collected from each animal via saphenous vein, for NEFA (NEFA 
kit, HR Series NEFA-HR, Wako Chemicals) and corticosterone (MP Biomedical, USA) 
concentration measurements on Days 1 (basal) and 32. Glucose area under the curve (AUC) was 
measured relative to each animal’s individual Day 11 glucose value and the net area was used to 
account for the lowering in blood glucose observed in both exercising groups. 
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Figure 5.1. Schematic of the experimental design. 
Basal saphenous vein measurement for corticosterone and non-esterified fatty acid (NEFA) 
concentrations occurred on day 1, prior to the provision of voluntary running wheels. Basal 
blood pressure was measured on day 5, while streptozotocin (STZ) was administered on day 7 
followed by another saphenous blood draw and blood pressure measurement on day 9. Prazosin 
was given on day 11 and on day 14 animals had their food reduced to 30% of their total body 
weight, to improve glycemia in the diabetic animals. Days 16 and 23 were two more saphenous 
draws, while day 19 was the final blood pressure measurement. Animals were euthanized on 
days 29-32 (endpoint).  
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Capillary-to Fiber Analysis: Skeletal muscle, tibialis anterior (TA) and soleus, from euthanized 
animals, was embedded in tissue freezing medium, frozen in liquid nitrogen and cryosectioned (10 µm 
thick). TA and soleus sections (10 µm thick) were fixed with 3.7% para-formaldehyde prior to being 
stained with fluorescein isothiocyanate-conjugated Griffonia simplicifolia isolectin B4 (1:100; Vector 
Laboratories, Canada). Sections were viewed using a Zeiss M200 inverted microscope with a 20x 
objective and images were captured using Metamorph imaging software. Capillary-to-fiber counts were 
averaged from 5-7 independent fields of view per animal by a blinded observer. 
Western Blotting: Immunoblotting was carried out on protein extracts from rat soleus or 
TA muscles as previously described (Aiken 2016). Frozen muscle (20 to 40 mg) was mixed at 
4°C with RIPA buffer. For each sample, protein extracts were prepared using two stainless 
carbide beads (Retsch, Fisher Scientific, Montreal, Canada) in the Retsch MM400 tissue lyser 
(30 pulses/sec, Retsch GmbH, Haan, Germany). Denatured samples (30 µg/well) were subjected 
to SDS-PAGE and blotted onto nitrocellulose membranes. After blocking with 5% fat-free milk 
at room temperature for 45 min, the blots were probed overnight at 4°C with primary antibodies 
against the following proteins: β-actin (sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), Mdm2 (non-commercial clone 2A10; (Aiken, 2016; Roudier 2013; Roudier 2012), VEGF 
(clone VG-1; 05-1117; Millipore, Etobicoke, ON, Canada), or TSP-1 (clone A6.1; MS-421-P0; 
Invitrogen, Burlington, ON, Canada). After incubation with secondary antibody [cat. no. P0260; 
Dako, Carpinteria, CA, USA], proteins were visualized with chemiluminescence (Millipore) on 
Imaging Station 4000MM Pro (Carestream Health, Rochester, NY, USA) or on X-ray film (CL-
XPosure Film; prod. no. 34090; Thermo Scientific, Rockford, IL, USA). Blots were analyzed 
with Carestream software. 
 Statistical Analysis: All data are represented as means ± SE, with a criterion of P<0.05 
and P<0.01 and were assessed as stated using two-way ANOVAs as a means of statistical 
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significance. Individual differences were calculated using Bonferroni’s post-hoc test (Statistica, 
StatSoft, Poland). A ttest was also used to compare values for non-diabetic and STZ-treated rats.  
 
Results 
 Capillary-to-fiber content: The effect of STZ-induced diabetes on the skeletal muscle 
microvasculature was evaluated using the capillary-to-fiber ratio (C:F) expressed relative to 
muscle mass (Fig. 5.2). There was obvious capillary rarefaction in the TA of the STZ-SED-H2O 
group when compared to the non-diabetic, control group (Fig. 5.2A and Fig 5.2A’, P<0.001), 
which was paralleled within the soleus of the STZ-SED-H2O animals (Fig. 5.3A and Fig. 5.3A’, 
P<0.001).  
C:F for both the STZ-SED-Praz and the STZ-EX-H2O groups were significantly higher 
from the STZ-SED-H2O group (Fig. 5.2B and 5.2B’, P<0.001), although they were not 
significantly different from each other, suggesting that individually, both prazosin and exercise 
were capable of improving the diabetes-induced loss of capillaries toward that observed in non-
diabetic control rats. The STZ-EX-Praz animals had significantly higher C:F in comparison to 
the STZ-EX-H2O and STZ-SED-Praz animals (P<0.001), signifying that co-treatment exerted an 
additive effect on angiogenesis. We also observed an increase in C:F within the soleus of the 
STZ-SED-Praz animals (P<0.01) and the STZ-EX-Praz animals (Fig. 5.3B and Fig. 5.3B’, 
P<0.05), however exercise was unable to improve the diabetes-induced rarefaction 
independently.  
 Circulating glucose concentrations: Hyperglycaemia was evident in all STZ-treated 
animals (Fig. 5.4A). When analyzed as an AUC from Day 11 onward (the date of prazosin 
initiation), there was a significant main effect of both exercise and prazosin to improve daily fed 
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glucose concentrations, with the most favourable response occurring in the STZ-EX-Praz group 
(Fig. 5.4A', P<0.01), suggesting that the co-treatment produced the most beneficial result. 
 Running distance: Daily running distance was graphed in relation to prazosin 
administration (Fig. 5.5A) and no difference was found between the average running distance in 
the two exercising groups (Fig. 5.5B). A significant correlation was observed between individual 
mean blood glucose concentrations and cumulative running distances (Fig. 5.5C, P<0.01).  
Corticosterone, NEFAs: STZ-induced diabetes affected the concentrations of circulating 
corticosterone and NEFAs. Prior to prazosin administration, corticosterone and NEFA 
concentrations were not different across the STZ-treatment group, so these data were pooled 
(Initial basal, Fig. 5.6A and 5.6B). All STZ-treated animals developed significantly elevated 
corticosterone concentrations (Fig. 5.6A, P<0.001) at the end of the treatment period, and only 
the prazosin group showed significantly decreased values (Fig. 5.6A’, P<0.05). There was a 
significant effect of voluntary exercise, prazosin and their combination, to improve NEFA values 
(Fig. 5.6B’, P<0.05).  
 Mdm2, VEGF-A, and TSP-1: VEGF-A and TSP-1, key pro- and anti-angiogenic 
molecules in skeletal muscle, are influenced by Mdm2, and these three markers have been used 
to understand the changes observed in skeletal muscle C:F. In both the TA and soleus muscles, 
STZ-treated rats had significantly decreased Mdm2 protein content vs. non-diabetic rats (Fig. 
5.7A, A', 5.7B, B', P<0.05). Within the TA, Mdm2 protein content was lowest in the STZ-SED-
H2O group, but was only significantly lower than the STZ-SED-Praz group (Fig. 5.7A", P>0.05).  
Soleus Mdm2 protein content was not significantly modified in the four different treatment 
groups (Fig. 5.7B"). STZ-treatment tended to decrease VEGF-A protein content within both 
muscles vs. the non-diabetic group (Fig. 5.8A, A', 5.8B, B', P>0.05). While prazosin treatment 
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(STZ-SED-Praz) induced the highest VEGF-A protein content within the TA, no significant 
difference was obtained when compared to the other groups (Fig. 5.8A"). VEGF-A protein 
content within the soleus was not altered with either exercise or prazosin treatment (Fig. 5.8B"). 
TSP-1 protein content was found to be increased in STZ-treated rats in both muscles, but not 
significantly (Fig. 5.9A, A', 5.9B, B', P>0.05). Although no significant effect of exercise and 
prazosin was found within either the TA or soleus, TSP-1 tended to be higher in the TA from the 
STZ-EX-Praz group and in the soleus for both STZ-EX-H2O and STZ-EX-Praz groups (Fig. 
5.9A", B", P>0.05).  
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Figure 5.2. Capillary-to-fibre ratio within the tibialis anterrior is improved after voluntary 
exercise and prazosin co-treatment. 
Capillary-to-fiber ratio (C:F) in the tibialis anterior (TA) after 19 days of voluntary exercise and 
prazosin co-treatment (A, B); n=5. C:F was analyzed using a two-way ANOVA with 
Bonferroni’s post hoc. A planned comparison was completed within the exercising groups (two-
tailed T-test) to examine the effect of the co-treatment on C:F. * Significantly different from all 
groups (P<0.05), ** significantly different from STZ-EX-H2O (P=0.02). All values are means ± 
SE. 
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Figure 5.3. Capillary-to-fibre ratio within the soleus is improved with voluntary exercise 
and prazosin treatment. 
Capillary-to-fiber ratio (C:F) in the soleus after 19 days of voluntary exercise and prazosin co-
treatment (A, B); n=5. C:F was analyzed using a two-way ANOVA with Bonferroni’s post hoc. 
*Significantly different from all groups (P<0.05). All values are means ± SE. 
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Figure 5.4. Voluntary exercise and prazosin co-treatment improves blood glucose 
concentrations.  
Blood glucose values across the experimental timeline (A) and expressed as area under the curve 
(AUC; A`). AUC values are calculated from day 11 (prazosin administration) until day 32 
(endpoint). A main effect of both prazosin (P<0.01) and exercise (P<0.01) to improve daily 
glucose concentrations was found, with the co-treatment (STZ-EX-Praz) producing the most 
significant improvement; n=6-10. The dotted line represents control AUC. AUC was analyzed 
using a two-way ANOVA with Bonferroni’s post hoc. All values are means ± SE. 
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Figure 5.5. Voluntary running distance is correlated to improved blood glucose 
concentrations. 
Voluntary running distances over time (A) and the total mean values (B) were graphed from the 
initiation of the co-treatment (prazosin administration). The mean values were correlated to mean 
blood glucose values (C) (r2=0.7015, P<0.01); n=6-10. All values are means ± SE (A, B). 
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Figure 5.6. Corticosterone and non-esterified free fatty acid concentrations. 
Corticosterone (A) and non-esterified fatty acid (NEFA) (B) concentrations were measured 
throughout the experimental protocol. The number of days relates to STZ injection. Basal is the 
cumulative data from 2 weeks prior to STZ injection. Prazosin was initiated on day 11. Bars that 
do not share similar letters, denote statistical significance (P<0.05) using a two-way ANOVA 
with Bonferroni’s post hoc; n=6-10. All values are means ± SE.
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Figure 5.7. Skeletal muscle Murine Double Minute-2 protein levels are decreased in 
streptozotocin-induced type-1 diabetes.  
A) Murine Double Minute-2 (Mdm2) protein in control (non-diabetic) and STZ-treated rat 
tibialis anterior (TA) muscles. A’) Mdm2 protein in non-diabetic and STZ-treated rat TA muscle. 
**P ≤ 0.01 following unpaired Student’s t-test analysis. A”) Mdm2 protein in the TA muscles of 
sedentary, prazosin-treated sedentary, exercised, or exercised and prazosin-treated STZ-treated 
rats. Different letters indicate significant difference, P ≤ 0.05 following 2-way ANOVA. B) 
Mdm2 protein in non-diabetic and STZ-treated rat soleus muscles. B’) Mdm2 protein in non-
diabetic and STZ-treated rat soleus muscle. *P ≤ 0.05 following unpaired Student’s t-test 
analysis. B”) Mdm2 protein in the soleus muscles of sedentary, prazosin-treated sedentary, 
exercised, or exercised and prazosin-treated STZ-treated rats. Same letters indicate no significant 
differences were found between groups following 2-way ANOVA. All data are means ± SEM 
(n=6 per group). 
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Figure 5.8.Streptozotocin-induced diabetes does not alter skeletal muscle vascular 
endothelial growth factor protein levels. 
A) Vascular Endothelial Growth Factor (VEGF) protein in control (non-diabetic) and STZ-
treated rat tibialis anterior (TA) muscles. A’) VEGF protein in non-diabetic and STZ-treated rat 
TA muscle. No significant difference following unpaired Student’s t-test analysis. A”) VEGF 
protein in the TA muscles of sedentary, prazosin-treated sedentary, exercised, or exercised and 
prazosin-treated STZ-treated rats. B) VEGF protein in non-diabetic and STZ-treated rat soleus 
muscles. B’) VEGF protein in non-diabetic and STZ-treated rat soleus muscle. No significant 
difference following unpaired Student’s t-test analysis. B”) VEGF protein in the soleus muscles 
of sedentary, prazosin-treated sedentary, exercised, or exercised and prazosin-treated STZ-
treated rats. Same letters indicate no significant differences between groups following 2-way 
ANOVA. All data are means ± SEM (n=6 per group). 
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Figure 5.9. Streptozotocin-induced diabetes does not alter skeletal muscle thrombospondin-
1 protein levels. 
A) Thrombospondin-1 (TSP-1) protein in control (non-diabetic) and STZ-treated tibialis anterior 
(TA) muscles. A’) TSP-1 protein in non-diabetic and STZ-treated rat TA muscle. No significant 
difference following unpaired Student’s t-test analysis. A”) TSP-1 protein in the TA muscles of 
sedentary, prazosin-treated sedentary, exercised, or exercised and prazosin-treated STZ-treated 
rats. B) TSP-1 protein in non-diabetic and STZ-treated rat soleus muscles. B’) TSP-1 protein in 
non-diabetic and STZ-treated rat soleus muscle. No significant difference following unpaired 
Student’s t-test analysis. B”) TSP-1 protein in the soleus muscles of sedentary, prazosin-treated 
sedentary, exercised, or exercised and prazosin-treated STZ-treated rats. Same letters indicate no 
significant differences between groups following 2-way ANOVA. All data are means ± SEM 
(n=6 per group). 
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Figure 5.10. Summary of the effects of prazosin and exercise within the tibialis anterior 
(TA) skeletal muscle of streptozotocin-treated rats. 
A) STZ-treatment causes increased fed blood glucose levels, elevations in corticosterone (Cort), 
NEFA and decreased insulin (Ins) content. Within the TA, STZ-treatment decreased capillary-
fiber ratio (C:F) and Murine Double Minute-2 (Mdm2) protein content while both Vascular 
Endothelial Growth Factor (VEGF) and Thrombospondin-1 (TSP-1) were unaffected. (B). STZ-
treated rats were exposed to either prazosin treatment, voluntary exercise, or a combination of 
both. Individually, prazosin and voluntary exercise increased C:F and decreased both NEFA and 
fed blood glucose concentrations. Prazosin treatment increased Mdm2 protein content while 
VEGF and TSP-1 were unaffected. Voluntary exercise caused no alterations to angiogenic 
proteins. The combination of prazosin with voluntary exercise resulted in the most improved fed 
blood glucose concentrations and C:F. Both Cort and NEFA concentrations were unaffected and 
there were no alterations to angiogenic proteins. 
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Discussion 
Uncontrolled type-1 diabetes has been shown to cause significant impairments within the 
skeletal muscle vasculature, primarily due to hyperglycaemia and endothelial dysfunction 
(Costantino 2015). Using a combined therapeutic approach, we have shown that exposure to 19 
days of combined voluntary exercise and prazosin treatment improved the C:F within the TA 
muscle and normalized the C:F within the soleus muscle of STZ-treated rats. The co-treatment 
caused additional improvements in glycaemic control and circulating lipid levels, thereby 
suggesting that the two treatments can act in an additive fashion to improve muscle 
capillarization and metabolism in this animal model of type-1 diabetes. To our knowledge, this is 
the first time that these two therapeutic modalities have been combined in an animal model 
(health or disease) and suggests that there is likely an additive effect of both prazosin and 
exercise on angiogenesis and metabolic rescue in diabetes.  
 The growth of new capillaries in response to exercising muscle is a highly regulated 
process (Gavin, 2009), which is stimulated by increased functional hyperaemia and shear stress 
(Hellsten 2014), mechanical stretch of the tissue in addition to increases in metabolic demand or 
reduced oxygen delivery (Egginton, 2009). These signals modulate the expression and activity of 
pro-angiogenic and angiostatic factors which act together to regulate sprouting angiogenesis 
(Egginton, 2011). Prazosin, an α1-adrenergic antagonist, increases skeletal muscle capillarization 
via a VEGF- and endothelial nitric oxide synthase-dependent pathway (eNOS) (Baum 2004; 
Williams 2006a), ultimately causing longitudinal splitting of existing capillaries (Zhou 1998), 
which is distinct from the angiogenic mechanism that is dominantly observed in exercising 
muscle.  
 It is well established that endurance exercise promotes new capillary growth (Hudlicka, 
1992a) in both animals and healthy humans (Olfert, 2016), however, literature regarding the 
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effect of exercise on the pathological effects of type-1 diabetes within the skeletal muscle 
vasculature is inconclusive (Henriksson, 1992a; Wallberg-Henriksson, 1984). In healthy rats, 
exercise training causes increased VEGF mRNA and protein content (Gavin, 2009), which 
stimulates further enhancements in capillarization. When examined in STZ-induced diabetic 
mice, treadmill endurance training was unable to improve quadriceps femoris cross-sectional 
fiber area or C:F after five weeks of exercise training (Kivela, 2006). In our study, uncontrolled 
STZ-induced diabetes caused significant capillary rarefaction in both the TA (Fig. 5.2A, A’) and 
soleus muscles (Fig. 5.3A, A’), which is consistent with previous studies (Krause 2009; Sexton, 
1994). When given access to voluntary exercise wheels, STZ-induced diabetic rats showed a 
significant increase in C:F in the TA (Fig. 5.2B, B’) and a slight, but not significant, tendency to 
increase C:F in the soleus (Fig. 5.3B, B’) when compared to sedentary STZ-treated rats. The 
exercise modality in our study was voluntary wheel running and this might have elicited different 
muscle recruitment between the TA vs. soleus muscles (Kano 1997), although there was no 
difference in volume of exercise between treatment groups (Fig. 5.5A, B). Additionally, 
angiogenic potential appears to be inversely proportional to the original capillarity, i.e. it is easier 
to induce in fast muscle than slow or cardiac muscle (Egginton, 2009), another possible 
explanation for the muscle type-specific differences observed in capillarity.  
The enhancement of skeletal muscle capillarization, through non-sprouting angiogenesis 
with prazosin treatment, results in an increase in capillarity in glycolytic and oxidative skeletal 
muscles in healthy rats (Akerstrom, 2014; Dawson, 1989a; Ziada, 1989a). However, to our 
knowledge, this study is the first to illustrate the beneficial effects of prazosin on skeletal muscle 
capillary rarefaction in STZ-induced diabetic rats. We observed a normalization of C:F in both 
TA and soleus muscles of sedentary, STZ-treated rats as their C:F values were equivalent to 
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those measured in the control group. When coupled with wheel running, there was an additive 
effect on the angiogenic response, specifically in the TA. It is worth noting that the skeletal 
muscle angiogenesis observed within both the TA and soleus (the normalization) occurred 
amidst significantly elevated circulating corticosterone levels (Fig. 5.6A, A’), a hormone which 
has been linked to capillary rarefaction (Shikatani, 2012). In addition to the fact that both 
treatment modalities result in distinct forms of angiogenesis, there is data suggesting that the 
combination of high-volume, low-intensity exercise, like voluntary wheel running, actually 
elicits a more rapid angioadaptive response than what is observed after treadmill exercise 
training (Olfert, 2016). 
 Exercise is a widely recognized strategy for improving glycaemia in diabetes (Chimen, 
2012), as regular exercise leads to the improvement of whole-body glucose and lipid metabolism 
and enhanced skeletal muscle glucose disposal (Goodyear 1998a) and insulin sensitivity (James 
1983; James 1985). We observed a significant effect of voluntary exercise to improve glycaemic 
control in the STZ-treated rats, and this result was amplified when the animals were co-
administered prazosin (Fig. 5.4A, A’). These improvements in blood glucose, regardless of 
prazosin administration, were also correlated to running distance (Fig. 5.5C), suggesting that 
higher running volumes caused better glycaemic control. In our study, sedentary STZ-induced 
diabetic rats treated with prazosin also showed improved plasma glucose values throughout the 
experimental protocol, an unexpected observation as the literature regarding the action of 
prazosin on glycaemia is inconsistent (Barbieri 1980; Goyal, 1996; Martin 1989). It seems that 
alterations to glycaemic status are generally accompanied by skeletal muscle angiogenesis, an 
effect that was recently observed in healthy rats (Akerstrom, 2014) thereby suggesting that 
increased capillarization likely enhances insulin sensitivity.  
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 The angiogenic response is controlled by a dynamic balance between anti- and pro-
angiogenic factors (Olfert, 2011).  VEGF-A and TSP-1 are key pro- and anti-angiogenic 
molecules (Malek 2009; Olfert 2009). Interestingly, we have recently brought evidence that the 
E3 ubiquitin ligase Mdm2 could be a central regulator of skeletal muscle angiogenesis, partly by 
regulating VEGF-A and TSP-1 expression (Aiken, 2016; Roudier, 2012).  
 Our current results show, for the first time, that STZ-treated rats had a significant 
decrease in Mdm2 protein levels in both the TA and soleus muscles, as summarized in Fig. 
5.10A. This reduction in Mdm2 could explain the lowered skeletal muscle capillarization in both 
muscles in sedentary diabetic rats, as Mdm2 protein levels have been shown to be closely related 
to endothelial content within the skeletal muscle (Roudier, 2012). It was previously observed that 
both capillarization and Mdm2 protein levels were significantly lower in a model of type-2 
diabetes and in skeletal muscles from Zucker diabetic fatty (ZDF) rats (Roudier, 2012). Further 
results demonstrated that voluntary running efficiently restored both the impaired skeletal muscle 
capillarization and Mdm2 protein levels within the ZDF rats. In contrast to these findings, the 
voluntary exercise stimulus applied within our study did not rescue the observed decrease in 
Mdm2 protein in the diabetic animals (Fig. 5.10B), and suggests that the physiological response 
of Mdm2 to exercise could be lost in uncontrolled, type-1 diabetic muscle. 
No significant alterations in TSP-1 or VEGF-A protein levels in response to diabetes 
induction, prazosin treatment or voluntary exercise were observed in either the TA or soleus 
muscles. In contrast, Kivela and colleagues (Kivela, 2006) have shown that STZ-induced 
diabetic mice had lower VEGF-A protein levels at 3 and 5 weeks post-diabetes induction and a 
concomitant increase in TSP-1 expression. In that study, while exercise served to delay the 
reduction in VEGF-A levels, it was not sufficient to attenuate the elevation in TSP-1 mRNA. 
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The C:F is increased as early as 14 days of treadmill running in rodent skeletal muscle (Slopack 
2014), therefore we hypothesize that alterations in VEGF-A and TSP-1 protein levels could have 
occurred at an earlier time point to stimulate the growth of capillaries. While VEGF-A protein 
could have been elevated prior to the measured time point in order to induce the angiogenic 
process, the trend for an increase in TSP-1 protein levels could indicate the stopping or slowing 
down of capillary growth, as the balance between oxygen and nutrient supply and demand had 
been achieved in the skeletal muscle. 
In summary, the significant improvement to glycemic control observed after co-treatment 
with voluntary exercise and prazosin administration could be the result of enhancements in 
insulin sensitivity and lipid metabolism, increased skeletal muscle glucose disposal and possibly 
improved diffusion conditions for glucose in the muscle as the result of heightened skeletal 
muscle angiogenesis. These results suggest that the combination of both voluntary exercise and 
prazosin administration could lead to a cooperative improvement in peripheral vascular 
complications linked to type-1 diabetes and may perhaps prevent future complications through 
the augmentation of skeletal muscle capillarization and glycaemic control. 
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Chapter 6 
Summary of findings and general discussion 
 The effect of diabetes mellitus within the skeletal muscle is profound and involves a 
number of key alterations that typically occur over a prolonged period of time. Both T1DM and 
T2DM are associated with elevations in GC concentrations, which are well-known to cause a 
variety of negative systemic side effects. The focus of this dissertation was to understand how 
elevations in GC concentrations can be associated with skeletal muscle insulin resistance and 
diabetes development and whether augmentation to the muscle microvasculature is beneficial or 
even possible during conditions that generate significant exposure to elevations in GCs. To 
examine these situations, two rodent models of diabetes were used; exogenous elevations in GCs 
either combined with a HFD (ROD model) or provided a standard chow diet, to reproduce 
T2DM, and STZ-treated rats to induce β-cell destruction, simulating T1DM.  
 GCs are associated with increased preference for energy dense foods (Dallman, 2010; 
Dallman, 2005)  (high fat, simple sugars) and are often associated with excessive weight gain 
(Zakrzewska, 1999). Dexamethasone, a synthetic analogue of cortisol, administered to diet-
induced obese mice, caused whole body glucose intolerance, insulin resistance and significant 
ectopic fat redistribution, especially within the TA muscle (Gounarides 2008). To further 
understand the mechanisms of altered metabolism in conditions of exogenous GC therapy, a 
rodent model of elevated GCs and high fat feeding was developed (Shpilberg, 2012). With two 
weeks of exogenous corticosterone treatment (4x100mg pellets) plus a HFD, male SD rats 
become severely hyperglycemic, hyperinsulinemic (Beaudry, 2013), and insulin resistant, they 
develop hepatic steatosis (D'souza, 2011), visceral adiposity with increased nonesterified free 
fatty acids (NEFAs) and ectopic fat deposition. What is interesting about this model is that with 
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corticosterone or a HFD alone, the animals do not develop the same impairments, but when the 
two treatment conditions are combined, there is a synergistic effect that amplifies the detrimental 
actions. However there is incomplete data examining this relationship within skeletal muscle. 
 Manuscript #1, entitled, 'Severe skeletal muscle metabolic impairments occur in response 
to concurrent high-fat feeding and glucocorticoid treatment in male Sprague Dawley rats' 
investigated the effect of exogenous corticosterone and a HFD, separately and in combination, 
on skeletal muscle, as it is a major determinant of whole body insulin sensitivity and T2DM 
development. Our findings confirm that high concentrations of GCs cause pronounced and 
targeted glycolytic skeletal muscle atrophy and insulin resistance, alterations which are 
augmented in response to the added lipid content associated with high-fat feeding. More 
specifically, the results expressed within this manuscript, suggest that while elevated GCs in 
isolation can cause significant skeletal muscle modifications, including impaired ISGU, reduced 
CSA and insulin signaling protein expression, the added HFD which caused much more IMCL 
accumulation, intensified all of these already detrimental effects. This information is critical for 
patients who are receiving exogenous GC therapy, as it shows how damaging poor nutrition or 
diet choices can be on skeletal muscle metabolism.  
 There is significant data proving that regular exercise is capable of improving glucose 
tolerance, insulin sensitivity, skeletal muscle insulin signaling and atrophy, in addition to ectopic 
lipid deposition both during and post exogenous GC administration (Barel, 2010; Beaudry, 2012; 
Czerwinski 1987; Lapier, 1997; Thomasson 2011). Much less is known in regards to the effect of 
regular exercise in rats fed a HFD while undergoing exogenous GC treatment. To further 
investigate possible therapeutic options for those individuals taking exogenous GCs and possibly 
consuming a diet high in fat, manuscript #2 entitled 'Voluntary exercise improves metabolic 
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profile in high-fat fed glucocorticoid treated rats' was focussed on assessing voluntary exercise as 
a potential mechanism to improve the metabolic side effects, including whole body glucose 
intolerance and insulin resistance, caused by this co-treatment. There was an additional focus on 
the skeletal muscle, as the significant atrophy and impaired glucose uptake now associated with 
this rodent model could be attenuated with regular exercise.  
 After 4 weeks of voluntary wheel running, the Cort-HFD animals showed improved 
glucose tolerance, insulin secretion, hyperglycemia, hyperinsulinemia and HOMA-IR values. 
There were also specific skeletal muscle improvements, with increased glycolytic muscle mass, 
TA CSA, oxidative capacity and capillarisation. An interesting aspect to this study was that these 
results were exercise volume specific, as less running correlated with a reduced amount of 
metabolic improvements, which provides practical human application. The results found within 
this manuscript offer further proof of the concept 'exercise is medicine' as a number of the 
improvements observed have also been seen with RU486 treatment, which is a pharmacological 
option for the treatment of hypercortisolemia. Improvements including glucose tolerance and 
insulin sensitivity (Bitar, 2001; Taylor 2009), lipid deposition, both within the viscera and 
skeletal muscle (Langley 1990; Okada 1992), and enhancements seen in skeletal muscle atrophy 
(Tischler, 1994), such as increased CSA (Wu 2010).  
 Both diabetes and chronic exposure to elevations in GCs are capable of causing capillary 
rarefaction through impaired skeletal muscle angiogenesis (Kivela, 2006; Shikatani, 2012). 
There is also a recognized relationship between circulating insulin levels, muscle microvascular 
perfusion and angiogenesis, which suggests that physiologic insulin concentrations can enhance 
muscle microvascular perfusion, without affecting total blood flow, subsequently enhancing 
muscle angiogenesis (Akerstrom, 2014; Kusters 2015a; Lambadiari 2015). There is additional 
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information that has found certain metabolic conditions, including obesity and diabetes, to blunt 
this response (Kivela, 2006; Li 2007) while pharmacologically enhanced hyperaemia can 
augment muscle microvascular recruitment (Cristiano Barbieri 1980; Dawson, 1989b). 
Manuscript # 3 entitled 'The metabolic effects of prazosin on insulin resistance in glucocorticoid-
treated rats' investigated whether it was possible to stimulate skeletal muscle angiogenesis, using 
a model of chronic hyperaemia through α1-adrenergic antagonism, in a rodent model of elevated 
GCs and insulin resistance, and whether the pharmacologically-induced vasodilation influenced 
glucose tolerance and insulin sensitivity. After 14 days of prazosin administration, concurrent 
with 16 days of exogenous Cort-treatment, there was a significant effect of prazosin to enhance 
the Cort-induced capillary rarefaction. The individual capillary-to-fibre values were correlated to 
improved insulin secretion throughout an OGTT, however there were no corresponding 
improvements in glucose uptake. These results are the first to examine the effect of prazosin 
administration in a model of GC-induced insulin resistance, and provide further evidence that 
there is a link between increased capillarization and insulin sensitivity. This study raised 
additional questions regarding the decreased insulin secreted during the OGTT. While 
technically these results imply an improvement in insulin sensitivity, when examined in concert 
with the glucose data, there seems to be a decrease in insulin secretion, even though there is still 
moderate hyperglycemia initiated by the OGTT. This suggests a possible impairment at the β-
cell level, which was outside of the scope of this manuscript. Interestingly, after further 
examination of the skeletal musculature, it was evident that the pathophysiological 
concentrations of circulating corticosterone caused significant damage, through increased 
atrophic signaling, decreased CSA and IRS-1 protein expression, which could not be treated with 
amelioration to the microvasculature. 
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 Impaired skeletal muscle vascularisation is not only the result of elevations in GCs, as 
both T1DM and T2DM result in micro- and macrovascular consequences thought to be induced 
through hyperglycemia and endothelial dysfunction. There are a number of studies that have 
examined the effect of exercise on the vascular system in healthy and T2DM subjects, and found 
exercise beneficial (increased VEGF expression, improved endothelial dysfunction and enhanced 
angiogenesis), while the research examining exercise within T1DM skeletal muscle is more 
limited and contradictory (Henriksson, 1992b; Leinonen. H., 1982; Wallberg-Henriksson, 1984). 
Regular exercise has been shown to improve vascular function in both animals (Kivela, 2006) 
and patients (Chimen, 2012) with T1DM, but these alterations were unable to fully restore the 
diabetes-induced defects (Fuchsjager-Maryl 2002).  
 There is recent evidence highlighting the concept that intusseusception/longitudinal 
splitting, which can be induced through prazosin administration or 'passive' training, requires less 
energy and therefore results in more rapid capillary adaptation when compared to exercise-
induced sprouting angiogenesis (Prior, 2004). This has led to the investigation into the utilization 
of multiple modes of capillary growth to provide further magnification of the angiogenic 
stimulus. Currently, the potential different stimuli and associated molecular responses in relation 
to the combination of both pharmacologically-induced and exercise-induced angiogenesis are 
still poorly understood and future investigation will help to improve models of exercise to 
maximize the benefits of rehabilitation therapies in the clinic.  
 The objective of manuscript #4, entitled 'The effects of voluntary exercise and prazosin 
on capillary rarefaction and metabolism in streptozotocin-induced diabetic male rats' was to 
determine whether it was possible to enhance skeletal muscle angiogenesis in a model of 
chemically-induced diabetes (STZ-treated rats) through the co-administration of prazosin and 
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voluntary exercise, which cause new capillary growth through distinct mechanisms. The results 
found within this manuscript are the first to demonstrate both a normalisation and significant 
improvement in the skeletal muscle capillary rarefaction caused by untreated chemically-induced 
T1DM, with prazosin administration and voluntary wheel running. These important angiogenic 
effects also occurred during chronic exposure to elevations in GC levels, an unfortunate 
consequence of untreated diabetes. There was an additional benefit of improved glycaemia, 
which was correlated to exercise volume, and was the most improved in the prazosin-exercise 
group. The exercising animals also saw considerable reductions in NEFA levels over the 
treatment period, which could further enhance glycaemic control. The results observed in this 
manuscript underscore the therapeutic potential of inducing capillary growth through multiple 
pathways which could possibly prevent the peripheral vascular complications that are associated 
with T1DM.   
Overall this thesis reveals that there is a significant relationship between elevations in GC 
concentrations, skeletal muscle insulin resistance and diabetes development; an association 
which becomes magnified with the addition of a HFD. This thesis provides considerable 
evidence proving that manipulation of the skeletal muscle microvasculature, either through 
voluntary exercise or pharmacologically enhanced hyperemia, can attenuate the 
hypercortisolemia-induced skeletal muscle capillary rarefaction and improve glucose metabolism 
through enhanced glucose uptake and insulin sensitivity (Figure 6.1). 
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Limitations 
 Although the research completed within this thesis reached its objectives, there are a 
number of important limitations associated with the major findings established within this 
dissertation. The study design in Chapter 2 is lacking a placebo standard diet (SD) control group. 
The primary measurement within this manuscript was the insulin-stimulated glucose transport 
data, and unfortunately there were some technical difficulties associated with the collection of 
the placebo-SD group, culminating in an n of 2. Overall, the lack of a placebo-SD control group 
makes it difficult to definitively determine the effects of Cort-treatment and a HFD, however, 
previously published work demonstrates that there is minimal to no difference between the 
control-HFD group and the control-SD group (Beaudry, 2013; Shpilberg, 2012) in regards to 
glucose tolerance and insulin sensitivity. This suggests that the control-HFD group would make 
an adequate primary control group. Further, within this same manuscript, the use of 3 O-H 
methyl glucose instead of 2 deoxyglucose, as a radioactive tracer to measure insulin-stimulated 
glucose transport, means it is possible that the effects of GCs on hexokinase action within the 
skeletal could have been missed. Overall, it is possible that the observed results under-represent 
the already significant skeletal muscle impairments induced with Cort-treatment, as it would be 
hypothesized that the Cort-treated rats would have impaired hexokinase activity. Finally, the 
study design of Chapter 3, through the utilization of voluntary running wheels, did not allow for 
the analysis of either exercise intensity or any possible acute effects of voluntary exercise. While 
the use of voluntary running wheels provided a more realistic exercise stimulus, as the rats were 
not forced to exercise train and could more accurately represent human activity, there was not a 
consistent exercise intensity for which to compare te obsereved adaptations. Also, as the animals 
were sacrificed throughout the day, and not immediately following wheel running, any possible 
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acute adaptations associated with exercise were not measured. However, the voluntary exercise 
stimulus used showed an obvious effect to improve a number of metabolic and muscular 
detriments caused by Cort-HFD treatment. 
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Figure 6.1. Proposed effects of voluntary exercise and prazosin on insulin resistant skeletal 
muscle. 
Glucocorticoids (GCs) exert specific actions on select proteins within the skeletal muscle cell 
regulating insulin signaling and the endothelial cell regulating angiogenesis (highlighted with      
). The targeted response being decreased insulin sensitivity leading to impaired insulin-
stimulated glucose uptake, significant glycolytic atrophy and capillary rarefaction. The 
introduction of exercise (voluntary wheel running) and increased shear stress (prazosin) 
(highlighted with      ), caused the attenuation and in some cases, reversal, of the specific 
impairments associated with elevations in GCs. Voluntary exercise resulted in the largest 
improvements, causing enhanced insulin sensitivity, glucose tolerance and angiogenesis, in 
addition to attenuated glycolytic atrophy, however further examination of the mechanism behind 
this improvement is warranted.  
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